

# Arthritis & Rheumatism

Official Journal of the American Rheumatism Association

VOLUME 31

JANUARY

NO. 1

Current Comment: Osteogenesis Imperfecta: A Model for Genetic Causes of Osteoporosis and Perhaps Several Other Common Diseases of Connective Tissue <i>Darwin J. Prockop</i> .....	1
One-Year Experience in Patients Treated with Auranofin Following Completion of a Parallel, Controlled Trial Comparing Auranofin, Gold Sodium Thiomaleate, and Placebo <i>H. James Williams, Stephen L. Dahl, John R. Ward, Miki Karg, Robert F. Willkens, Robert F. Meenan, Mary Altz-Smith, Daniel O. Clegg, William M. Mikkelsen, Donald R. Kay, Arthur Weinstein, Maria Guttadauria, Harold E. Paulus, and Stanley B. Kaplan</i> .....	9
Characteristics of Responders and Nonresponders to Slow-Acting Antirheumatic Drugs in Juvenile Rheumatoid Arthritis <i>Edward H. Giannini, Earl J. Brewer, Nina Kuzmina, Lev Alekseev, and Boris P. Shokh</i> .....	15
Dissection of the Mechanisms of Immune Injury in Rheumatoid Arthritis, Using Total Lymphoid Irradiation <i>J. S. H. Gaston, S. Strober, J. J. Solovera, D. Gandour, N. Lane, D. Schurman, R. T. Hoppe, R. C. Chin, E. M. Eugui, J. H. Vaughan, and A. C. Allison</i> .....	21
Clonal Proliferation of Large Granular Lymphocytes in Rheumatoid Arthritis <i>Thomas P. Loughran, Jr., Gordon Starkebaum, Pamela Kidd, and Paul Neiman</i> .....	31
Natural Course of Joint Destruction and Fluctuation of Serum C1q Levels in Patients with Rheumatoid Arthritis <i>Takahiro Ochi, Rokuro Iwase, Kunio Yonemasu, Mitsuhiro Matsukawa, Minoru Yoneda, Masao Yukioka, and Keiro Ono</i> .....	37
Radiographic and Joint Count Findings of the Hand in Rheumatoid Arthritis: Related and Unrelated Findings <i>Howard A. Fuchs, Leigh F. Callahan, Jeremy J. Kaye, Raye H. Brooks, E. Paul Nance, and Theodore Pincus</i> .....	44
Increased Helper Inducer and Decreased Suppressor Inducer Phenotypes in the Rheumatoid Joint <i>H. Paul Lasky, Kenneth Bauer, and Richard M. Pope</i> .....	52
Incidence of Anti-Human Ig with Restricted Specificity in Japanese, Kuwaiti, and Swedish Patients with Rheumatoid Arthritis <i>R. Grubb, H. Matsumoto, and M. A. Sattar</i> .....	60
Antioxidant Activity of Synovial Fluid, Hyaluronic Acid, and Two Subcomponents of Hyaluronic Acid: Synovial Fluid Scavenging Effect is Enhanced in Rheumatoid Arthritis Patients <i>Hideki Sato, Terumi Takahashi, Hirotsugu Ide, Toshiyuki Fukushima, Minoru Tabata, Fusao Sekine, Kazuo Kobayashi, Masao Negishi, and Yukie Niwa</i> .....	63
A DR4-Associated DR-DQ Haplotype is Significantly Associated with Rheumatoid Arthritis <i>Johan Wallin, Björn Carlsson, Håkan Ström, and Erna Möller</i> .....	72
B Cell Hyperactivity and Its Relation to Distinct Clinical Features and the Degree of Disease Activity in Patients with Systemic Lupus Erythematosus <i>Tsuyoshi Sakane, Noboru Suzuki, Shinsuke Takada, Yuji Ueda, Yohko Murakawa, Tomiko Tsuchida, Yasutaka Yamauchi, and Tadimitsu Kishimoto</i> .....	80
Impaired Mobility of Human T Lymphocyte Surface Molecules During Inactive Systemic Lupus Erythematosus: Relationship to a Defective cAMP Pathway <i>Gary M. Kammer and Elizabeth Mitchell</i> .....	88
Monoclonal Rheumatoid Factor-IgG Immune Complexes: Poor Fixation of Opsonic C4 and C3 Despite Efficient Complement Activation <i>Yin C. Ng, D. Keith Peters, and Mark J. Walport</i> .....	99
Characterization of the Antigen Reactive with Anti-Scl-70 Antibodies and Its Application in an Enzyme-Linked Immunosorbent Assay <i>C. Juarez, J. L. Vila, C. Gelpi, M. Agusti, M. J. Amengual, M. A. Martinez, and J. L. Rodriguez</i> .....	108

# Arthritis & Rheumatism

Official Journal of the American Rheumatism Association

VOLUME 31

JANUARY

NO. 1

Current Comment: Osteogenesis Imperfecta: A Model for Genetic Causes of Osteoporosis and Perhaps Several Other Common Diseases of Connective Tissue <i>Darwin J. Prockop</i> .....	1
One-Year Experience in Patients Treated with Auranofin Following Completion of a Parallel, Controlled Trial Comparing Auranofin, Gold Sodium Thiomaleate, and Placebo <i>H. James Williams, Stephen L. Dahl, John R. Ward, Miki Karg, Robert F. Willkens, Robert F. Meenan, Mary Altz-Smith, Daniel O. Clegg, William M. Mikkelsen, Donald R. Kay, Arthur Weinstein, Maria Guttadauria, Harold E. Paulus, and Stanley B. Kaplan</i> .....	9
Characteristics of Responders and Nonresponders to Slow-Acting Antirheumatic Drugs in Juvenile Rheumatoid Arthritis <i>Edward H. Giannini, Earl J. Brewer, Nina Kuzmina, Lev Alekseev, and Boris P. Shokh</i> .....	15
Dissection of the Mechanisms of Immune Injury in Rheumatoid Arthritis, Using Total Lymphoid Irradiation <i>J. S. H. Gaston, S. Strober, J. J. Solovera, D. Gandour, N. Lane, D. Schurman, R. T. Hoppe, R. C. Chin, E. M. Eugui, J. H. Vaughan, and A. C. Allison</i> .....	21
Clonal Proliferation of Large Granular Lymphocytes in Rheumatoid Arthritis <i>Thomas P. Loughran, Jr., Gordon Starkebaum, Pamela Kidd, and Paul Neiman</i> .....	31
Natural Course of Joint Destruction and Fluctuation of Serum C1q Levels in Patients with Rheumatoid Arthritis <i>Takahiro Ochi, Rokuro Iwase, Kunio Yonemasu, Mitsuhiro Matsukawa, Minoru Yoneda, Masao Yukioka, and Keiro Ono</i> .....	37
Radiographic and Joint Count Findings of the Hand in Rheumatoid Arthritis: Related and Unrelated Findings <i>Howard A. Fuchs, Leigh F. Callahan, Jeremy J. Kaye, Raye H. Brooks, E. Paul Nance, and Theodore Pincus</i> .....	44
Increased Helper Inducer and Decreased Suppressor Inducer Phenotypes in the Rheumatoid Joint <i>H. Paul Lasky, Kenneth Bauer, and Richard M. Pope</i> .....	52
Incidence of Anti-Human Ig with Restricted Specificity in Japanese, Kuwaiti, and Swedish Patients with Rheumatoid Arthritis <i>R. Grubb, H. Matsumoto, and M. A. Sattar</i> .....	60
Antioxidant Activity of Synovial Fluid, Hyaluronic Acid, and Two Subcomponents of Hyaluronic Acid: Synovial Fluid Scavenging Effect is Enhanced in Rheumatoid Arthritis Patients <i>Hideki Sato, Terumi Takahashi, Hirotsugu Ide, Toshiyuki Fukushima, Minoru Tabata, Fusao Sekine, Kazuo Kobayashi, Masao Negishi, and Yukie Niwa</i> .....	63
A DR4-Associated DR-DQ Haplotype is Significantly Associated with Rheumatoid Arthritis <i>Johan Wallin, Björn Carlsson, Håkan Ström, and Erna Möller</i> .....	72
B Cell Hyperactivity and Its Relation to Distinct Clinical Features and the Degree of Disease Activity in Patients with Systemic Lupus Erythematosus <i>Tsuyoshi Sakane, Noboru Suzuki, Shinsuke Takada, Yuji Ueda, Yohko Murakawa, Tomiko Tsuchida, Yasutaka Yamauchi, and Tadimitsu Kishimoto</i> .....	80
Impaired Mobility of Human T Lymphocyte Surface Molecules During Inactive Systemic Lupus Erythematosus: Relationship to a Defective cAMP Pathway <i>Gary M. Kammer and Elizabeth Mitchell</i> .....	88
Monoclonal Rheumatoid Factor-IgG Immune Complexes: Poor Fixation of Opsonic C4 and C3 Despite Efficient Complement Activation <i>Yin C. Ng, D. Keith Peters, and Mark J. Walport</i> .....	99
Characterization of the Antigen Reactive with Anti-Scl-70 Antibodies and Its Application in an Enzyme-Linked Immunosorbent Assay <i>C. Juarez, J. L. Vila, C. Gelpi, M. Agusti, M. J. Amengual, M. A. Martinez, and J. L. Rodriguez</i> .....	108

# Brief Reports

Nailfold Capillary Microscopy in Polymyositis and Dermatomyositis <i>M. Lynn Ganczarczyk, Peter Lee, and Sara K. Armstrong</i> .....	116
Arthritis in Idiopathic Hypereosinophilic Syndrome <i>J. Manuel Martín-Santos, Juan Mulero, J. Luis Andréu, Luis F. de Villa, Luis Bernaldo-de Quirós, and Enrique Noguera</i> .....	120
Interleukin-1 Activates Phospholipase A <sub>2</sub> in Human Synovial Cells <i>Steven C. Gilman, Joseph Chang, Pamela R. Zeigler, Joanne Uhl, and Eugene Mochan</i> .....	126
HLA and Immunoglobulin Allotypes in Mixed Connective Tissue Disease <i>C. M. Black, P. J. Maddison, K. I. Welsh, R. Bernstein, J. C. Woodrow, and R. S. Pereira</i> .....	131
A New Autoantibody in Patients with Rheumatoid Arthritis: Characterization of the Anti-HaT-1 Antibody System <i>Yoichi Abe, Shinichi Inada, and Katsutaka Torikai</i> .....	135
Special Article: Current Developments in Rheumatology in The Soviet Union <i>Valentina A. Nassonova</i> .....	140
Letters	
Tertatolol-Induced Lupus <i>J. Roudier and P. D. Delmas</i> .....	145
Thalidomide-Induced Neuropathy in Rheumatoid Arthritis Patients <i>Oscar Gutiérrez-Rodríguez, Pérez Starusta-Bacal, and Oscar Gutiérrez-Montes</i> .....	145
The Effect of Lymphoid Irradiation on the Progression of Joint Damage in Intractable Rheumatoid Arthritis <i>David L. Scott, John G. Hanly, Michael Moriarty, and Barry Bresnihan</i> .....	146
Impotence in Scleroderma <i>Marie Mannino and Catherine Marino</i> .....	148
Diflunisal-Associated Thrombocytopenia in a Patient with Rheumatoid Arthritis <i>Arthur M. Bobrove</i> .....	148
Sural Nerve Biopsy in Systemic Necrotizing Vasculitis <i>James R. Davidson and Walter R. Sundstrom</i> .....	149
Comment on the Article by Lahita et al <i>Daniel J. Wallace</i> .....	150
Reply <i>Robert G. Lahita, H. Leon Bradlow, Songya Pang, Maria New, and Ellen Ginzler</i> .....	151
Comment on the Article by Hasselbacher <i>Stephen L. Schechter</i> .....	152
A Description of Rheumatology Practice II <i>L. A. Healey, Harvey E. Golden, Herbert Kaplan, and Paulding Phelps</i> .....	152
ARA Announcements .....	A50

## VOLUME 31

## JANUARY SUPPLEMENT

## NO. 1

1987 Regional Meetings of the American Rheumatism Association .....	R1
1987 Regional Meetings of the Arthritis Health Professions Association.....	R55

## VOLUME 31

## FEBRUARY

## NO. 2

Current Comment: Erythrocyte Complement Receptor Type 1, Immune Complexes, and the Rheumatic Diseases <i>Mark J. Walport and Peter J. Lachmann</i> .....	153
Identification of Brain Lesions in Neuropsychiatric Systemic Lupus Erythematosus by Magnetic Resonance Scanning <i>W. Joseph McCune, Anne MacGuire, Alex Aisen, and Stephen Gebarski</i> .....	159
Long-Term Prospective Trial of Low-Dose Methotrexate in Rheumatoid Arthritis <i>Michael E. Weinblatt, David E. Trentham, Patricia A. Fraser, Donald E. Holdsworth, Kenneth R. Falchuk, Barbara N. Weissman, and Jonathan S. Coblyn</i> .....	167

<b>Inhibition of In Vitro Proliferative Response of Cultured T Lymphocytes to Interleukin-2 by Gold Sodium Thiomalate</b>	
<i>Robert E. Wolf and Vicky C. Hall</i> .....	176
<b>Tenderness in 75 Anatomic Sites: Distinguishing Fibromyalgia Patients from Controls</b>	
<i>Robert W. Simms, Don L. Goldenberg, David T. Felson, and John H. Mason</i> .....	182
<b>The Terminal Complement Complex, C5b-9, A Marker of Disease Activity in Patients with Systemic Lupus Erythematosus</b>	
<i>Maria S. Gawryl, David S. Chudwin, Paul F. Langlois, and Thomas F. Lint</i> .....	188
<b>Clinical Correlations and Prognosis Based on Serum Autoantibodies in Patients with Systemic Sclerosis</b>	
<i>Virginia D. Steen, Donald L. Powell, and Thomas A. Medsger, Jr.</i> .....	196
<b>Radiographic Assessment and Psychologic Variables as Predictors of Pain and Functional Impairment in Osteoarthritis of the Knee or Hip</b>	
<i>Mary N. Summers, William E. Haley, John D. Reveille, and Graciela S. Alarcón</i> .....	204
<b>An Enzymatically Induced Structural Transformation in Articular Cartilage: Its Significance with Respect to Matrix Breakdown</b>	
<i>Neil D. Broom</i> .....	210
<b>The AI/RHEUM Knowledge-Based Computer Consultant System in Rheumatology: Performance in the Diagnosis of 59 Connective Tissue Disease Patients from Japan</b>	
<i>James F. Porter, Lawrence C. Kingsland, III, Donald A. B. Lindberg, Indravadan Shah, James M. Benge, Susan E. Hazelwood, Donald R. Kay, Mitsuo Homma, Masashi Akizuki, Makoto Takano, and Gordon C. Sharp</i> .....	219
<b>Anti-Ro (SS-A) Antibodies from Ro (SS-A)-Immunized Mice</b>	
<i>Myra O. Rosario, Owen F. Fox, Eugen Koren, and John B. Harley</i> .....	227
<b>Stimulation of Rabbit Synoviocyte Prostaglandin E<sub>2</sub> Synthesis by Lipopolysaccharides and Their Subunit Structures</b>	
<i>Ralph J. Rothenberg, Douglas England, Nilofer Qureshi, and Kuni Takayama</i> .....	238
<b>Evidence that a Humoral Immune Response to Autologous Cartilage Proteoglycan Can Participate in the Induction of Cartilage Pathology</b>	
<i>Thomas F. Kresina, Jung U. Yoo, and Victor M. Goluberg</i> .....	248
<b>Articular Responses to Purified Cartilage Proteoglycans</b>	
<i>Raymond J. Boniface, Paul R. Cain, and Christopher H. Evans</i> .....	258
<b>Brief Reports</b>	
<b>Stability of Normal Joint Findings in Persistent Classic Rheumatoid Arthritis</b>	
<i>W. Neal Roberts, Lawren H. Daltroy, and Ronald J. Anderson</i> .....	267
<b>Acquired Immunodeficiency Syndrome Mimicking Sjögren's Syndrome and Systemic Lupus Erythematosus</b>	
<i>Luc S. de Clerck, Marie M. Couttenye, Marc E. de Broe, and Wim J. Stevens</i> .....	272
<b>Arthritis in Patients with Psoriasis is Associated with an Immunoglobulin Gene Polymorphism</b>	
<i>L. I. Sakkas, A. G. Demaine, G. S. Panayi, and K. I. Welsh</i> .....	276
<b>Human Parvovirus B19 DNA in Synovial Fluid</b>	
<i>B. A. C. Dijkmans, A. M. W. van Elsacker-Niele, M. M. M. Salimans, G. A. van Albada-Kuipers, E. de Vries, and H. T. Weiland</i> .....	279
<b>Synovial Complications of Spondyloepiphyseal Dysplasia of Late Onset</b>	
<i>P. N. Sambrook, J. P. de Jager, G. D. Champion, B. D. Doust, E. E. McGirr, K. S. Kozłowski, and D. O. Sillence</i> .....	282
<b>Degenerative Spondylolisthesis, Synovial Cyst of the Zygapophyseal Joints, and Sciatic Syndrome: Report of Two Cases and Review of the Literature</b>	
<i>Pierre Reust, Daniel Wendling, René Lazier, Gérard Pageaut, Alain Reverdin, Guy Jacquet, Michel Guidet, and Georges H. Fallet</i> .....	288
<b>Clostridial Septic Arthritis: Case Report and Review of the Literature</b>	
<i>Douglas J. Fauser and Joseph D. Zuckerman</i> .....	295
<b>Letters</b>	
<b>On the Treatment of Rheumatoid Arthritis with M&amp;Ms (Motrin &amp; Methotrexate)</b>	
<i>Israeli A. Jaffe</i> .....	299
<b>Immune Thrombocytopenia in Association with Oral Gold Treatment</b>	
<i>Flavia M. Cicuttini, James S. Wiley, and Kevin J. Fraser</i> .....	299
<b>Wegener's Granulomatosis with Acute Pericardial Tamponade</b>	
<i>Nancy L. Meryhew, Robert J. Bache, and Ronald P. Messner</i> .....	300



Lupus Anticoagulant, Anti-Ro (SS-A) Antibodies, and Fetal Wastage in Systemic Lupus Erythematosus <i>Oswaldo Hubscher, Alicia Eimon, Roberto M. Arana, and Dardo A. Riveros</i> .....	302
Episodic Polyarthralgia Associated with Hashimoto's Thyroiditis <i>Thomas Hunter, Ian M. Chalmers, W. James Dube, and Maria-Louise Schroeder</i> .....	303
Comment on the Article by Breedveld et al <i>Graciela S. Alarcón</i> .....	304
ARA Announcements .....	A22

## VOLUME 31

## MARCH

## NO. 3

Current Comment: Methotrexate in Rheumatoid Arthritis <i>Daniel E. Furst and Joel M. Kremer</i> .....	305
The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis <i>Frank C. Arnett, Steven M. Edworthy, Daniel A. Bloch, Dennis J. McShane, James F. Fries, Norman S. Cooper, Louis A. Healey, Stephen R. Kaplan, Matthew H. Liang, Harvinder S. Luthra, Thomas A. Medsger, Jr., Donald M. Mitchell, David H. Neustadt, Robert S. Pinals, Jane G. Schaller, John T. Sharp, Ronald L. Wilder, and Gene G. Hunder</i> .....	315
Antibodies to Types I, II, IX, and XI Collagen in the Serum of Patients with Rheumatic Diseases <i>Guyène Charrière, Daniel J. Hartmann, Eric Vignon, Marie-Claire Ronzière, Daniel Herbage, and Gérard Ville</i> .....	325
Abnormal Glycosylation of Serum IgG from Patients with Chronic Inflammatory Diseases <i>Milan Tomana, Ralph E. Schrohenloher, William J. Koopman, Graciela S. Alarcón, and William A. Paul</i> .....	333
Arthritis-Associated Changes in Flow Cytometric Characteristics of Cultured Synovial Fibroblasts <i>Erkki Eerola, Kari Pulkki, Lauri J. Pelliniemi, Kaisa Granfors, Eero Vuorio, and Auli Toivanen</i> .....	339
The Importance of Age, Education, and Comorbidity in the Substantial Earnings Losses of Individuals with Symmetric Polyarthritis <i>Jean M. Mitchell, Richard V. Burkhauser, and Theodore Pincus</i> .....	348
Lupus Pregnancy: A Prospective Study of Placental Changes <i>John G. Hanly, Dafna D. Gladman, Toby H. Rose, Carl A. Laskin, and Murray B. Urowitz</i> .....	358
DNA Sequence and Conformation Specificity of Lupus Autoantibodies: Preferential Binding to the Left-Handed Z-DNA Form of Synthetic Polynucleotides <i>T. J. Thomas, Nancy L. Meryhew, and Ronald P. Messner</i> .....	367
Clinical Associations of Anticentromere Antibodies and Antibodies to Topoisomerase I: A Study of 355 Patients <i>E. S. Weiner, W. C. Earnshaw, J.-L. Senécal, B. Bordwell, P. Johnson, and N. F. Rothfield</i> .....	378
Autoantibodies to Mitochondria in Systemic Sclerosis: Frequency and Characterization Using Recombinant Cloned Autoantigen <i>David R. Fregeau, Patrick S. C. Leung, Ross L. Coppel, L. Jane McNeilage, Thomas A. Medsger, Jr., and M. Eric Gershwin</i> .....	386
Renal Vascular Histology and Morphometry in Systemic Sclerosis: A Case-Control Autopsy Study <i>David C. Trostle, Carlos D. Bedetti, Virginia D. Steen, M. Kadwan Al-Sabbagh, Benny Zee, and Thomas A. Medsger, Jr.</i> .....	393
Enhanced Production of Interleukin-2 in Patients with Progressive Systemic Sclerosis: Hyperactivity of CD4-Positive T Cells? <i>Hisanori Umehara, Shunichi Kumagai, Hiroshi Ishida, Toshihiko Suginoishi, Michiyuki Maeda, and Hiroo Imura</i> .....	401
Synovial Fluid Inorganic Pyrophosphate Concentration and Nucleotide Pyrophosphohydrolase Activity in Basic Calcium Phosphate Deposition Arthropathy and Milwaukee Shoulder Syndrome <i>John W. Rachow, Lawrence M. Ryan, Daniel J. McCarty, and Paul C. Halverson</i> .....	408
Encapsulation of Indomethacin in Liposomes Provides Protection Against Both Gastric and Intestinal Ulceration When Orally Administered to Rats <i>Ellen C. Soehngen, Evelyn Godin-Ostro, Francis G. Fielder, Richard S. Ginsberg, Michael A. Slusher, and Alan L. Weiner</i> .....	414

## Brief Reports

The Relationship of Socioeconomic Status to Subsequent Health Status in Systemic Lupus Erythematosus <i>John M. Esdaile, John S. Sampalis, Diane Lacaille, and Deborah Danoff</i> .....	423
Epidemiology of Reiter's Syndrome in Rochester, Minnesota: 1950-1980 <i>Clement J. Michet, E. B. V. Machado, David J. Ballard, and Charles H. McKenna</i> .....	428
Common Tests for Rheumatoid Factors: Poorly Standardized But Ubiquitous <i>David H. Goddard and Mary E. Moore</i> .....	432
Some Adverse Reactions to Allopurinol May Be Mediated by Lymphocyte Reactivity to Oxypurinol <i>B. T. Emmerson, R. A. Hazelton, and I. H. Frazer</i> .....	436
Tibialis Posterior Tendon Rupture: A Cause of Rheumatoid Flat Foot <i>Daniel J. Downey, Peter A. Simkin, Laurence A. Mack, Michael L. Richardson, Ray F. Kilcoyne, and Sigvard T. Hansen</i> .....	441
Spinal Cord Compression by Epidural Lipomatosis in Juvenile Rheumatoid Arthritis <i>Ivonne L. Arroyo, Karyl S. Barron, and Earl J. Brewer, Jr.</i> .....	447
<b>Letters</b>	
Ossification of the Posterior Longitudinal Ligament in Ankylosing Spondylitis <i>Ignazio Olivieri, Donatella Trippi, Gabriele Gemignani, Giampiero Pasero, and Rossella Grazzini</i> ..	452
Regarding the Ankylosing Spondylitis/Klebsiella/HLA-B27 Problem: More Inconclusive Proof! <i>Vivienne R. Winrow, J. R. Archer, and Diane J. Mitchell</i> .....	453
Reply to Letter by Winrow et al <i>John S. Sullivan, Andrew F. Geczy, and John K. Prendergast</i> .....	453
Reply to Letter by Winrow et al <i>A. Toubert and B. Amor</i> .....	454
Treatment of Gold-Induced Thrombocytopenia with High-Dose Gamma Globulin <i>Michael Stein, Kenneth B. Miller, and Raymond E. H. Partridge</i> .....	454
The Effect of Nalidixic Acid, Cinoxacin, and $\beta$ -Cyanoalanine on Cultured Chondrocytes <i>Leon J. Atencia, Leon Sokoloff, and Renate D. Kimbrough</i> .....	455
ARA Announcements .....	A29

VOLUME 31

APRIL

NO. 4

Evidence for the Presence of Autoantibodies to the Collagen-Like Portion of C1q in Systemic Lupus Erythematosus <i>Ursula Antes, Hans-Peter Heinz, and Michael Loos</i> .....	457
Cyclophosphamide-Induced Bladder Toxicity in Wegener's Granulomatosis <i>Thomas J. Stillwell, Ralph C. Benson, Jr., Richard A. DeRemee, Thomas J. McDonald, and Louis H. Weiland</i> .....	465
Team Versus Non-Team Outpatient Care in Rheumatoid Arthritis: A Comprehensive Outcome Evaluation Including an Overall Health Measure <i>Monica Ahlmen, Marianne Sullivan, and Anders Bjelle</i> .....	471
Augmented Interleukin-1 Production and HLA-DR Expression in the Synovium of Rheumatoid Arthritis Patients: Possible Involvement in Joint Destruction <i>Nobuyuki Miyasaka, Kazuto Sato, Makoto Goto, Minoru Sasano, Motonobu Natsuyama, Kazuhiko Inoue, and Kuzuki Nishioka</i> .....	480
Spirochetal Antigens and Lymphoid Cell Surface Markers in Lyme Synovitis: Comparison with Rheumatoid Synovium and Tonsillar Lymphoid Tissue <i>Allen C. Steere, Paul H. Duray, and Eugene C. Butcher</i> .....	487
Two Ro (SS-A) Autoantibody Responses in Systemic Lupus Erythematosus: Correlation of HLA-DR/DQ Specificities with Quantitative Expression of Ro (SS-A) Autoantibody <i>Robert G. Hamilton, John B. Harley, Wilma B. Bias, Marianne Roebber, Morris Reichlin, Marc C. Hochberg, and Frank C. Arnett</i> .....	496
Quantitative Immunoassay of Anti-La Antibodies Using Purified Recombinant La Antigen <i>E. William St. Clair, David S. Pisetsky, Charles F. Reich, Jasmine C. Chambers, and Jack D. Keene</i> .....	506
Antibody to Threonyl-Transfer RNA Synthetase in Myositis Sera <i>Ira N. Targoff, Frank C. Arnett, and Morris Reichlin</i> .....	515

Correlates Between Autoantibodies to Nucleolar Antigens and Clinical Features in Patients with Systemic Sclerosis (Scleroderma)	
<i>Georg Reimer, Virginia D. Steen, Carol A. Penning, Thomas A. Medsger, Jr., and Eng M. Tan ....</i>	525
Ten-Year Followup Study of Patients with <i>Yersinia</i> Arthritis	
<i>Marjatta Leirisalo-Repo and Hannu Suoranta.....</i>	533
Progressive Depletion of Hyaluronic Acid in Early Experimental Osteoarthritis in Dogs	
<i>Daniel Henri Manicourt and Julio Cesar Pita .....</i>	538
Brief Reports	
Interstitial Pneumonitis in Antinuclear Antibody-Negative Systemic Lupus Erythematosus: A New Clinical Manifestation and Possible Association with Anti-Ro (SS-A) Antibodies	
<i>Madelaine T. Hedgpeth and Dennis W. Boulware .....</i>	545
Effects of Warming Up on Reliability of Anthropometric Techniques in Ankylosing Spondylitis	
<i>W. Neal Roberts, Matthew H. Liang, Lorna M. Pallozzi, and Lawren H. Daltroy .....</i>	549
Identification of Cartilage Matrix Glycoprotein in Synovial Fluid in Human Osteoarthritis	
<i>Rose S. Fife.....</i>	553
Increase in Levels of Serum Keratan Sulfate Following Cartilage Proteoglycan Degradation in the Rabbit Knee Joint	
<i>James M. Williams, Colleen Downey, and Eugene J.-M. A. Thonar .....</i>	557
Spontaneous Cartilage Degeneration in Guinea Pigs	
<i>A. M. Bendele and J. F. Hulman .....</i>	561
Hairy Cell Leukemia Presenting as a Lupus-Like Illness	
<i>Roger W. Strickland, Alex Limmani, James G. Wall, and Jayashree Krishnan .....</i>	566
Special Article: Winners of the 1987 Slide Competition and Future Plans for the Clinical Teaching Slide Collection on the Rheumatic Diseases	
<i>Sidney Block and the ARA Audiovisual Aids Subcommittee.....</i>	569
Letters	
Monarthritis Revealing Non-Hodgkin's T Cell Lymphoma of the Synovium	
<i>Xavier Mariette, Anne de Roquancourt, Marie-Françoise d'Agay, Christian Gisselbrecht, Jean-Pierre Clauvel, and Eric Oksenhendler .....</i>	571
Comment on the Article by Fronek et al	
<i>B. P. Wordsworth.....</i>	572
Reply	
<i>Zdenka Fronek, Peter H. Schur, and J. G. Seidman.....</i>	573
Wilson's Disease Presenting as Isolated Arthritis of the Hip	
<i>Gilles Lugassy, Joseph Michaeli, and Ran Oren .....</i>	573
Comment on the Article by Myers et al	
<i>Robert W. Hoffman .....</i>	575
Complications of Oral Contraceptives and Antiphospholipid Antibodies: Reply to the Letter by Bruneau et al	
<i>Ronald A. Asherson, E. Nigel Harris, Graham R. V. Hughes, and Roy G. Farquharson.....</i>	575
ARA Announcements .....	A22

## VOLUME 31

## APRIL SUPPLEMENT

NO. 4

52nd Annual Meeting of the American Rheumatism Association .....	S1
23rd Annual Meeting of the Arthritis Health Professions Association.....	S146

## VOLUME 31

## MAY

NO. 5

A Long-Term Prospective Study of the Use of Methotrexate in Rheumatoid Arthritis: Update After a Mean of Fifty-Three Months	
<i>Joel M. Kremer and Joong K. Lee .....</i>	577
Effects of Fasting on Disease Activity, Neutrophil Function, Fatty Acid Composition, and Leukotriene Biosynthesis in Patients with Rheumatoid Arthritis	
<i>Ingäld Hafström, Bo Ringertz, Hans Gyllenhammar, Jan Palmblad, and Mats Harms-Ringdahl .....</i>	585

<b>Pain Management in Rheumatoid Arthritis Patients: A Cognitive-Behavioral Approach</b> <i>Jerry C. Parker, Robert G. Frank, Niels C. Beck, Karen L. Smarr, Keith L. Buescher, Les R. Phillips, Elaine I. Smith, Sharon K. Anderson, and Sara E. Walker</i> .....	593
<b>Reduced Mandibular Dimensions and Asymmetry in Juvenile Rheumatoid Arthritis: Pathogenetic Factors</b> <i>Anne E. Stabrun, Tore A. Larheim, Hans M. Höyeraal, and Marek Rösler</i> .....	602
<b>The Use of Methotrexate in Steroid-Resistant Systemic Lupus Erythematosus</b> <i>R. J. Rothenberg, F. M. Graziano, J. T. Grandone, J. W. Goldberg, D. F. Bjarnason, and A. G. Finesilver</i> .....	612
<b>A Recombinant Autoantigen Derived from the Human (U1) Small Nuclear RNP-Specific 68-kd Protein: Expression in <i>Escherichia coli</i> and Serodiagnostic Application</b> <i>Hans Jürgen Netter, Hans Herbert Guldner, Carin Szostecki, Heinz-Jürgen Lakomek, and Hans Will</i> .....	616
<b>Antineurofilament Antibody Evaluation in Neuropsychiatric Systemic Lupus Erythematosus: Combination with Anticardiolipin Antibody Assay and Magnetic Resonance Imaging</b> <i>Mark L. Robbins, Steven E. Kornguth, Carolyn L. Bell, Tom Kalinke, Douglas England, Patrick Turski, and Frank M. Graziano</i> .....	623
<b>Increased Levels of Plasma Anaphylatoxins in Systemic Lupus Erythematosus Predict Flares of the Disease and May Elicit Vascular Injury in Lupus Cerebritis</b> <i>Patricia Hopkins, H. Michael Belmont, Jill Buyon, Mark Philips, Gerald Weissmann, and Steven B. Abramson</i> .....	632
<b>B Cells Expressing CD5 are Increased in Sjögren's Syndrome</b> <i>Michael Dauphinée, Zair Tovar, and Norman Talal</i> .....	642
<b>Serum Keratan Sulfate Levels in Osteoarthritis Patients</b> <i>M. Barry E. Sweet, Angelina Coelho, Christine M. Schnitzler, Thomas J. Schnitzer, Mary Ellen Lenz, Itzhak Jakim, Klaus E. Kuettner, and Eugene J.-M. A. Thonar</i> .....	648
<b>Activation of Rat Synovium by Iron</b> <i>Maria de Sousa, Roselynn Dynesius-Trentham, Fernando Mota-Garcia, Manuel Teixeira da Silva, and David E. Trentham</i> .....	653
<b>Brief Reports</b>	
<b>Comparison of Parotid and Minor Salivary Gland Biopsy Specimens in the Diagnosis of Sjögren's Syndrome</b> <i>Christopher M. Wise, Carlos A. Agudelo, Elliott L. Semble, Thomas E. Stump, and Ralph D. Woodruff</i> .....	662
<b>Frequency of Infection among Patients with Rheumatoid Arthritis Versus Patients with Osteoarthritis or Soft Tissue Rheumatism</b> <i>G. A. van Albada-Kuipers, J. Linthorst, E. A. J. Peeters, F. C. Breedveld, B. A. C. Dijkmans, J. Hermans, J. P. Vandenbroucke, and A. Cats</i> .....	667
<b>Immunologic Dysfunction in Scleroderma: Evidence for Increased Mast Cell Releasability and HLA-DR Positivity in the Dermis</b> <i>Mark E. Pearson, J. Clark Huff, Ralph C. Giorno, Sucheelar Panicheewa, Henry N. Claman, and James C. Steigerwald</i> .....	672
<b>Polymyalgia Rheumatica: A Syndrome Associated With HLA-DR4 Antigen</b> <i>Maria-Cinta Cid, Guadalupe Ercilla, Jaume Vilaseca, Raimon Sanmarti, Jaume Villalta, Miguel Ingelmo, and Alvaro Urbano-Marquez</i> .....	678
<b>Successful Management of Catastrophic Gastrointestinal Involvement in Polyarteritis Nodosa</b> <i>David R. Karp, Owen S. Kantor, John D. Halverson, and John P. Atkinson</i> .....	683
<b>Dose-Dependent Induction of Anti-Native DNA Antibodies in Cats by Propylthiouracil</b> <i>David P. Aucoin, Robert L. Rubin, Mark E. Peterson, Marcus M. Reidenberg, Dennis E. Drayer, Arthur I. Hurvitz, and Robert G. Lahita</i> .....	688
<b>Letters</b>	
<b>High-Dose Intravenous Cyclophosphamide Treatment of Systemic Lupus Erythematosus-Associated Aplastic Anemia</b> <i>Anne Winkler, Robert W. Jackson, Donald S. Kay, Edith Mitchell, Sharon Carmignani, and Gordon C. Sharp</i> .....	693
<b>Systemic Lupus Erythematosus in a Patient Previously Diagnosed as Having Shulman Disease</b> <i>Edward M. Sills</i> .....	694
<b>Riboflavin-Responsive Multiple Acyl Coenzyme A Dehydrogenase Deficiency Presenting as a Proximal Myopathy in a Young Adult</b> <i>Gary S. Gilkeson and David S. Caldwell</i> .....	695
<b>ARA Announcements</b> .....	A32



Neonatal Lupus Risk to Newborns of Mothers with Systemic Lupus Erythematosus <i>Michael D. Lockshin, Eloisa Bonfa, Keith Elkon, and Maurice L. Druzin</i> .....	697
A Controlled Trial Comparing Sulfasalazine, Gold Sodium Thiomalate, and Placebo in Rheumatoid Arthritis <i>H. J. Williams, J. R. Ward, S. L. Dahl, D. O. Clegg, R. F. Willkens, T. Oglesby, M. H. Weisman, S. Schlegel, R. M. Michaels, M. E. Luggen, R. P. Polisson, J. Z. Singer, S. M. Kantor, J. B. Shiroky, R. E. Small, M. I. Gomez, J. C. Reading, and M. J. Egger</i> .....	702
A Model of Health Status for Rheumatoid Arthritis: A Factor Analysis of the Arthritis Impact Measurement Scales <i>John H. Mason, Jennifer J. Anderson, and Robert F. Meenan</i> .....	714
What are We Measuring? An Examination of Self-Reported Functional Status Measures <i>Jane Sinden Spiegel, Barbara Leake, Timothy M. Spiegel, Harold E. Paulus, Robert L. Kane, Nancy B. Ward, and John E. Ware, Jr.</i> .....	721
Soluble Interleukin-2 Receptors in Systemic Lupus Erythematosus <i>Robert E. Wolf and William G. Brelsford</i> .....	729
Molecular Heterogeneity of Complement Component C4-Null and 21-Hydroxylase Genes in Systemic Lupus Erythematosus <i>Rose Goldstein, Frank C. Arnett, Robert H. McLean, Wilma B. Bias, and Madeleine Duvic</i> .....	736
Trends in Incidence and Clinical Presentation of Temporal Arteritis in Olmsted County, Minnesota, 1950-1985 <i>E. B. V. Machado, Clement J. Michet, David J. Ballard, Gene G. Hunder, C. Mary Beard, Chu-Pin Chu, and W. Michael O'Fallon</i> .....	745
Chondrocalcinosis in Surgically Resected Joints <i>Leon Sokoloff and Andre A. Varma</i> .....	750
Use of T Cell Cloning to Detect In Vivo Mutations Induced by Cyclophosphamide <i>Robert G. Palmer, Caroline A. Smith-Burchnell, Bryan K. Pelton, Winsome Hylton, and A. Michael Denman</i> .....	757
Aminobisphosphonate Inhibition of Interleukin-1-Induced Bone Resorption in Mouse Calvariae <i>Paul L. J. Tan, June M. Katz, Ruth Ames, David E. Caughey, Harley D. Gray, H. Kaye Ibbertson, and James D. Watson</i> .....	762
Adjuvant-Induced Polyarthritis: Synovial Cell Activation Prior to Polyarthritis Onset <i>Juan Pedro López-Bote, Carmelo Bernabeu, Alberto Marquet, Jesús M. Fernández, and Vicente Larraga</i> .....	769
Brief Reports	
Antibodies Against Native Type II Collagen Do Not Precede the Clinical Onset of Rheumatoid Arthritis <i>Timo Möttönen, Pekka Hannonen, Martti Oka, Jaakko Rautiainen, Ilmari Jokinen, Heikki Arvilommi, Timo Palosuo, and Kimmo Aho</i> .....	776
Synovial Fluid Lymphocytes in Different Subtypes of Juvenile Rheumatoid Arthritis <i>Ville Bergroth, Yrjö T. Kontinen, Pirkko Pelkonen, Mervi Haapala, Jarkko Haapasaari, Dan Nordström, Ilkka Kunnamo, and Claes Friman</i> .....	780
Interleukin-6 in Synovial Fluid and Serum of Patients with Rheumatoid Arthritis and Other Inflammatory Arthritides <i>Frédéric A. Houssiau, Jean-Pierre Devogelaer, Jo Van Damme, Charles Nagant de Deuxchaisnes, and Jacques Van Snick</i> .....	784
Repeat Radiation Synovectomy with Dysprosium 165-Ferric Hydroxide Macroaggregates in Rheumatoid Knees Unresponsive to Initial Injection <i>Michael Vella, Joseph D. Zuckerman, Sonya Shortkroff, Prasanna Venkatesan, and Clement B. Sledge</i> .....	789
Costochondral Involvement in Systemic Candidiasis in Heroin Addicts: Clinical, Scintigraphic, and Histologic Features in 26 Patients <i>J. M. Miro, M. A. Brancos, R. Abello, F. Lomena, J. Bisbe, T. Ribalta, and J. Rotes-Querol</i> .....	793
Apophyseal Arthritis Limits Lumbar Motion in Patients with Ankylosing Spondylitis <i>Peter A. Simkin, Daniel J. Downey, and Ray F. Kilcoyne</i> .....	798
Comparison of Parenteral Adrenocorticotrophic Hormone with Oral Indomethacin in the Treatment of Acute Gout <i>David Axelrod and Stafford Preston</i> .....	803

Neuromuscular Histopathology in (New Zealand Black × New Zealand White) $F_1$ and MRL- <i>lpr/lpr</i> Autoimmune Mice: Models for Skeletal Muscle Involvement in Connective Tissue Disease Neil L. Rosenberg .....	806
<b>Letters</b>	
Thromboangiitis Obliterans (Buerger's Disease) and Smokeless Tobacco J. T. Lie .....	812
Tophi on the Lymphedematous Foot of a Normouricemic Man Thomas Hunter and David R. Burdge .....	813
Recurrent Ibuprofen-Induced Aseptic Meningitis: Third Episode After Only 200 Mg of Generic Ibuprofen Mark A. Durbach, James Freeman, and H. Ralph Schumacher, Jr. ....	813
Arthritis of the Knees in B Cell Chronic Lymphocytic Leukemia: A Patient with Immunologic Evidence of B Lymphocytic Synovial Infiltration Frédéric Gagnerie, Bruno Taillan, Liana Euller-Ziegler, Jean Kermarec, Francisque Commandre, and Gérard Ziegler .....	815

## VOLUME 31

## JULY

## NO. 7

Current Comment: Measurement of Systemic Lupus Erythematosus Activity in Clinical Research Matthew H. Liang, Steven A. Socher, W. Neal Roberts, and John M. Esdaile .....	817
Deficient Phytohemagglutinin-Induced Interleukin-2 Activity in Patients with Inactive Systemic Lupus Erythematosus is Correctable by the Addition of Phorbol Myristate Acetate Yohko Murakawa and Tsuyoshi Sakane .....	826
Network Regulation in Rheumatoid Arthritis: Studies of DR+ T Cells, Anti-DR, Antiidiotypic Antibodies, and Clinical Disease Activity Robert P. Searles, Susan M. Savage, Celestyn M. Brożek, Lorraine L. Marnell, and Charles L. Hoffman .....	834
Elevated Soluble Interleukin-2 Receptor Levels in the Sera and Synovial Fluids of Patients with Rheumatoid Arthritis E. C. Keystone, K. M. Snow, C. Bombardier, Chi-Hsing Chang, D. L. Nelson, and L. A. Rubin ..	844
Treatment of Lupus Nephritis with Total Lymphoid Irradiation: Observations During a 12-79-Month Followup Samuel Strober, M. Carmen Fariñas, Elizabeth H. Field, Jose J. Solovera, Bryce A. Kiberd, Bryan D. Myers, and Richard T. Hoppe .....	850
Dyslipoproteinemia in Pediatric Systemic Lupus Erythematosus Norman T. Ilowite, Paul Samuel, Ellen Ginzler, and Marc S. Jacobson .....	859
Hybridoma Lupus Autoantibodies Can Bind Major Cytoskeletal Filaments in the Absence of DNA-Binding Activity Jean-Luc Senécal and Joyce Rauch .....	864
Correlates of a Clinical Classification Schema for the Arthritis Helplessness Subscale Mitchell J. Stein, Kenneth A. Wallston, Perry M. Nicassio, and Nancy M. Castner .....	876
Synovial Fluid Collagenase in Patients with Destructive Arthritis of the Shoulder Joint P. A. Dieppe, T. Cawston, E. Mercer, G. V. Campion, J. Hornby, C. W. Hutton, M. Doherty, I. Watt, A. D. Woolf, and B. Hazleman .....	882
Radial and Spinal Bone Mineral Density in a Patient Population Richard B. Mazess, Howard S. Barden, and Mark Ettinger .....	891
Morphologic Characteristics of Developing Osteoarthrotic Lesions in the Knee Cartilage of STR/IN Mice Michael Schünke, Bernhard Tillmann, Martina Brück, and Wolfgang Müller-Ruchholtz .....	898
<b>Brief Reports</b>	
The Effects of Leucovorin (Folinic Acid) on Methotrexate Therapy in Rheumatoid Arthritis Patients Moshe Tishler, Dan Caspi, Beno Fishel, and Michael Yaron .....	906
Peripheral Lymphocyte Depletion in Gold Sodium Thiomalate-Treated Rheumatoid Arthritis Patients Max S. Lundberg, Grant W. Cannon, and John R. Ward .....	909
Synovial Lymphocyte Response to Chlamydial Stimulation Associated with Intrasyovial Chlamydial Antigen in a Patient with "Rheumatoid Arthritis" Denys K. Ford, Graham D. Reid, Sathish Magge, and H. Ralph Schumacher .....	914
Clinical Assessment of Atlantoaxial Instability Using the Sharp-Purser Test Gregory Uitvlugt and Samuel Indenbaum .....	918

Phenothiazine-Induced Systemic Lupus Erythematosus with Superior Vena Cava Syndrome: Case Report and Review of the Literature <i>Virginia D. Steen and Rosalind Ramsey-Goldman</i> .....	923
Bromocriptine Suppresses Postpartum Exacerbation of Collagen-Induced Arthritis <i>A. Whyte and R. O. Williams</i> .....	927
In Memoriam: James Carl Steigerwald .....	929
Letters	
<i>Strongyloides stercoralis</i> Hyperinfection Mimicking Systemic Lupus Erythematosus Flare <i>Avi Livneh, Eugene A. Coman, Sangho Cho, and Esther Lipstein-Kresch</i> .....	930
Acute Periarthritis in a Patient with Infectious Mononucleosis <i>Murray Baron</i> .....	931
<i>Mycobacterium terrae</i> Tenosynovitis <i>Lisa Brandabur Kremer, Frank S. Rhame, and James H. House</i> .....	932
Old World Spondylarthropathy: The Gorilla Connection <i>Bruce M. Rothschild and Robert Woods</i> .....	934
Report of a Patient with Camptodactyly, Arthropathy, and Epiphyseal Dysplasia <i>M'Hamed Hamza, Mohamed Elleuch, Ali Ferchiou, and Amel Amara</i> .....	935
ARA Announcements .....	A22
Applications Invited for Editor, <i>Arthritis and Rheumatism</i> , 1990-1995 Term.....	A21

## VOLUME 31

## AUGUST

## NO. 8

Light and Electron Microscopic Studies on the Synovial Membrane in Reiter's Syndrome: Immunocytochemical Identification of Chlamydial Antigen in Patients with Early Disease <i>H. Ralph Schumacher, Jr., Sathish Magge, P. Varghese Cherian, Joseph Sleckman, Susan Rothfuss, Gilda Clayburne, and Marie Sieck</i> .....	937
Synovial Microenvironment-T Cell Interactions: Human T Cells Bind to Fibroblast-Like Synovial Cells in Vitro <i>Barton F. Haynes, Betty J. Grover, Leona P. Whichard, Laura P. Hale, James A. Nunley, Donald E. McCollum, and Kay H. Singer</i> .....	947
Analysis of the Histologic Variation of Synovitis in Rheumatoid Arthritis <i>Madeleine Rooney, Deborah Condell, William Quinlan, Leslie Daly, Alex Whelan, Conleth Feighery, and Barry Bresnihan</i> .....	956
Suppression of Human Fibroblast Proliferation by D-Pencillamine and Copper Sulfate In Vitro <i>Tsukasa Matsubara and Kazushi Hirohata</i> .....	964
Sex Hormone Status and Osteoporosis in Postmenopausal Women with Rheumatoid Arthritis <i>P. N. Sambrook, J. A. Eisman, G. D. Champion, and N. A. Pocock</i> .....	973
The Efficacy and Safety of Auranofin in the Treatment of Juvenile Rheumatoid Arthritis: A Long-Term Open Study <i>Roberto Marcolongo, Alessandro Mathieu, Riccarda Pala, Nicola Giordano, Antonella Fioravanti, and Rita Panzarasa</i> .....	979
Complement C4B-Null Alleles in Felty's Syndrome <i>Wendy Thomson, Paul A. Sanders, Martin Davis, Judith Davidson, Philip A. Dyer, and David M. Grennan</i> .....	984
DQB Polymorphism and Genetic Susceptibility to Felty's Syndrome <i>Alex K. L. So, Catherine A. Warner, David Sansom, and Mark J. Walport</i> .....	990
N-Acetylprocainamide is a Less Potent Inducer of T Cell Autoreactivity than Procainamide <i>Bruce Richardson, Elizabeth Cornacchia, Joseph Golbus, Jonathan Maybaum, John Strahler, and Samir Hanash</i> .....	995
Anti-IgE Autoantibodies in Systemic Lupus Erythematosus: Prevalence and Biologic Activity <i>Barry L. Gruber, Lee D. Kaufman, Mary J. Marchese, William Roth, and Allen P. Kaplan</i> .....	1000
Subacute Cutaneous Lupus Erythematosus: Clinical, Serologic, Immunogenetic, and Therapeutic Considerations in Seventy-Two Patients <i>Jeffrey P. Callen and Jon Klein</i> .....	1007
Possible Involvement of Epstein-Barr Virus in Polyclonal B Cell Activation in Sjögren's Syndrome <i>Kunio Yamaoka, Nobuyuki Miyasaka, and Kohtaro Yamamoto</i> .....	1014
Acromegalic Arthropathy: Characteristics and Response to Therapy <i>Mark W. Layton, Edward J. Fudman, Ariel Barkan, Ethan M. Braunstein, and Irving H. Fox</i> .....	1022

Distribution of Chondroitin 4-Sulfate and Chondroitin 6-Sulfate in Human Articular and Growth Cartilage <i>Paulo A. S. Mourão</i> .....	1028
<b>Brief Reports</b>	
Psoriatic Arthritis and Acquired Immunodeficiency Syndrome <i>Luis R. Espinoza, Alberto Berman, Frank B. Vasey, Cay Cahalin, Robert Nelson, and Bernard F. Germain</i> .....	1034
Detection of Tumor Necrosis Factor $\alpha$ but not Tumor Necrosis Factor $\beta$ in Rheumatoid Arthritis Synovial Fluid and Serum <i>T. Saxne, M. A. Palladino, Jr., D. Heinegård, N. Talal, and F. A. Wollheim</i> .....	1041
Modulation of Urokinase-Type Plasminogen Activator Messenger RNA Levels in Human Synovial Fibroblasts by Interleukin-1, Retinoic Acid, and a Glucocorticoid <i>Gerard Vitti and John A. Hamilton</i> .....	1046
Anticardiolipin Antibodies in Lyme Disease <i>C. G. Mackworth-Young, E. N. Harris, A. C. Steere, F. Rizvi, S. E. Malawista, G. R. V. Hughes, and A. E. Gharavi</i> .....	1052
Histologic Localization of Lipid in the Articular Tissues in Calcium Pyrophosphate Dihydrate Crystal Deposition Disease <i>Takashi Ohira, Koichiro Ishikawa, Ikuko Masuda, Mitsuru Yokoyama, and Itsuo Honda</i> .....	1057
Demonstration and Characterization of a Transient Arthritis in Rats Following Sensitization of Synovial Mast Cells with Antigen-Specific IgE and Parenteral Challenge with Specific Antigen <i>Daniel G. Malone and Dean D. Metcalfe</i> .....	1063
<b>Current Controversies in Rheumatology</b>	
The Treatment of Wegener's Granulomatosis with Trimethoprim/Sulfamethoxazole: Illusion or Vision? <i>Richard A. DeRemee</i> .....	1068
Response: The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Wegener's Granulomatosis <i>Randi Y. Leavitt, Gary S. Hoffman, and Anthony S. Fauci</i> .....	1073
<b>Letters</b>	
T Cell Immunoregulation in Rheumatoid Synovitis <i>Roberto Gerli, Alberto Bertotto, Pietro Rambotti, Paola Barbieri, M. Laura Ciompi, and Stefano Bombardieri</i> .....	1075
Adult T Cell Leukemia Presenting with Proliferative Synovitis <i>Atsuo Taniguchi, Yoshitaka Takenaka, Yumiko Noda, Yukio Ueno, Kanji Shichikawa, Kazuto Sato, Nobuyuki Miyasaka, and Kusuki Nishioka</i> .....	1076
Crohn's Disease Associated with Arthritis: A Possible Role for Cross-Reactivity Between Gut Bacteria and Cartilage in the Pathogenesis of Arthritis <i>Maries F. van den Broek, Levinus B. A. van de Putte, and Wim B. van den Berg</i> .....	1077
Thyroid Disorders are Related to Secondary Sjögren's Syndrome in Unselected Systemic Lupus Erythematosus Patients <i>Helgi Jonsson, Ola Nived, and Gunnar Sturfelt</i> .....	1079
ARA Announcements .....	A28
Applications Invited for Editor, <i>Arthritis and Rheumatism</i> , 1990-1995 Term .....	A29

## VOLUME 31

## SEPTEMBER

## NO. 9

Serum and Plasma Inhibit Neutrophil Stimulation by Hydroxyapatite Crystals: Evidence that Serum $\alpha_2$ -HS Glycoprotein is a Potent and Specific Crystal-Bound Inhibitor <i>Robert A. Terkeltaub, Denise A. Santoro, Gretchen Mandel, and Neil Mandel</i> .....	1081
In Vitro Rheumatoid Factor Synthesis in Patients Taking Second-Line Drugs for Rheumatoid Arthritis: Independent Associations with Disease Activity <i>Nancy J. Olsen, Leigh F. Callahan, and Theodore Pincus</i> .....	1090
Studies of a Common Idiotypic PR4 in Autoimmune Rheumatic Disease <i>W. Williams, A. Zumla, R. Behrens, M. Locniskar, A. Voller, K. P. W. J. McAdam, and D. A. Isenberg</i> .....	1097
Lupus Retinopathy: Patterns, Associations, and Prognosis <i>Frances J. Stafford-Brady, Murray B. Urowitz, Dafna D. Gladman, and Michael Easterbrook</i> .....	1105



Sulfasalazine in the Treatment of Ankylosing Spondylitis: A Twenty-Six-Week, Placebo-Controlled Clinical Trial	
<i>M. Nissilä, K. Lehtinen, M. Leirisalo-Repo, R. Luukkainen, O. Mutru, and U. Yli-Kerttula</i>	1111
The Diagnosis of Polyarteritis Nodosa. I. A Literature-Based Decision Analysis Approach	
<i>Daniel A. Albert, David Rimon, and Marc D. Silverstein</i>	1117
The Diagnosis of Polyarteritis Nodosa. II. Empirical Verification of a Decision Analysis Model	
<i>Daniel A. Albert, Marc D. Silverstein, Kathryn Paunicka, Geetha Reddy, Rowland W. Chang, and Charles Derus</i>	1128
A Controlled Study of the Effects of a Supervised Cardiovascular Fitness Training Program on the Manifestations of Primary Fibromyalgia	
<i>Glenn A. McCain, David A. Bell, François M. Mai, and Paul D. Halliday</i>	1135
An Evaluation of Serum Osteocalcin in Paget's Disease of Bone and Its Response to Diphosphonate Treatment	
<i>Les A. Coulton, Christopher J. Preston, Malcolm Couch, and John A. Kanis</i>	1142
Mechanisms of Joint Damage in an Experimental Model of Hemophilic Arthritis	
<i>Rajan Madhok, David Bennett, R. D. Sturrock, and Charles D. Forbes</i>	1148
Suppression of Streptococcal Cell Wall-Induced Arthritis by a Potent Protease Inhibitor, Bis(5-Amidino-2-Benzimidazolyl)Methane	
<i>J. Dieter Geratz, Katherine B. Pryzwansky, John H. Schwab, Sonia K. Anderle, and Richard R. Tidwell</i>	1156
<b>Brief Reports</b>	
HLA-B27-Associated Arthropathy in Childhood: Long-Term Clinical and Diagnostic Outcome	
<i>Kathleen A. Sheerin, Edward H. Giannini, Earl J. Brewer, Jr., and Karyl S. Barron</i>	1165
Partial C4A Deficiency is Associated with Susceptibility to Systemic Lupus Erythematosus in Black Americans	
<i>Wendell A. Wilson, Myriam C. Perez, and Patricia E. Armatis</i>	1171
High-Affinity Interleukin-2 Receptors on Blood Lymphocytes are Decreased During Active Rheumatoid Arthritis	
<i>Paul Emery, Nigel Wood, Kay Gentry, Alex Stockman, Ian R. Mackay, and Ora Bernard</i>	1176
Accelerated Nodulosis and Vasculitis During Methotrexate Therapy for Rheumatoid Arthritis	
<i>Rafael Segal, Dan Caspi, Moshe Tishler, Beno Fishel, and Michael Yaron</i>	1182
Giant Cell Inflammation Compared with Amyloidosis of the Internal Elastic Lamina in Temporal Arteries	
<i>Thos. J. Muckle</i>	1186
Reactive Arthritis Associated with <i>Shigella sonnei</i> Infection	
<i>Anneli Lauhio, Juhani Lähdevirta, Rita Janes, Sirkka Kontiainen, and Heikki Repo</i>	1190
Reversal of Progressive Necrotizing Vasculitis with Intravenous Pulse Cyclophosphamide and Methylprednisolone	
<i>John G. Fort and John L. Abruzzo</i>	1194
Livedo Reticularis and Peripheral Gangrene Associated with Primary Hyperoxaluria	
<i>Bruce A. Baethge, I. Daniel Sanusi, Michael D. Landreneau, Michael S. Rohr, and John C. McDonald</i>	1199
Editorial: Hypothesis: Rheumatoid Factors are Antiidiotypes Related to Bacterial or Viral Fc Receptors	
<i>Ralph C. Williams, Jr.</i>	1204
<b>Letters</b>	
Comment on the Article by Studenski et al	
<i>Daniel J. Wallace</i>	1208
Reply	
<i>Stephanie Studenski, Richard Polisson, and Nancy B. Allen</i>	1208
Comment on the Articles by Firestein and Zvaifler	
<i>Martin Ridley and Gabriel Panayi</i>	1209
Reply	
<i>Gary S. Firestein and Nathan J. Zvaifler</i>	1210
Severe Hemorrhage in a Patient with Circulating Anticoagulant, Acquired Hypoprothrombinemia, and Systemic Lupus Erythematosus	
<i>Peter Small</i>	1210
Anticardiolipin Antibody and Complement	
<i>Hwee-Ming Cheng, and Sook-Fan Yap</i>	1211

False-Positive Test Result for IgM Anticardiolipin Antibody Due to IgM Rheumatoid Factor <i>M. S. Agopian, F. N. Boctor, and J. B. Peter</i> .....	1212
IgM Reduction in Systemic Lupus Erythematosus <i>G. Senaldi, R. Ireland, A. J. Bellingham, D. Vergani, K. Veerapan, and F. Wang</i> .....	1213
Tenosynovitis Caused by <i>Exophiala mansonii</i> in an Immunocompromised Host <i>G. Collée, L. H. M. Verhoef, J. W. van 't Wout, P. van Brummelen, F. Eulderink, and B. A. C. Dijkmans</i> .....	1213
Erdheim-Chester Disease Associated with Hydrocalycosis and Arthropathy <i>R. Brown, R. van den Berg, N. P. Hurst, and P. W. Allen</i> .....	1215
ARA Announcements .....	A27
Applications Invited for Editor, <i>Arthritis and Rheumatism</i> , 1990-1995 Term .....	A28

## VOLUME 31

## OCTOBER

## NO. 10

ARA Presidential Address: Current Issues in Rheumatology: An Essay on the American Rheumatism Association's Future Leadership Role <i>Paulding Phelps</i> .....	1217
Heterogeneous Synthetic Phenotype of Cloned Scleroderma Fibroblasts May Be Due to Aberrant Regulation in the Synthesis of Connective Tissues <i>Theresa L. Whiteside, Marina Ferrarini, Patricia Hebda, and Robert B. Buckingham</i> .....	1221
Phenotypic Analysis of Synovial Tissue and Peripheral Blood Lymphocytes Isolated from Patients with Rheumatoid Arthritis <i>John J. Cush and Peter E. Lipsky</i> .....	1230
The Incidence of Rheumatoid Arthritis is Predicted by Rheumatoid Factor Titer in a Longitudinal Population Study <i>Antonio del Puente, William C. Knowler, David J. Pettitt, and Peter H. Bennett</i> .....	1239
Self-Evaluation Processes and Adjustment to Rheumatoid Arthritis <i>Susan J. Blalock, Brenda McEvoy DeVellis, Robert F. DeVellis, and Suzanne van H. Sauter</i> .....	1245
Temporal Patterns of Response to D-Penicillamine, Hydroxychloroquine, and Placebo in Juvenile Rheumatoid Arthritis Patients <i>Catherine van Kerckhove, Edward H. Giannini, and Daniel J. Lovell</i> .....	1252
Systemic Joint Laxity (the Hypermobile Joint Syndrome) is Associated with Temporomandibular Joint Dysfunction <i>David Harinstein, Robert B. Buckingham, Thomas Braun, K. Oral, Dorothy H. Bauman, Paul J. Killian, and Leo P. Bidula</i> .....	1259
Human Autoantibody Secreted by Immortalized Lymphocyte Cell Line Against the 68K Polypeptide of the U1 Small Nuclear Ribonucleoprotein <i>Jintao Chen, Yoshihiko Takeda, W. Eric Vanderslice, Gordon C. Sharp, Ingvar Pettersson, Anders Rosén, Hans Wigzell, and Richard J. Wang</i> .....	1265
Low-Dose Gold Compounds Inhibit Fibroblast Proliferation and Do Not Affect Interleukin-1 Secretion by Macrophages <i>Tsukasa Matsubara, Yasuhiro Saegusa, and Kazushi Hirohata</i> .....	1272
Stimulation of the Hyaluronic Acid Levels of Human Synovial Fibroblasts by Recombinant Human Tumor Necrosis Factor $\alpha$ , Tumor Necrosis Factor $\beta$ (Lymphotoxin), Interleukin-1 $\alpha$ , and Interleukin-1 $\beta$ <i>Debra M. Butler, Gerard F. Vitti, Tali Leizer, and John A. Hamilton</i> .....	1281
Effects of Recombinant Human Interleukin-1 $\beta$ on Rabbit Articular Chondrocytes: Stimulation of Prostanoid Release and Inhibition of Cell Growth <i>Jia E. Chin and Yuan Lin</i> .....	1290
Treatment with Gamma-Interferon Triggers the Onset of Collagen Arthritis in Mice <i>Nils Johan Mauritz, Rikard Holmdahl, Roland Jonsson, Peter H. Van der Meide, Annika Scheynius, and Lars Klareskog</i> .....	1297
Brief Reports	
Jaw Deformity Caused by Juvenile Rheumatoid Arthritis and its Correction <i>Robert W. T. Myall, Roger A. West, Heidi Horwitz, and Jane G. Schaller</i> .....	1305
Tuberculous Rheumatism (Poncet's Disease) in a Child <i>T. R. Southwood, E. J. Hancock, R. E. Petty, P. N. Malleon, and P. N. Thiessen</i> .....	1311
Sex Hormone Status of Male Patients with Rheumatoid Arthritis: Evidence of Low Serum Concentrations of Testosterone at Baseline and After Human Chorionic Gonadotropin Stimulation <i>Maurizio Cutolo, Enrico Balleari, Massimo Giusti, Mario Monachesi, and Silvano Accardo</i> .....	1314

Serum Immunoreactive Erythropoietin in Rheumatoid Arthritis: Impaired Response to Anemia <i>Marc C. Hochberg, Cynthia M. Arnold, Beth B. Hogans, and Jerry L. Spivak</i> .....	1318
A Novel Autoantibody Causing a Peripheral Fluorescent Antinuclear Antibody Pattern is Specific for Nuclear Pore Complexes <i>André Dagenais, Viviane Bibor-Hardy, and Jean-Luc Senécal</i> .....	1322
Special Article Report of the Committee for the Publication of <i>Arthritis and Rheumatism</i> <i>Andrew H. Kang and the American Rheumatism Association Committee for the Publication of Arthritis and Rheumatism</i> .....	1328
Letters Reference Reagents for Antinuclear Antibodies <i>E. M. Tan, T. E. W. Feltkamp, D. Alarcon-Segovia, R. L. Dawkins, M. Homma, J. R. Kalden, P. H. Lambert, A. Lange, R. N. Maini, F. C. McDuffie, J. S. McDougal, R. Norberg, and M. Wilson</i> .....	1331
Destructive Spondylarthropathy and Chronic Renal Failure <i>N. P. Hurst and R. Van den Berg</i> .....	1331
Unusual Features of Iliopsoas Bursitis <i>Simon M. Helfgott</i> .....	1331
Bromocriptine and Cyclosporin A Combination Therapy in Rheumatoid Arthritis <i>Maxime Dougados, Line Duchesne, and Bernard Amor</i> .....	1333
Reply to the Letter by Hoffman <i>Linda K. Myers, Edward J. Ball, Gabriel Nunez, and Peter Stastny</i> .....	1334
Mycosis Fungoides with Polyarthritis <i>Robert G. Berger</i> .....	1335
Book Review .....	1336
ARA Announcements.....	A9
Applications Invited for Editor, <i>Arthritis and Rheumatism</i> , 1990-1995 Term .....	A10

## VOLUME 31

## NOVEMBER

## NO. 11

Autoantibodies to Intracellular Proteins in Human Systemic Lupus Erythematosus Are Not Due to Random Polyclonal B Cell Activation <i>Azzudin E. Gharavi, Jia-Li Chu, and Keith B. Elkon</i> .....	1337
Formal Education Level as a Significant Marker of Clinical Status in Rheumatoid Arthritis <i>Leigh F. Callahan and Theodore Pincus</i> .....	1346
Serum Levels of Interleukin-2 Receptor and Activity of Rheumatic Diseases Characterized by Immune System Activation <i>David H. Campen, David A. Horwitz, Francisco P. Quismorio, Jr., Glenn R. Ehresmann, and W. John Martin</i> .....	1358
Synovial Fibroblast-Like Cells Synthesize Seven Proteins of the Complement System <i>Yitzhak Katz and Robert C. Strunk</i> .....	1365
Nonlinkage of the T Cell Receptor $\alpha$ , $\beta$ , and $\gamma$ Genes to Systemic Lupus Erythematosus in Multiplex Families <i>David W. Wong, Zvi Bentwich, Carlos Martinez-Tarquino, J. G. Seidman, Allan D. Duby, Thomas Quertermous, and Peter H. Schur</i> .....	1371
Postdysenteric Reactive Arthritis: A Clinical and Immunogenetic Study Following an Outbreak of Salmonellosis <i>R. D. Inman, M. E. A. Johnston, M. Hodge, J. Falk, and A. Helewa</i> .....	1377
Synovial Fluid Eosinophilia in Lyme Disease <i>Jonathan Kay, Andrew H. Eichenfield, Balu H. Athreya, Robert A. Doughty, and H. Ralph Schumacher, Jr.</i> .....	1384
Progressive Ankylosis in Mice: An Animal Model of Spondylarthropathy. I. Clinical and Radiographic Findings <i>Maren L. Mahowald, Hollis Krug, and Joel Taurog</i> .....	1390
Examination of Subchondral Bone Architecture in Experimental Osteoarthritis by Microscopic Computed Axial Tomography <i>Mark W. Layton, Steven A. Goldstein, Robert W. Goulet, Lee A. Feldkamp, David J. Kubinski, and Giles G. Bole</i> .....	1400

Effect of Inhibitors of Eicosanoid Metabolism in Murine Collagen-Induced Arthritis <i>Don E. Griswold, Leonard M. Hillegass, Paul C. Meunier, Michael J. DiMartino, and Nabil Hanna</i> .....	1406
Plasma and Bone Osteocalcin Levels in Rats with Type II Collagen-Induced Arthritis <i>Hiroshi Tanaka, Hiroshi Shirota, Manabu Kuwada, Kuniaki Terato, and Kouichi Katayama</i> .....	1413
Interleukin-1 Stimulation of Phospholipase Activity in Rat Synovial Fibroblasts: Possible Regulation by Cyclooxygenase Products <i>Richard W. Godfrey, William J. Johnson, and Sylvia T. Hoffstein</i> .....	1421
<b>Brief Reports</b>	
A 16/6 Idiotype-Positive Anti-DNA Antibody is Encoded by a Conserved V <sub>H</sub> Gene with No Somatic Mutation <i>Pojen P. Chen, Ming-Fei Liu, Suman Sinha, and Dennis A. Carson</i> .....	1429
A Retrospective Study of Antibodies Against Basement Membrane Antigens (Type IV Collagen and Laminin) in Patients with Primary and Secondary Raynaud's Phenomenon <i>Armando Gabrielli, Maria Montroni, Serena Rupoli, Maria Luisa Caniglia, Frank DeLustro, and Giovanni Danieli</i> .....	1432
Scleromyxedema Myopathy: Case Report and Review of the Literature <i>David J. Helfrich, E. R. Walker, A. Julio Martinez, and Thomas A. Medsger, Jr.</i> .....	1437
Lipid Microspherules in Synovial Fluid of Patients with Pigmented Villonodular Synovitis <i>Kazuhiro Ugai, Masahiro Kurosaka, and Kazushi Hirohata</i> .....	1442
Special Article: Evaluation of Clinical Competence in Rheumatology Training Programs <i>Edward D. Harris, Jr. and John A. Benson, Jr.</i> .....	1447
Government Affairs: FDA Arthritis Advisory Committee Meeting: Serious Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs; Drug-Containing Renal and Biliary Stones; Diclofenac and Carprofen Approved <i>Harold E. Paulus</i> .....	1450
<b>Letters</b>	
Comment on the Article by Summers et al <i>Igor Steiman</i> .....	1452
Are Hand Radiographs the Most Suitable for the Diagnosis of Rheumatoid Arthritis? <i>Heikki Isomäki, Kalevi Kaarela, and Jukka Martio</i> .....	1452
Reply <i>Frank C. Arnett</i> .....	1453
Intracardiac Thrombus in Systemic Lupus Erythematosus Associated with Lupus Anticoagulant <i>Willem F. Lubbe and Ronald A. Asherson</i> .....	1453
Comment on the Letter by Calin et al <i>Peter McCluskey and Denis Wakefield</i> .....	1454
Absence of Abnormal Epstein-Barr Virus Serologic Findings in Patients with Fibrositis <i>Kenneth H. Fye, Q. E. Whiting-O'Keefe, Evelyne T. Lennette, and Carol Jessop</i> .....	1455
ARA Announcements .....	A19
Applications Invited for Editor, <i>Arthritis and Rheumatism</i> , 1990-1995 Term .....	A20

## VOLUME 31

## DECEMBER

## NO. 12

Histopathologic Findings in the Liver of Rheumatoid Arthritis Patients Treated with Long-Term Bolus Methotrexate <i>Julio Aponte and Mary Petrelli</i> .....	1457
Hepatic Ultrastructure after Methotrexate Therapy for Rheumatoid Arthritis <i>David J. Bjorkman, Elizabeth H. Hammond, Randall G. Lee, Daniel O. Clegg, and Keith G. Tolman</i> .....	1465
Prostaglandin E <sub>2</sub> Modulation of Rheumatoid Factor Synthesis <i>Alejandro Alvarellos, Peter E. Lipsky, and Hugo E. Jasin</i> .....	1473
Changes in B Lymphocyte Function in Rheumatoid Arthritis and Lupus Nephritis after Total Lymphoid Irradiation <i>J. J. Solovera, M. C. Fariñas, and S. Strober</i> .....	1481



A Novel Neuronal Antigen Identified by Scra from Patients with Systemic Lupus Erythematosus <i>John G. Hanly, Selva Rajaraman, Sharon Behmann, and Judah A. Denburg</i> .....	1492
Actions of Recombinant Human $\gamma$ -Interferon and Tumor Necrosis Factor $\alpha$ on the Proliferation and Osteoblastic Characteristics of Human Trabecular Bone Cells in Vitro <i>Maxine Gowen, Brian R. MacDonald, and R. Graham G. Russell</i> .....	1500
Stimulation of Interleukin-1 $\alpha$ and Interleukin-1 $\beta$ Release from Human Monocytes by Cyanogen Bromide Peptides of Type II Collagen <i>Makoto Goto, Sadayoshi Yoshinoya, Terumasa Miyamoto, Minoru Sasano, Mashihiro Okamoto, Kusuki Nishioka, Kuniaki Terato, and Yutaka Nagai</i> .....	1508
Reduced Natural Killer Cell Activity in Patients with Systemic Sclerosis: Correlation with Clinical Disease Type <i>Edward B. Miller, John C. Hiserodt, Laverne E. Hunt, Virginia D. Steen, and Thomas A. Medsger, Jr.</i> .....	1515
The Effects of Scleroderma Serum on Human Microvascular Endothelial Cells: Induction of Antibody-Dependent Cellular Cytotoxicity <i>Rory M. Marks, Maria Czerniecki, Brian S. Andrews, and Ronald Penny</i> .....	1524
A Comparison of Cyclobenzaprine and Placebo in the Management of Fibrositis: A Double-Blind Controlled Study <i>Robert M. Bennett, Robert A. Gatter, Stephen M. Campbell, Ronald P. Andrews, Sharon R. Clark, and Joseph A. Scarola</i> .....	1535
Suppression of Monosodium Urate Crystal-Induced Acute Inflammation by Diets Enriched with Gamma-Linolenic Acid and Eicosapentaenoic Acid <i>Guillermo A. Tate, Brian F. Mandell, Rashida A. Karmali, Michael Laposata, Daniel G. Baker, H. Ralph Schumacher, Jr., and Robert B. Zurier</i> .....	1543
Brief Reports	
Acute Nonlymphocytic Leukemia Following Short-Term, Intermittent, Intravenous Cyclophosphamide Treatment of Lupus Nephritis <i>Robert B. Gibbons and Eric Westerman</i> .....	1552
Structure of T Cell Antigen Receptor $\beta$ Chain in Synovial Fluid Cells from Patients with Rheumatoid Arthritis <i>E. C. Keystone, M. Minden, R. Klock, L. Poplonski, J. Zalcberg, T. Takadera, and T. W. Mak</i> .....	1555
Assessment of Disease Activity in Essential Cryoglobulinemia by Serum Levels of a Basement Membrane Antigen, Laminin <i>Armando Gabrielli, Gabriele Marchegiani, Serena Rupoli, Giuseppina Ansuini, Dietrich G. Brocks, Giovanni Danieli, and Rupert Timpl</i> .....	1558
Sequential Development of Antibodies to Specific Sm Polypeptides in a Patient with Systemic Lupus Erythematosus: Evidence for Independent Regulation of Anti-Double-Stranded DNA and Anti-Sm Antibody Production <i>E. J. ter Borg, G. Horst, E. Hummel, D. Jaarsma, P. C. Limburg, and C. G. M. Kallenberg</i> .....	1563
HLA-DR Antigens and Anticardiolipin Antibodies in Northern Italian Systemic Lupus Erythematosus Patients <i>M. Savi, G. F. Ferraccioli, T. M. Neri, P. Zanelli, P. P. Dall'aglio, A. Tincani, G. Balestrieri, G. Carella, and R. Cattaneo</i> .....	1568
Radiologic Vignette: The Acute Neuropathic Joint <i>Anne C. Brower</i> .....	1571
Special Article: Multipurpose Arthritis Centers: A Ten-Year Progress Report <i>Bernhard H. Singesen, John B. Winfield, Kenneth D. Brandt, Naomi F. Rothfield, and Steven J. Hausman</i> .....	1574
Letters	
Comment on the Letter by Jaffe <i>David Buhner</i> .....	1584
Reply <i>Israeli A. Jaffe</i> .....	1585
Fatal Methotrexate Pneumonitis in Rheumatoid Arthritis <i>Eric D. Newman and Thomas M. Harrington</i> .....	1585
Methotrexate-Associated Bone Marrow Suppression Following Surgery <i>Walter L. Howland</i> .....	1586

Beneficial Effects of Leucovorin after Methotrexate Treatment in Rheumatoid Arthritis: A Case Report	
<i>J. Robert Polk</i> .....	1587
Multicentric Reticulohistiocytosis in a 9-Year-Old Boy	
<i>Roald Omdal, Åge Lærdal, and Kjell H. Kjellevoid</i> .....	1588
Interleukin-2 Inhibitor and Measurement of Interleukin-2 in Synovial Fluid of Patients with Rheumatoid Arthritis	
<i>Paul Emery and Ian R. Mackay</i> .....	1590
Pseudothrombophlebitis Caused by Nontraumatic Compartmental Syndrome of the Calf	
<i>Raymond Wargovich and Antonio J. Reginato</i> .....	1591
Reviewers .....	1593
Contents, Volume 31, 1988 .....	1596
Indexes .....	1613
ARA Announcements .....	A15







# AUTHOR INDEX

*Arthritis and Rheumatism*, Volume 31, Numbers 1 through 12, 1988

- A**
- Abe Y, 135  
 Abello R, 793  
 Abramson SB, 632  
 Abruzzo JL, 1194  
 Accardo S, 1314  
 Agopian MS, 1212  
 Agudelo CA, 662  
 Agusti M, 108  
 Ahlmen M, 471  
 Aho K, 776  
 Aisen A, 159  
 Akizuki M, 219  
 Alarcón GS, 204, 304, 333  
 Alarcon-Segovia D, 1331  
 Albert DA, 1117, 1128  
 Alekseev L, 15  
 Allen NB, 1208  
 Allen PW, 1215  
 Allison AC, 21  
 Al-Sabbagh MR, 393  
 Altz-Smith M, 9  
 Alvarellos A, 1473  
 Amara A, 935  
 Amengual MJ, 108  
 Ames R, 762  
 Amor B, 454, 1333  
 Anderle SK, 1156  
 Anderson JJ, 714  
 Anderson RJ, 267  
 Anderson SK, 593  
 Andréu JL, 120  
 Andrews BS, 1524  
 Andrews RP, 1535  
 Ansuini G, 1558  
 Antes U, 457  
 Aponte J, 1457  
 Arana RM, 302  
 Archer JR, 453  
 Arend WP, 929  
 Armatas PE, 1171  
 Armstrong SK, 116  
 Arnett FC, 315, 496, 515, 736, 1453  
 Arnold CM, 1318  
 Arroyo IL, 447  
 Arvilommi H, 776  
 Asherson RA, 575, 1453  
 Atencia LJ, 455  
 Athreya BH, 1384  
 Atkinson JP, 683  
 Aucoin DP, 688  
 Axelrod D, 803
- B**
- Bache RJ, 300  
 Baethge BA, 1199  
 Baker DG, 1543  
 Balestrieri G, 1568  
 Ball EJ, 1334  
 Ballard DJ, 428, 745  
 Balleari E, 1314  
 Barbieri P, 1075  
 Barden HS, 891  
 Barkan A, 1022  
 Baron M, 931  
 Barron KS, 447, 1165  
 Bauer K, 52  
 Bauman DH, 1259  
 Beard CM, 745  
 Beck NC, 593  
 Bedetti CD, 393  
 Behmann S, 1492  
 Behrens R, 1097  
 Bell CL, 623  
 Bell DA, 1135  
 Bellingham AJ, 1213  
 Belmont HM, 632  
 Bendele AM, 561  
 Bengtson JM, 219  
 Bennett D, 1148  
 Bennett PH, 1239  
 Bennett RM, 1535  
 Benson JA Jr, 1447  
 Benson RC Jr, 465  
 Bentwich Z, 1371  
 Berger RG, 1335  
 Bergroth V, 780  
 Berman A, 1034  
 Bernabeu C, 769  
 Bernaldo-de Quirós L, 120  
 Bernard O, 1176  
 Bernstein R, 131  
 Bertotto A, 1075  
 Bias WB, 496, 736  
 Bibor-Hardy V, 1322  
 Bidula LP, 1259  
 Bisbe J, 793  
 Bjarnason DF, 612  
 Bjelle A, 471  
 Bjorkman DJ, 1465  
 Black CM, 131  
 Blalock SJ, 1245  
 Bloch DA, 315  
 Block S, 569  
 Bobrove AM, 148  
 Boctor FN, 1212  
 Bole GG, 1400  
 Bombardier C, 844  
 Bombardieri S, 1075  
 Bonfa E, 697  
 Boniface RJ, 258  
 Bordwell B, 378  
 Boulware DW, 545  
 Bradlow HL, 151  
 Brancos MA, 793  
 Brandt KD, 1574  
 Braun T, 1259  
 Braunstein EM, 1022  
 Breedveld FC, 667  
 Brelsford WG, 729  
 Bresnihan B, 146, 956  
 Brewer EJ Jr, 15, 447, 1165  
 Brooks DG, 1558  
 Brooks RH, 44  
 Broom ND, 210  
 Brower AC, 1571  
 Brown R, 1215  
 Brozek CM, 834  
 Brück M, 898  
 Buckingham RB, 1221, 1259  
 Buescher KL, 593  
 Buhner D, 1584  
 Burdge DR, 813  
 Burkhauser RV, 348  
 Butcher EC, 487  
 Butler DM, 1281  
 Buyon J, 632
- C**
- Cahalán C, 1034  
 Cain PR, 258  
 Caldwell DS, 695  
 Callahan LF, 44, 1090, 1346  
 Callen JP, 1007  
 Campbell SM, 1535  
 Campen DH, 1358  
 Campion GV, 882  
 Caniglia ML, 1432  
 Cannon GW, 909  
 Carella G, 1568  
 Carlsson B, 72  
 Carmignani S, 693  
 Carson DA, 1429  
 Caspi D, 906, 1182  
 Castner NM, 876  
 Cats A, 667  
 Cattaneo R, 1568  
 Caughey DE, 762  
 Cawston T, 882  
 Chalmers IM, 303  
 Chambers JC, 506  
 Champion GD, 282, 973  
 Chang C-H, 844  
 Chang J, 126  
 Chang RW, 1128  
 Charrière G, 325  
 Chen J, 1265  
 Chen PP, 1429  
 Cheng H-M, 1211  
 Cherian PV, 937  
 Chin JE, 1290  
 Chin RC, 21  
 Cho S, 930  
 Chu C-P, 745  
 Chu J-L, 1337  
 Chudwin DS, 188  
 Cicuttini FM, 299  
 Cid M-C, 678  
 Ciompi ML, 1075  
 Claman HN, 672  
 Clark SR, 1535  
 Clauvel J-P, 571  
 Clayburne G, 937  
 Clegg DO, 9, 702, 1465  
 Coblyn JS, 167  
 Coelho A, 648  
 Collée G, 1213  
 Coman EA, 930  
 Commandre F, 815  
 Condell D, 956  
 Cooper NS, 315  
 Coppel RL, 386  
 Cornacchia E, 995  
 Couch M, 1142  
 Coulton LA, 1142  
 Couttenye MM, 272  
 Cush JJ, 1230  
 Cutolo M, 1314  
 Czerniecki M, 1524
- D**
- d'Agay M-F, 571  
 Dagenais A, 1322  
 Dahl SL, 9, 702  
 Dall'aglio PP, 1568  
 Daltroy LH, 267, 549  
 Daly L, 956  
 Danieli G, 1432, 1558  
 Danoff D, 423  
 da Silva MT, 653  
 Dauphinée M, 642  
 Davidson J, 984  
 Davidson JR, 149  
 Davis M, 984  
 Dawkins RL, 1331  
 de Broe ME, 272  
 de Clerck LS, 272  
 de Jager JP, 282  
 del Puente A, 1239  
 Delmas PD, 145  
 DeLustro F, 1432  
 Demaine AG, 276  
 Denburg JA, 1492  
 Denman AM, 757  
 DeRemee RA, 465, 1068  
 de Roquancourt A, 571  
 Derus C, 1128

de Sousa M, 653  
 DeVellis BM, 1245  
 DeVellis RF, 1245  
 de Villa LF, 120  
 Devogelaer J-P, 784  
 de Vries E, 279  
 Dieppe PA, 882  
 Dijkmans BAC, 279, 667, 1213  
 DiMartino MJ, 1406  
 Doherty M, 882  
 Dougados M, 1333  
 Doughty RA, 1384  
 Doust BD, 282  
 Downey C, 557  
 Downey DJ, 441, 798  
 Drayer DE, 688  
 Druzin ML, 697  
 Dube WJ, 303  
 Duby AD, 1371  
 Duchesne L, 1333  
 Duray PH, 487  
 Durback MA, 813  
 Duvic M, 736  
 Dyer PA, 984  
 Dynesius-Trentham R, 653

## E

Earnshaw WC, 378  
 Easterbrook M, 1105  
 Edworthy SM, 315  
 Eerola E, 339  
 Egger MJ, 702  
 Ehresmann GR, 1358  
 Eichenfield AH, 1384  
 Eimon A, 302  
 Eisman JA, 973  
 Elkon KB, 697, 1337  
 Elleuch M, 935  
 Emery P, 1176, 1590  
 Emmerson BT, 436  
 England D, 238, 623  
 Ercilla G, 678  
 Esdaile JM, 423, 817  
 Espinoza LR, 1034  
 Ettinger M, 891  
 Eugui EM, 21  
 Eulderink F, 1213  
 Euler-Ziegler L, 815  
 Evans CH, 258

## F

Falchuk KR, 167  
 Falk J, 1377  
 Fallet GH, 288  
 Fariñas MC, 850, 1481  
 Farquharson RG, 575  
 Fauci AS, 1073  
 Fauser DJ, 295  
 Feighery C, 956  
 Feldkamp LA, 1400

Felson DT, 182  
 Feltkamp TEW, 1331  
 Ferchiou A, 935  
 Fernández JM, 769  
 Ferraccioli GF, 1568  
 Ferrarini M, 1221  
 Field EH, 850  
 Fielder FG, 414  
 Fife RS, 553  
 Finesilver AG, 612  
 Fioravanti A, 979  
 Firestein GS, 1210  
 Fishel B, 906, 1182  
 Forbes CD, 1148  
 Ford DK, 914  
 Fort JG, 1194  
 Fox IH, 1022  
 Fox OF, 227  
 Frank RG, 593  
 Fraser KJ, 299  
 Fraser PA, 167  
 Frazer IH, 436  
 Freeman J, 813  
 Fregeau DR, 386  
 Fries JF, 315  
 Friman C, 780  
 Fronck Z, 573  
 Fuchs HA, 44  
 Fudman EJ, 1022  
 Fukushima T, 63  
 Furst DE, 305  
 Fye KH, 1455

## G

Gabrielli A, 1432, 1558  
 Gagnerie F, 815  
 Ganczarczyk ML, 116  
 Gandour D, 21  
 Gaston JSH, 21  
 Gatter RA, 1535  
 Gawryl MS, 188  
 Gebarski S, 159  
 Geczy AF, 453  
 Gelpi C, 108  
 Gemignani G, 452  
 Gentry K, 1176  
 Geratz JD, 1156  
 Gerli R, 1075  
 Germain BF, 1034  
 Gershwin ME, 386  
 Gharavi AE, 1052, 1337  
 Giannini EH, 15, 1165, 1252  
 Gibbons RB, 1552  
 Gilkeson GS, 695  
 Gilman SC, 126  
 Ginsberg RS, 414  
 Ginzler E, 151, 859  
 Giordano N, 979  
 Giorno RC, 672  
 Gisselbrecht C, 571  
 Giusti M, 1134

Gladman DD, 358, 1105  
 Goddard DH, 432  
 Godfrey RW, 1421  
 Godin-Ostro E, 414  
 Golbus J, 995  
 Goldberg JW, 612  
 Goldberg VM, 248  
 Golden HE, 152  
 Goldenberg DL, 182  
 Goldstein R, 736  
 Goldstein SA, 1400  
 Gomez MI, 702  
 Goto M, 480, 1508  
 Goulet RW, 1400  
 Gowen M, 1500  
 Grandone JT, 612  
 Granfors K, 339  
 Gray HD, 762  
 Graziano FM, 612, 623  
 Grazzini R, 452  
 Grennan DM, 984  
 Griswold DE, 1406  
 Grover BJ, 947  
 Grubb R, 60  
 Gruber BL, 1000  
 Guidet M, 288  
 Guldner HH, 616  
 Gutiérrez-Montes O, 145  
 Gutiérrez-Rodríguez O, 145  
 Guttadauria M, 9  
 Gyllenhammar H, 585

## H

Haapala M, 780  
 Haapasaari J, 780  
 Hafström I, 585  
 Hale LP, 947  
 Haley WE, 204  
 Hall VC, 176  
 Halliday PD, 1135  
 Halverson JD, 683  
 Halverson PC, 408  
 Hamilton JA, 1046, 1281  
 Hamilton RG, 496  
 Hammond EH, 1465  
 Hamza M'H, 935  
 Hanash S, 995  
 Hancock EJ, 1311  
 Hanly JG, 146, 358, 1492  
 Hanna N, 1406  
 Hannonen P, 776  
 Hansen ST, 441  
 Harinstein D, 1259  
 Harley JB, 227, 496  
 Harms-Ringdahl M, 585  
 Harrington TM, 1585  
 Harris ED, Jr., 1447  
 Harris EN, 575, 1052  
 Hartmann DJ, 325  
 Hausman SJ, 1574  
 Haynes BF, 947

Hazelton RA, 436  
 Hazelwood SE, 219  
 Hazleman B, 882  
 Healey LA, 152, 315  
 Hebda P, 1221  
 Hedgpeth MT, 545  
 Heinegård D, 1041  
 Heinz H-P, 457  
 Helewa A, 1377  
 Helfgott SM, 1331  
 Helfrich DJ, 1437  
 Herbage D, 325  
 Hermans J, 667  
 Hillegass LM, 1406  
 Hirohata K, 964, 1272, 1442  
 Hiserodt JC, 1515  
 Hochberg MC, 496, 1318  
 Hodge M, 1377  
 Hoffman CL, 834  
 Hoffman GS, 1073  
 Hoffman RW, 575  
 Hoffstein ST, 1421  
 Hogans BB, 1318  
 Holdsworth DE, 167  
 Holmdahl R, 1297  
 Homma M, 219, 1331  
 Honda I, 1057  
 Hopkins P, 632  
 Hoppe RT, 21, 850  
 Hornby J, 882  
 Horst G, 1563  
 Horwitz DA, 1358  
 Horwitz H, 1305  
 House JH, 932  
 Houssiau FA, 784  
 Howland WL, 1586  
 Höyeraal HM, 602  
 Hubscher O, 302  
 Huff JC, 672  
 Hughes GRV, 575, 1052  
 Hulman JF, 561  
 Hummel E, 1563  
 Hunder GG, 315, 745  
 Hunt LE, 1515  
 Hunter T, 303, 813  
 Hurst NP, 1215, 1331  
 Hurvitz AI, 688  
 Hutton CW, 882  
 Hylton W, 757

## I

Ibbertson HK, 762  
 Ide H, 63  
 Ilowite NT, 859  
 Imura H, 401  
 Inada S, 135  
 Indenbaum S, 918  
 Ingelmo M, 678  
 Inman RD, 1377  
 Inoue K, 480  
 Ireland R, 1213

Isenberg DA, 1097  
Ishida H, 401  
Ishikawa K, 1057  
Isomaki H, 1452  
Iwase R, 37

## J

Jaarsma D, 1563  
Jackson RW, 693  
Jacobson MS, 859  
Jacquet G, 288  
Jaffe IA, 299, 1585  
Jakim I, 648  
Janes R, 1190  
Jasin HE, 1473  
Jessop C, 1455  
Johnson P, 378  
Johnson WJ, 1421  
Johnston MEA, 1377  
Jokinen I, 776  
Jonsson H, 1079  
Jonsson R, 1297  
Juarez C, 108

## K

Kaarela K, 1452  
Kalden JR, 1331  
Kalinke T, 623  
Kallenberg CGM, 1563  
Kammer GM, 88  
Kane RL, 721  
Kang AH, 1328  
Kanis JA, 1142  
Kantor OS, 683  
Kantor SM, 702  
Kaplan AP, 1000  
Kaplan H, 152  
Kaplan SB, 9  
Kaplan SR, 315  
Karg M, 9  
Karmali RA, 1543  
Karp DR, 683  
Katayama K, 1413  
Katz JM, 762  
Katz Y, 1365  
Kaufman LD, 1000  
Kay DR, 9, 219  
Kay DS, 693  
Kay J, 1384  
Kaye JJ, 44  
Keene JD, 506  
Kermarec J, 815  
Keystone EC, 844, 1555  
Kiberd BA, 850  
Kidd P, 31  
Kilcoyne RF, 441, 798  
Killian PJ, 1259  
Kimbrough RD, 455  
Kingsland LC III, 219  
Kishimoto T, 80  
Kjelleveid KH, 1588

Klareskog L, 1297  
Klein J, 1007  
Klock R, 1555  
Knowler WC, 1239  
Kobayashi K, 63  
Kontinen S, 1190  
Kontinen YT, 780  
Koopman WJ, 333  
Koren E, 227  
Kornguth SE, 623  
Kozlowski KS, 282  
Kremer JM, 305, 577  
Kremer LB, 932  
Kresina TF, 248  
Krishnan J, 566  
Krug H, 1390  
Kubinski DJ, 1400  
Kuettner KE, 648  
Kumagai S, 401  
Kunnamo I, 780  
Kurosaka M, 1442  
Kuwada M, 1413  
Kuzmina N, 15

## L

Lacaille D, 423  
Lachmann PJ, 153  
Lærdal A, 1588  
Lagier R, 288  
Lähdevirta J, 1190  
Lahita RG, 1511, 688  
Lakomek H-J, 616  
Lambert PH, 1331  
Landreneau MD, 1199  
Lane N, 21  
Lange A, 1331  
Langlois PF, 188  
Laposata M, 1543  
Larheim TA, 602  
Larraga V, 769  
Laskin CA, 358  
Lasky HP, 52  
Lauhio A, 1190  
Layton MW, 1022, 1400  
Leake B, 721  
Leavitt RY, 1073  
Lee JK, 577  
Lee P, 116  
Lee RG, 1465  
Lehtinen K, 1111  
Leirisalo-Repo M, 533, 1111  
Leizer T, 1281  
Lennette ET, 1455  
Lenz ME, 648  
Leung PSC, 386  
Liang MH, 315, 549, 817  
Lie JT, 812  
Limburg PC, 1563  
Limmani A, 566  
Lin Y, 1290

Lindberg DAB, 219  
Lint TF, 188  
Linthorst J, 667  
Lipsky PE, 1230, 1473  
Lipstein-Kresch E, 930  
Liu M-F, 1429  
Livneh A, 930  
Lockshin MD, 697  
Locniskar M, 1097  
Lomena F, 793  
Loos M, 457  
López-Bote JP, 769  
Loughran TP Jr, 31  
Lovell DJ, 1252  
Lubbe WF, 1453  
Lugassy G, 573  
Luggen ME, 702  
Lundberg MS, 909  
Luthra HS, 315  
Luukkainen R, 1111

## M

MacDonald BR, 1500  
MacGuire A, 159  
Machado EB, 428, 745  
Mack LA, 441  
Mackay IR, 1176, 1590  
Mackworth-Young CG, 1052  
Maddison PJ, 131  
Madhok R, 1148  
Maeda M, 401  
Magge S, 914, 937  
Mahowald ML, 1390  
Mai FM, 1135  
Maini RN, 1331  
Mak TW, 1555  
Malawista SE, 1052  
Malleson PN, 1311  
Malone DG, 1063  
Mandel G, 1081  
Mandel N, 1081  
Mandell BF, 1543  
Manicourt DH, 538  
Mannino M, 148  
Marchegiani G, 1558  
Marchese MJ, 1000  
Marcolongo R, 979  
Marrionette X, 571  
Marino C, 148  
Marks RM, 1524  
Marnell LL, 834  
Marquet A, 769  
Martin WJ, 1358  
Martinez AJ, 1437  
Martinez MA, 108  
Martinez-Tarquino C, 1371  
Martín-Santos JM, 120  
Martio J, 1452  
Mason JH, 182, 714  
Massimo G, 1314  
Masuda I, 1057  
Mathieu A, 979  
Matsubara T, 964, 1272  
Matsukawa M, 37  
Matsumoto H, 60  
Mauritz NJ, 1297  
Maybaum J, 995  
Mazess RB, 891  
McAdam KP, 1097  
McCain GA, 1135  
McCarty DJ, 408  
McCluskey P, 1454  
McCollum DE, 947  
McCune WJ, 159  
McDonald JC, 1199  
McDonald TJ, 465  
McDougal JS, 1331  
McDuffie FC, 1331  
McGirr EE, 282  
McKenna CH, 428  
McLean RH, 736  
McNeilage LJ, 386  
McShane DJ, 315  
Medsger TA Jr, 196, 315, 386, 393, 525, 1437, 1515  
Meenan RF, 9, 714  
Mercer E, 882  
Meryhew NL, 300, 367  
Messner RP, 300, 367  
Metcalfe DD, 1063  
Meunier PC, 1406  
Michaeli J, 573  
Michaels RM, 702  
Michel CJ, 428, 745  
Mikkelsen WM, 9  
Miller EB, 1515  
Miller KB, 454  
Minden M, 1555  
Miro JM, 793  
Mitchell DJ, 453  
Mitchell DM, 315  
Mitchell E, 88, 693  
Mitchell JM, 348  
Miyamoto T, 1508  
Miyasaka N, 480, 1014, 1076  
Mochan E, 126  
Möller E, 72  
Monachesi M, 1314  
Montroni M, 1432  
Moore ME, 432  
Moriarty M, 146  
Mota-Garcia F, 653  
Möttönen T, 776  
Mourão PAS, 1028  
Muckle TJ, 1186  
Mulero J, 120  
Müller-Ruchholtz W, 898  
Murakawa Y, 80, 826  
Mutru O, 1111  
Myall RWT, 1305

Myers BD, 850  
Myers LK, 1334

N

Nagai Y, 1508  
Nagant de Deuxchaisnes C, 784  
Nance EP, 44  
Nassonova VA, 140  
Natsuyama M, 480  
Negishi M, 63  
Neiman P, 31  
Nelson DL, 844  
Nelson R, 1034  
Neri TM, 1568  
Netter HJ, 616  
Neustadt DH, 315  
New M, 151  
Newman ED, 1585  
Ng YC, 99  
Nicassio PM, 876  
Nishioka K, 480, 1076, 1408  
Nissilä M, 1111  
Nived O, 1079  
Niwa Y, 63  
Noda Y, 1076  
Noguera E, 120  
Norberg R, 1331  
Nordström D, 780  
Nunez G, 1334  
Nunley JA, 947

O

Ochi T, 37  
O'Fallon WM, 745  
Oglesby T, 702  
Ohira T, 1057  
Oka M, 776  
Okamoto M, 1508  
Oksenhendler E, 571  
Olivieri I, 452  
Olsen NJ, 1090  
Omdal R, 1588  
Ono K, 37  
Oral K, 1259  
Oren R, 573

P

Pageaut G, 288  
Pala R, 979  
Palladino MA, Jr., 1041  
Pallozzi LM, 549  
Palmbld J, 585  
Palmer RG, 757  
Palosuo T, 776  
Panayi GS, 276, 1209  
Pang S, 151  
Panicheewa S, 672  
Panzarasa R, 979  
Parker JC, 593  
Partridge REH, 454

Pasero G, 452  
Paul WA, 333  
Paulus HE, 9, 721, 1450  
Paunicka K, 1128  
Pearson ME, 672  
Peeters EAJ, 667  
Pelkonen P, 780  
Pelliniemi LJ, 339  
Pelton BK, 757  
Penning CA, 525  
Penny R, 1524  
Pereira RS, 131  
Perez MC, 1171  
Peter JB, 1212  
Peters DK, 99  
Peterson ME, 688  
Petrelli M, 1457  
Petersson I, 1265  
Pettitt DJ, 1239  
Petty RE, 1311  
Phelps P, 152, 1217  
Philips M, 632  
Phillips LR, 593  
Pinals RS, 315  
Pincus T, 44, 348, 1090, 1346  
Pisetsky DS, 506  
Pita JC, 538  
Pocock NA, 973  
Polisson RP, 702, 1208  
Polk JR, 1587  
Pope RM, 52  
Poplonski L, 1555  
Porter JF, 219  
Powell DL, 196  
Prendergast JK, 453  
Preston CJ, 1142  
Preston S, 803  
Prockop DJ, 1  
Pryzwansky KB, 1156  
Pulkki K, 339

Q

Quertermous T, 1371  
Quinlan W, 956  
Quismorio FP, Jr., 1358  
Qureshi N, 238

R

Rachow JW, 408  
Rajaraman S, 1492  
Rambotti P, 1075  
Ramsey-Goldman R, 923  
Rauch J, 864  
Rautiainen J, 776  
Reading JC, 702  
Reddy G, 1128  
Reginato AJ, 1591  
Reich CF, 506  
Reichlin M, 496, 515  
Reid GD, 914

Reidenberg MM, 688  
Reimer G, 525  
Repo H, 1190  
Reust P, 288  
Reveille JD, 204  
Reverdin A, 288  
Rhame FS, 932  
Ribalta T, 793  
Richardson B, 995  
Richardson ML, 441  
Ridley M, 1209  
Rimon D, 1117  
Ringertz B, 585  
Riveros DA, 302  
Rizvi F, 1052  
Robbins ML, 623  
Roberts WN, 267, 549, 817  
Rodriguez JL, 108  
Roebber M, 496  
Rohr MS, 1199  
Ronzière M-C, 325  
Rooney M, 956  
Rosario MO, 227  
Rose TH, 358  
Rosenberg NL, 806  
Rosén A, 1265  
Rösler M, 602  
Rotes-Querol J, 793  
Roth SH, 1336  
Roth W, 1000  
Rothenberg RJ, 238, 612  
Rothfield NF, 378, 1574  
Rothfuss S, 937  
Rothschild BM, 934  
Roudier J, 145  
Rubin LA, 844  
Rubin RL, 688  
Rupoli S, 1432, 1558  
Russell RGG, 1500  
Ryan LM, 408

S

Saegusa Y, 1272  
St Clair EW, 506  
Sakane T, 80, 826  
Sakkas LI, 276  
Salimans MMM, 279  
Sambrook PN, 282, 973  
Sampalis JS, 423  
Samuel P, 859  
Sanders PA, 984  
Sanmarti R, 678  
Sansom D, 990  
Santoro DA, 1081  
Sanusi ID, 1199  
Sasano M, 480, 1508  
Sato H, 63  
Sato K, 480, 1076  
Sattar MA, 60  
Sauter SVH, 1245  
Savage SM, 834  
Savi M, 1568  
Saxne T, 1041  
Scarola JA, 1535  
Schaller JG, 315, 1305  
Schechter SL, 152  
Scheynius A, 1297  
Schlegel S, 702  
Schnitzer TJ, 648  
Schnitzler CM, 648  
Schroeder M-L, 303  
Schrohenloher RE, 333  
Schumacher HR Jr, 813, 914, 937, 1384, 1543  
Schünke M, 898  
Schur PH, 573, 1371  
Schurman D, 21  
Schwab JH, 1156  
Scott DL, 146  
Searles RP, 834  
Segal R, 1182  
Seidman JG, 573, 1371  
Sekine F, 63  
Semble EL, 662  
Senaldi G, 1213  
Senécal J-L, 378, 864, 1322  
Shah I, 219  
Sharp GC, 219, 693, 1265  
Sharp JT, 315  
Sheerin KA, 1165  
Shichikawa K, 1076  
Shiroky JB, 702  
Shirota H, 1413  
Shokh BP, 15  
Shortkroff S, 789  
Sieck M, 937  
Sillence DO, 282  
Sills EM, 694  
Silverstein MD, 1117, 1128  
Simkin PA, 441, 798  
Simms RW, 182  
Singer JZ, 702  
Singer KH, 947  
Singsen BH, 1574  
Sinha S, 1429  
Sleckman J, 937  
Sledge CB, 789  
Slusher MA, 414  
Small P, 1210  
Small RE, 702  
Smarr KL, 593  
Smith EI, 593  
Smith-Burchnell CA, 757  
Snow KM, 844  
So AKL, 990  
Socher SA, 817  
Soehngen EC, 414  
Sokoloff L, 455, 750  
Solovera JJ, 21, 850, 1481  
Southwood TR, 1311  
Spiegel JS, 721  
Spiegel TM, 721



Spivak JL, 1318  
 Stabrun AE, 602  
 Stafford-Brady FJ, 1105  
 Starkebaum G, 31  
 Starusta-Bacal P, 145  
 Stastny P, 1334  
 Steen VD, 196, 393, 525, 923, 1515  
 Steere AC, 487, 1052  
 Steigerwald JC, 672  
 Steiman I, 1452  
 Stein M, 454  
 Stein MJ, 876  
 Stevens WJ, 272  
 Stillwell TJ, 465  
 Stockman A, 1176  
 Strahler J, 995  
 Strickland RW, 566  
 Strober S, 21, 850, 1481  
 Ström H, 72  
 Strunk RC, 1365  
 Studenski S, 1208  
 Stump TE, 662  
 Sturfelt G, 1079  
 Sturrock RD, 1148  
 Suginooshita T, 401  
 Sullivan JS, 453  
 Sullivan M, 471  
 Summers MN, 204  
 Sundstrom WR, 149  
 Suoranta H, 533  
 Suzuki N, 80  
 Sweet MBE, 648  
 Szostecki C, 616

## T

Tabata M, 63  
 Taillan B, 815  
 Takada S, 80  
 Takadera T, 1555  
 Takahashi T, 63  
 Takano M, 219  
 Takayama K, 238  
 Takeda Y, 1265  
 Takenaka Y, 1076  
 Talal N, 642, 1041  
 Tan EM, 525, 1331  
 Tan PLJ, 762  
 Tanaka H, 1413  
 Taniguchi A, 1076  
 Targoff IN, 515  
 Tate GA, 1543

Taurog J, 1390  
 ter Borg EJ, 1563  
 Terato K, 1413, 1508  
 Terkeltaub RA, 1081  
 Thiessen PN, 1311  
 Thomas TJ, 367  
 Thomson W, 984  
 Thonar EJ-MA, 557, 648  
 Tidwell RR, 1156  
 Tillmann B, 898  
 Timpl R, 1558  
 Tincani A, 1568  
 Tishler M, 906, 1182  
 Toivanen A, 339  
 Tolman KG, 1465  
 Tomana M, 333  
 Torikai K, 135  
 Toubert A, 454  
 Tovar Z, 642  
 Trentham DE, 167, 653  
 Trippi D, 452  
 Trostle DC, 393  
 Tsuchida T, 80  
 Turski P, 623

## U

Ueda Y, 80  
 Ueno Y, 1076  
 Ugai K, 1442  
 Uhl J, 126  
 Uitvlugt G, 918  
 Umehara H, 401  
 Urbano-Marquez A, 678  
 Urowitz MB, 358, 1105

## V

van Albada-Kuipers GA, 279, 667  
 van Brummelen P, 1213  
 van Damme J, 784  
 van den Berg R, 1215, 1331  
 van den Berg WB, 1077  
 van den Broek MF, 1077  
 Vandenbroucke JP, 667  
 van de Putte LBA, 1077  
 Van der Meide PH, 1297  
 Vanderslice WE, 1265  
 van Elsacker-Niele AMW, 279  
 van Kerckhove C, 1252  
 van Snick J, 784  
 van't Wout JW, 1213

Varma AA, 750  
 Vasey FB, 1034  
 Vaughan JH, 21  
 Veerapan K, 1213  
 Vella M, 789  
 Venkatesan P, 789  
 Vergani D, 1213  
 Verhoef LHM, 1213  
 Vignon E, 325  
 Vila JL, 108  
 Vilaseca J, 678  
 Villalta J, 678  
 Ville G, 325  
 Vitti G, 1046, 1281  
 Voller A, 1097  
 Vuorio E, 339

## W

Wakefield D, 1454  
 Walker ER, 1437  
 Walker SE, 593  
 Wall JG, 566  
 Wallace DJ, 150, 1208  
 Wallin J, 72  
 Wallston KA, 876  
 Walport MJ, 99, 153, 990  
 Wang F, 1213  
 Wang RJ, 1265  
 Ward JR, 9, 702, 909  
 Ward NB, 721  
 Ware JE Jr, 721  
 Wargovich R, 1591  
 Warner CA, 990  
 Watson JD, 762  
 Watt I, 882  
 Weiland HT, 279  
 Weiland LH, 465  
 Weinblatt ME, 167  
 Weiner AL, 414  
 Weiner ES, 378  
 Weinstein A, 9  
 Weisman MH, 702  
 Weissman BN, 167  
 Weissmann G, 632  
 Welsh KI, 131, 276  
 Wendling D, 288  
 West RA, 1305  
 Westerman E, 1552  
 Whelan A, 956  
 Whichard LP, 947  
 Whiteside TL, 1221  
 Whiting-O'Keefe QE, 1455

Whyte A, 927  
 Wigzell H, 1265  
 Wilder RL, 315  
 Wiley JS, 299  
 Will H, 616  
 Williams HJ, 9, 702  
 Williams JM, 557  
 Williams RC, Jr., 1204  
 Williams RO, 927  
 Williams W, 1097  
 Wilkens RF, 9, 702  
 Wilson M, 1331  
 Wilson WA, 1171  
 Winfield JB, 1574  
 Winkler A, 63  
 Winrow VR, 453  
 Wise CM, 662  
 Wolf RE, 176, 729  
 Wollheim FA, 1041  
 Wong DW, 1371  
 Wood N, 1176  
 Woodrow JC, 131  
 Woodruff RD, 662  
 Woods R, 934  
 Woolf AD, 882  
 Wordsworth BP, 572

## Y

Yamamoto K, 1014  
 Yamaoka K, 1014  
 Yamauchi Y, 80  
 Yap S-F, 1211  
 Yaron M, 906, 1182  
 Yli-Kerttula U, 1111  
 Yokoyama M, 1057  
 Yoneda M, 37  
 Yonemasu K, 37  
 Yoo JU, 248  
 Yoshinoya S, 1508  
 Yukioka M, 37

## Z

Zalcberg J, 1555  
 Zanelli P, 1568  
 Zee B, 393  
 Zeigler PR, 126  
 Ziegler G, 815  
 Zuckerman JD, 295, 789  
 Zumla A, 1097  
 Zurier RB, 1543  
 Zvaifler NJ, 1210

## SUBJECT INDEX

*Arthritis and Rheumatism*, Volume 31, Numbers 1 through 12, 1988

### A

- Abdominal discomfort, adrenocorticotrophic hormone and indomethacin in gout and, 803
- Abdominal involvement, in polyarteritis nodosa, 683
- Abscess, in childhood tuberculous rheumatism, 1311
- Acquired immunodeficiency syndrome (AIDS)
  - mimicking Sjögren's syndrome and SLE, 272
  - psoriatic arthritis and, 1034
- Acromegalic arthropathy, 1022
- Actinomycin D, recombinant human IL-1 $\beta$ , rabbit chondrocytes and, 1290
- Activation antigens, phenotypic analysis of lymphocytes in RA and, 1230
- Acute arthritis, in spondylepiphyseal dysplasia, 282
- Acute neuropathic joint, 1571
- Acute nonlymphocytic leukemia, after intravenous cyclophosphamide in lupus nephritis, 1552
- Acute pericardial tamponade, in Wegener's granulomatosis, 300
- Acute-phase reactants
  - eicosanoid metabolism in murine collagen arthritis and, 1406
  - IL-6 and, in RA and inflammatory arthritides, 784
- Adenosine, T cell function and, in SLE, 88
- Adhesion antigens, phenotypic analysis of lymphocytes in RA and, 1230
- Adjuvant polyarthritis, synovial cells in, 769
- Adrenal glands, sex hormones in RA in men and, 1314
- Adrenocorticotrophic hormone, parenteral, indomethacin and, in acute gout, 803
- Adrenocorticotropin, in RA in men, 1314
- Adverse reactions
  - adrenocorticotrophic hormone and indomethacin in gout and, 803
  - to allopurinol, lymphocyte reactivity to oxypurinol and, 436
  - to cyclobenzaprine in fibrositis, 1535
  - to methotrexate in steroid-resistant SLE, 612
  - in RA
    - to auranofin, 979
    - to GST and sulfasalazine, 702
    - to methotrexate, 167, 305, 577
  - sulfasalazine in AS and, 1111
- Age
  - income loss in polyarthritis and, 348
  - in RA
    - formal education, clinical status and, 1346
    - IgG glycosylation and, 333
    - temporal arteritis and, 745
- Age at onset
  - HLA and immunoglobulin allotypes and, in MCTD, 131
  - mandibular dimensions in JRA and, 602
  - Ro (SS-A) autoantibodies and, in SLE, 496
- Aging, hyaluronic acid depletion in canine OA and, 538
- AI/RHEUM knowledge-based computer, use of, in rheumatology, 219
- Albumin
  - C1q autoantibodies in SLE and, 457
  - IgE and, in transient arthritis in rats, 1063
  - inhibition of neutrophil stimulation and, 1081
- Alcohol, methotrexate in RA and, 1457
- Aldolase, in scleromyxedema myopathy, 1437
- Alkaline phosphatase
  - bone cells,  $\gamma$ -IFN, tumor necrosis factor  $\alpha$  and, 1500
  - osteocalcin and, in Paget's disease of bone, 1142
- Alkylating agents, TLI in lupus nephritis and, 850
- Allied health professionals, in outpatient team care in RA, 471
- Allopurinol, adverse reactions to, 436
- Allotypes, immunoglobulins and, 60, 131
- All-trans-retinoic acid
  - hyaluronic acid stimulation and, 1281
  - urokinase, plasminogen activator mRNA and, in fibroblasts, 1046
- Alopecia, low-dose methotrexate in RA and, 167
- $\alpha_1$ -acid glycoprotein
  - IL-6 in RA and inflammatory arthritides and, 784
  - inhibition of neutrophil stimulation and, 1081
- $\alpha_1$ -antitrypsin, IL-6 in RA and inflammatory arthritides and, 784
- $\alpha_1$ -proteinase, inhibition of neutrophil stimulation and, 1081
- $\alpha_2$ -HS glycoprotein, inhibition of neutrophil stimulation and, 1081
- American Board of Internal Medicine, evaluation of rheumatology training programs and, 1447
- American Rheumatism Association (ARA)
  - Audiovisual Aids Subcommittee, 569
  - Committee for the Publication of *Arthritis and Rheumatism*, report of, 1328
  - Council on Rheumatologic Care (CORC), 1217
  - criteria for RA, 267, 1239
  - 1987 revised, 315, 1452
  - Education Council, 1217
  - future leadership role of, 1217
  - Presidential Address, 1217
  - Slide competition and collection, 569
- Amino acids, antimitochondrial antibodies in scleroderma and, 386
- Aminoacylation inhibition, anti-threonyl-tRNA synthetase in myositis and, 515
- Aminobisphosphonate, IL-1, bone resorption and, in mice, 762
- Amyloidosis, giant cell inflammation and, 1186
- Anaphylatoxins, disease flares, vascular injury and, in SLE, 632
- Anatomic sites, tenderness in, 182
- Androgens
  - osteoporosis and, in RA, in postmenopausal women, 973
  - in SLE, 150
- Androstenedione, in RA in men, 1314

- Anemia**  
 aplastic, in SLE, cyclophosphamide in, 693  
 hemolytic, Coombs-positive, propylthiouracil in cats and, 688  
 iron deficiency, immunoreactive erythropoietin and, in RA, 1318
- Angiography**  
 fluorescein, C3a, C5a and, in CNS lupus, 632  
 visceral, in diagnosis of polyarteritis nodosa, 1117, 1128
- Animal studies. See Bovine, Canine, Chicken, Feline, Gorilla, Rabbit, Rat studies**
- Ankle**  
 acute periartthritis in, in infectious mononucleosis, 931  
 effusions of, in childhood tuberculous rheumatism, 1311  
 joint, protease inhibitors in experimental arthritis and, 1156  
 in spondylepiphyseal dysplasia, 282
- Ankylosing spondylitis (AS)**  
 apophyseal arthritis and lumbar motion in, 798  
 childhood HLA-B27-associated arthropathy and, 1165  
 effect of warming up on anthropometric techniques in, 549  
 HLA-B27 in, 453, 1454  
 ossification of posterior longitudinal ligament in, 452  
 progressive postural changes in, 570  
 sulfasalazine in, 1111
- Ankylosis, progressive, in mice, 1390**
- Annular disease, in subacute cutaneous LE, 1007**
- Anorexia, propylthiouracil in cats and, 688**
- Anterior cruciate ligament, hyaluronic acid in canine OA and, 538**
- Anterior uveitis, in AS, 1454**
- Anthropometry, effect of warming up on reliability of, in AS, 549**
- Anti-allotype, anti-human Ig in RA and, 60**
- Anti-basement membrane antibodies, in Raynaud's phenomenon, 1432**
- Antibodies**  
 anti-basement membrane, 1432  
 anticardiolipin, 358, 575, 623, 1052, 1211, 1212, 1568  
 anti-CD2, 947  
 anticentromere, 196, 378  
 anticollagen, 325, 776  
 anticytoskeletal, 864  
 anti-DNA, 367, 864, 1000, 1097, 1429  
 anti-dsDNA, 1563, 1568  
 anti-4B4, 52  
 anti-HaT-1, 135  
 antiidiotypic, 834  
 anti-La, 496, 506, 697  
 anti-LFA-3, 947  
 anti-native DNA, 688  
 antineurofilament, 623  
 antinuclear (ANA), 525, 545, 688, 1322, 1331  
 antinucleolar, 525  
 antiphospholipid, 358  
 anti-PL-7, 515  
 anti-PM-Scl, 525  
 antiproteoglycan, 248  
 anti-RNP, 697  
 anti-Ro, 358, 697  
 anti-Ro (SS-A), 227, 302, 496, 545, 1007, 1568
- Antibodies (*cont'd*)**  
 anti-Scl-70, 108, 196  
 anti-68K polypeptide reactivity and, 1265  
 anti-Sm, 1563  
 antispriochete, 1052  
 anti-topo I, 108, 378  
 anti-2H4, 52  
 anti-U1 RNP, 616, 1265  
 anti-U3 RNP, 525  
 anti-viral capsid antigen, 1014  
 autoantibodies to intracellular proteins in SLE and, 1337  
 collagen, 325  
 cytoplasmic, 1007  
 cytoskeletal, 864  
 dsDNA, 457  
 hybridoma, 864  
 IgG, 776, 1337  
 IgM, 776  
 monoclonal, 52, 227, 248, 487, 1097, 1230  
 native collagen, 325  
 natural killer cells in SSc and, 1515  
 neuronal, 1492  
 16/6 idiotype-positive anti-DNA, 1429  
 synovial fibroblast-T cell interactions and, 947
- Antibody-dependent cellular cytotoxicity, microvascular endothelial, in scleroderma, 1524**
- Anticardiolipin antibodies**  
 IgM, IgM-RF and, 1212  
 in lupus pregnancy, 358  
 in Lyme disease, 1052  
 oral contraceptives and, 575  
 in SLE, 623, 1211, 1568
- Anti-CD2 antibodies, synovial fibroblast-T cell interactions and, 947**
- Anticentromere antibodies**  
 anti-topo I and, 378  
 in SSc, 196
- Antichlamydia, in Reiter's syndrome, 937**
- Anticoagulant, circulating, in phenothiazine-induced SLE, 923**
- Anticollagen, in rheumatic diseases, 325, 776**
- Anticytoskeletal neurofilament protein antigens, in neuropsychiatric SLE, 623**
- Anti-DNA**  
 antibodies, 1097, 1429  
 in SLE, 367, 1000  
 hybridoma SLE anticytoskeletal antibodies and, 864
- Anti-DR, network regulation in RA and, 834**
- Anti-dsDNA, in SLE, 1563, 1568**
- Anti-Fc receptors, RF, Fc receptors and, in RA, 1204**
- Anti-4B4 antibodies, in RA joint, 52**
- Anti-fungal drugs, in tenosynovitis, 1213**
- Anti-Glm(a), in RA, 60**
- Antigens**  
 activation, 1230  
 activation of rat synovium by iron and, 653  
 adhesion, 1230  
 antimitochondrial antibodies in scleroderma and, 386  
 antineurofilament antibodies in neuropsychiatric SLE and, 623  
 anti-viral capsid, EBV and, in Sjögren's syndrome, 1014

## Antigens (cont'd)

- arthritis in Crohn's disease and, 1077
- autoantibodies to intracellular proteins in SLE and, 1337
- Ba, 80
- basement membrane, 1432, 1558
- CD3, CD4, 1230
- chlamydial, 914, 937
- collagen arthritis and  $\gamma$ -IFN in mice and, 1297
- cytoplasmic HEP-2 cellular, 227
- HLA. *See* HLA antigens
- HNK-1, 31
- hybridoma SLE anticytoskeletal antibodies and, 864
- Ia, 780
- IgE, in transient arthritis in rats, 1063
- intracellular, 1492
- laminin, 1558
- LFA-1, 1230
- LFA-3, 947
- Mycobacterium leprae*-derived, 1097
- nDNA, 367
- novel neuronal (97K), 1492
- nuclear HEP-2 cellular, 227
- nucleolar, 525
- O, synoviocyte PGE<sub>2</sub> synthesis by LPS and, 238
- peripheral fluorescent ANA in PM and, 1322
- PL-7, 515
- PM-Scl, 525
- RNP, 616
- Scl-70, 108
- spirochetal, 487
- stimulation by, IL-2 receptors on lymphocytes in RA and, 1176
- synovial fluid lymphocytes in JRA and, 780
- T cells and, 995, 1230, 1371, 1555
- Tac, 780
- VLA-1, 1230
- Anti-HaT-1 antibody system, in RA, 135
- Antihistamines, IgE and, in transient arthritis in rats, 1063
- Anti-histidyl-tRNA synthetase, anti-PL-7 and, in myositis, 515
- Anti-human immunoglobulins, in RA, 60
- Antiidiotypes
  - antibodies, network regulation in RA and, 834
  - RF, Fc receptors and, 1204
- Anti-IgE, autoantibodies, in SLE, 1000
- Anti-IL-1 $\beta$ , IL-1 and, in RA, 480
- Antiimmunoglobulin, in RA, 60
- Antiinflammatory drugs, auranofin and, in JRA, 979
- Anti-Jo-1, anti-threonyl-tRNA synthetase in myositis and, 515
- Anti-La
  - antibodies, 506, 697
  - Ro (SS-A) and, in SLE, 496
- Antilaminin, basement membrane antigens and, in Raynaud's phenomenon, 1432
- Anti-La (SS-B)
  - antibodies, HLA-DR antigens, anticardiolipin antibodies and, in SLE, 1568
  - in subacute cutaneous LE, 1007
- Anti-LFA-3 antibodies, synovial fibroblast-T cell interactions and, 947
- Anti-native collagen, type II, in RA, 776
- Anti-native DNA antibodies, in cats receiving propylthiouracil, 688
- Antineurofilament antibodies, in neuropsychiatric SLE, 623
- Antinuclear antibodies (ANA)
  - lack of, in interstitial pneumonitis in SLE, 545
  - peripheral fluorescent, in polymyositis, 1322
  - propylthiouracil in cats and, 688
  - reference reagents for, 1331
  - in SSC, 525
- Antioxidants, in synovial fluid and hyaluronic acid in RA, 63
- Antiperoxidase, chlamydial antigen in Reiter's syndrome and, 937
- Antiphospholipid antibodies, in lupus pregnancy, 358
- Anti-PL-7, in myositis, 515
- Anti-PM-Scl antibodies, in SSC, 525
- Antiproteoglycan antibodies, cartilage, immune synovitis and, 248
- Anti-RNA polymerase I, antinucleolar antibodies in PSS and, 525
- Anti-RNP, antibodies, in neonatal lupus, 697
- Anti-Ro
  - antibodies, 358, 697
  - Ro (SS-A) in SLE and, 496
- Anti-Ro (SS-A)
  - antibodies, 227, 302, 545
  - HLA-DR antigens, anticardiolipin antibodies and, in SLE, 1568
  - in subacute cutaneous LE, 1007
- Anti-Scl-70
  - antibodies, characterization of Scl-70 antigen and, 108
  - in SSC, 196
- Anti-Sm, in SLE, 1563
- Anti-Sm/RNP, HLA-DR antigens, anticardiolipin antibodies and, in SLE, 1568
- Antispirochete antibodies, anticardiolipin antibodies and, in Lyme disease, 1052
- Anti-threonyl-tRNA synthetase, in myositis, 515
- Anti-topo I antibodies, 108, 378
- Antitrypsin,  $\alpha_1$ , IL-6 in RA and inflammatory arthritides and, 784
- Antituberculous drugs, in childhood tuberculous rheumatism, 1311
- Anti-2H4 antibodies, in RA joint, 52
- Anti-U1 snRNP cell line, anti-68K polypeptide reactivity and, 1265
- Anti-U3 RNP antibodies, antinucleolar antibodies in PSS and, 525
- Anti-viral capsid antigen antibodies, EBV and, in Sjögren's syndrome, 1014
- Aorta, endothelial cellular cytotoxicity in scleroderma and, 1524
- Aplastic anemia, cyclophosphamide in, in SLE, 693
- Apolipoprotein, lipoprotein, inhibition of neutrophils and, 1081
- Apophyseal arthritis, lumbar motion in AS and, 798
- Apoprotein A-I, in dyslipoproteinemia in pediatric SLE, 859
- Arachidonic acid
  - fasting in RA and, 585
  - metabolism of, in murine collagen arthritis, 1406
  - phospholipase activity in rat synovial fibroblasts and, 1421



- Arterial thrombosis, lupus anticoagulant and, 570
- Arteries
- renal vascular, in SSc, 393
  - temporal, amyloidosis, giant cell inflammation and, 1186
- Arteritis
- cranial, HLA-DR4 antigen in polymyalgia rheumatica and, 678
  - giant cell, 678
  - temporal, incidence and clinical presentation of, 745
- Arthralgia
- childhood HLA-B27-associated arthropathy and, 1165
  - disease activity in essential cryoglobulinemia and, 1558
- Arthritis
- acute, 282
  - apophyseal, 798
  - ARA revised criteria for classification of RA and, 315, 1452
  - childhood HLA-B27-associated arthropathy and, 1165
  - chlamydial antigen in Reiter's syndrome and, 937
  - chronic, 533
  - clostridial septic, 295
  - collagen, 927, 1297, 1406, 1413
  - in Crohn's disease, 1077
  - destructive, 882, 1148
  - enteric, 1077
  - erosive, 1076
  - etiopathogenesis of, cartilage, immune synovitis and, 248
  - experimental, 1148
  - gouty, 803
  - hemophilic, 1148
  - HLA and immunoglobulin allotypes and, in MCTD, 131
  - in idiopathic hypereosinophilic syndrome, 120
  - isolated, of hip, Wilson's disease presenting as, 573
  - lupus, 1063
  - naifold capillary microscopy and, in PM and DM, 116
  - NIH, multipurpose centers, ten-year progress report, 1574
  - peri-, 931
  - peripheral, 131
  - poly-. *See* Polyarthritis
  - psoriatic, 276, 947, 1034
  - purified cartilage proteoglycan and, 258
  - reactive, 339, 533, 1041, 1190, 1377
  - septic, 295
  - streptococcal cell wall-induced, 1156
  - synovial fibroblasts in, 339
  - synovial fluid eosinophilia in Lyme disease and, 1384
  - transient, 1063
  - tuberculous rheumatism, 1311
  - Yersinia*, 533
- Arthritis and Rheumatism
- Committee for the Publication of, report, 1328
  - references to tests for RF in, 432
- Arthritis Foundation, ARA and, 1217
- Arthritis Helplessness Index, clinical classification schema for, 876
- Arthritis Impact Measurement Scales (AIMS)
- factor analysis of, in RA, 714
  - socioeconomic status, health status and, in SLE, 424
- Arthrocentesis, monoarthritis revealing non-Hodgkin's T cell lymphoma and, 571
- Arthropathy
- acromegalic, 1022
  - calcium phosphate deposition, in Milwaukee shoulder, 408
  - camptodactyly, epiphyseal dysplasia and, 935
  - hydrocalycosis and, in Erdheim-Chester disease, 1215
  - inflammatory, IL-2 receptors in RA and, 844
  - psoriatic, immunoglobulin gene polymorphism and, 276
  - pyrophosphate, of shoulder, synovial fluid collagenase in, 882
- Arthroscopy
- complement protein synthesis and, 1365
  - in synovitis in RA, 956
- Articular cartilage
- chondroitin sulfate in, 1028
  - enzyme-induced transformation of, 210
  - keratan sulfate after cartilage PG degradation of in knee, 557
  - lipids in, in CPPD crystal deposition disease, 1057
  - in OA, 538, 898
  - pathology of, immune synovitis and, 248
  - purified, response of, to proteoglycans, 258
- Articular chondrocytes, rabbit, recombinant human IL-1 $\beta$  and, 1290
- Articular erosions, IgG glycosylation in RA and, 333
- Articular involvement
- joint destruction, C1q and, in RA, 37
  - lipids and, in CPPD crystal deposition disease, 1057
  - in progressive ankylosis in mice, 1390
  - in psoriatic arthritis and AIDS, 1034
  - purified cartilage proteoglycans and, 258
  - in SLE, 1000
- Articular spondylolysis, synovial cysts, sciatica and, 288
- Aseptic meningitis, ibuprofen-induced, 813
- Aseptic necrosis, of hip, MRI of, 570
- Atherosclerosis, premature, in SLE, 859
- Atlantoaxial subluxation, assessment of, with Sharp-Purser test, 918
- Atrophic joints, acute neuropathic joint and, 1571
- Attention diversion, pain management in RA and, 593
- Auranofin
- GST and, 9, 1272
  - immune thrombocytopenia after, 299
  - in JRA, 979
  - peripheral blood lymphocyte depletion, GST and, in RA, 909
- Autoantibodies
- anti-HaT-1 antibody system in RA and, 135
  - anti-Ro (SS-A) monoclonal antibodies in mice and, 227
  - anti-68K polypeptide reactivity and, 1265
  - characterization of Scl-70 antigen and, 108
  - $\gamma$ -IFN and, in collagen arthritis in mice, 1297
  - lupus, DNA binding and, 367
  - in lupus pregnancy, 358
  - novel, fluorescent ANA and, in polymyositis, 1322
  - 16/6 idiotype-positive anti-DNA antibody and, 1429
  - in SLE, 457, 496, 864, 1000, 1337
  - in SSc, 196, 386, 525, 1515
  - U1 RNP 68-kd protein autoantigen and, 616
- Autoantigens
- antimitochondrial antibodies in SSc and, 386
  - recombinant, human U1 RNP 68-kd protein, 616

Autoimmune disease, PR4 common idotype in, 1097  
 Autoimmune mice, CD5 expression in Sjögren's syndrome and, 642  
 Autoimmunity  
   immune synovitis, cartilage pathology and, 248  
   N-acetylprocainamide, T cell autoreactivity and, 995  
   propylthiouracil in cats and, 688  
 Autologous mixed lymphocyte reaction, RA joint and, 52  
 Avascular lesions, nailfold capillary microscopy in PM and DM and, 116  
 Axial arthropathy, in acromegaly, 1022  
 Axial joints  
   destruction of, C1q and, in RA, 37  
   in progressive ankylosis in mice, 1390

## B

B cells  
   CD5 expression in Sjögren's syndrome and, 642  
   DQ $\beta$  polymorphism in Felty's syndrome and, 990  
   function of, in RA and lupus nephritis after TLI, 1481  
   in Lyme synovitis, 487  
   lymphocyte leukemia and, knee arthritis in, 815  
   PGE $_2$  modulation of RF synthesis and, 1473  
   polyclonal, activation of, EBV and, in Sjögren's syndrome, 1014  
   in SLE, 80, 1337  
   stimulatory factor 2, in RA and inflammatory arthritides, 784  
   synovial fibroblast-T cell interactions and, 947  
 Ba antigen, B cell hyperactivity in SLE and, 80  
 Bacteria  
   Fc receptors, RF, anti-idiotypes and, 1204  
   in gut, arthritis in Crohn's disease and, 1077  
   U1 RNP 68-kd protein autoantigen and, 616  
 Bacterial endocarditis, IL-2 receptors and disease activity in, 1358  
 Balanitis, in progressive ankylosis in mice, 1390  
 BALB/c mice, Ro (SS-A)-immunized, anti-Ro (SS-A) antibodies in, 227  
 "Bamboo" spine, in progressive ankylosis in mice, 1390  
 Basement membrane  
   antigens, 1432, 1558  
   trophoblast, in lupus pregnancy, 358  
 Basic calcium phosphate (BCP)  
   inhibition of neutrophil stimulation and, 1081  
   in Milwaukee shoulder, 408  
 Basophils, anti-IgE autoantibodies in SLE and, 1000  
 BB' polypeptide, anti-Sm and, in SLE, 1563  
 Behavioral factors, pain management in RA and, 593  
 Beta-blockers, tertatolol, lupus and, 145  
 $\beta$ -cyanoalanine, nalidixic acid, cinoxacin, chondrocytes and, 455  
 $\beta$ -galactosidase, recombinant La antigen in ELISA and, 506  
 $\beta_2$ -IFN (IL-6), in RA and inflammatory arthritides, 784  
 BHK-21 cells, peripheral fluorescent ANA in polymyositis and, 1322  
 Biliary cirrhosis, antimitochondrial antibodies in PSS and, 386  
 Biliary stones, drug-containing, 1450

Biomechanics, OA cartilage morphology in knee in STR/IN mice and, 898  
 Biomedical research, in multipurpose arthritis centers, 1574  
 Biopsy  
   bone marrow, in hairy cell leukemia presenting as SLE, 566  
   chlamydial antigen in Reiter's syndrome and, 937  
   cyclophosphamide and methylprednisolone in vasculitis and, 1194  
   in diagnosis of polyarteritis nodosa, 1117, 1128  
   HLA-DR4 antigen in polymyalgia rheumatica and, 678  
   knee, 956  
   liver, after methotrexate in RA, 167, 1117, 1128, 1457, 1465  
   muscle, 1437, 1591  
   salivary gland, in AIDS mimicking Sjögren's syndrome and SLE, 272  
   in Sjögren's syndrome, 662  
   skin, immunologic dysfunction in scleroderma and, 672  
   sural nerve, in systemic necrotizing vasculitis, 149  
   synovial, 21, 282, 956  
   in temporal arteritis, 745  
   temporal artery, giant cell inflammation, amyloidosis and, 1186  
 Birefringent lipid microspherules, in pigmented villonodular synovitis, 1442  
 Bis(5-amidino-2-benzimidazolyl)methane, in experimental arthritis, 1156  
 Bladder toxicity, cyclophosphamide-induced, in Wegener's granulomatosis, 465  
 Blood transfusions, AIDS mimicking Sjögren's syndrome and SLE after, 272  
 Blood vessels  
   chlamydial antigen in Reiter's syndrome and, 937  
   livedo reticularis, gangrene and, in hyperoxaluria, 1199  
   in Lyme synovitis, 487  
 Blood, cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis and, 465  
 Body weight, prediction of bone mineral density and, 891  
 Bone  
   carpal, destruction of, C1q and, in RA, 37  
   cells,  $\gamma$ -IFN, tumor necrosis factor  $\alpha$  and, 1500  
   chondroitin sulfate in cartilage and, 1028  
   costochondral involvement in heroin addicts and, 793  
   erosions of, in progressive ankylosis in mice, 1390  
   formation of, osteocalcin in rat collagen arthritis and, 1413  
   marrow, 305, 566, 1156, 1586  
   mineral density of, 891, 973  
   osteocalcin levels in, in rat collagen arthritis, 1413  
   Paget's disease of, diphosphonate and osteocalcin in, 1142  
   remodeling of, CT studies in experimental OA and, 1400  
   resorption of, IL-1, aminobisphosphonate and, in mice, 762  
   sex hormones, osteoporosis and, in RA, 973  
   subchondral, CT evaluation of, in OA, 1400  
   tarsal, osteocalcin in, in rat collagen arthritis, 1413  
   trabecular, CT evaluation of, in experimental OA, 1400  
 Book Review, *Drugs for Rheumatic Disease* (Paulus et al), 1336  
*Borrelia burgdorferi*, in Lyme synovitis, 487

- Bovine studies
  - anti-Ro (SS-A) monoclonal antibodies in mice and, 227
  - in SLE, 367, 457
- Bowel involvement, in polyarteritis nodosa, 683
- Brain, in SLE, 159, 623, 632
- Bromocriptine
  - cyclosporin A and, in RA, 1333
  - in postpartum collagen arthritis, 927
- Buerger's disease, smokeless tobacco and, 812
- Bursitis
  - iliopsoas, unusual features of, 1331
  - olecranon, in idiopathic hypereosinophilic syndrome, 120

## C

- C3H/HeJ mice, gold, fibroblasts, macrophages, IL-1 and, 1272
- Calcifications
  - chondroitin sulfate in cartilage and, 1028
  - in progressive ankylosis in mice, 1390
- Calcinosis, serum autoantibodies in SSc and, 196
- Calcium
  - aminobisphosphonate, IL-1, bone resorption and, in mice, 762
  - phospholipase in rat synovial fibroblasts and, 126
  - phytohemagglutinin, IL-2 and, in SLE, 826
- Calcium phosphate deposition arthropathy, in Milwaukee shoulder, 408
- Calcium pyrophosphate dihydrate (CPPD)
  - arthropathy, PPI and nucleotide pyrophosphohydrolase in, 408
  - crystal deposition disease, lipid in articular tissue in, 1057
  - crystals, 282, 1081
- Calvariae, mouse, aminobisphosphonate, IL-1, bone resorption and, 762
- Camptodactyly, arthropathy, epiphyseal dysplasia and, 935
- Cancer
  - cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis and, 465
  - methotrexate in RA and, 305
- Candidiasis, costochondral involvement in, in heroin addicts, 793
- Canine studies, of OA, 538, 553
- Capillaries
  - naïfold microscopy of, in PM and DM, 116
  - synovial, activation of rat synovium by iron and, 653
- Carbohydrates, abnormal IgG glycosylation in RA and, 333
- Carcinoma, cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis and, 465
- Cardiac involvement
  - anticentromere antibodies, anti-topo I and, in rheumatic diseases, 378
  - acute pericardial tamponade in Wegener's granulomatosis, 300
  - intracardiac thrombus in SLE with lupus anticoagulant, 1453
  - serum autoantibodies in SSc and, 196
- Cardiovascular fitness training, in primary fibromyalgia, 1135
- Carpal bone, destruction of, C1q and, in RA, 37
- Carprofen, approval of, 1450

## Cartilage

- arthritis in Crohn's disease and, 1077
- articular. *See* Articular cartilage
- costochondral involvement in heroin addicts and, 793
- CT evaluation of subchondral bone in experimental OA and, 1400
- degradation of, 561, 898
- fragments of, IL-1 production by type II collagen and, 1500
- growth of, chondroitin sulfate in, 1028
- hyaluronic acid depletion in canine OA and, 538
- joint damage in hemophilic arthritis and, 1148
- knee, OA lesions in, in STR/IN mice, 898
- matrix
  - enzymatically induced cartilage transformation and, 210
  - glycoprotein, in synovial fluid in human OA, 553
  - pathology of, humoral immune response and, 248
  - proteoglycans in, 248, 258, 557, 648
- Catalase, fibroblast proliferation, penicillamine, CuSO<sub>4</sub> and, 964
- CD2 T cells, synovial fibroblast interactions with, 947
- CD3 antigen, phenotypic analysis of lymphocytes in RA and, 1230
- CD3 cells, in SLE, 88
- CD4 antigen, phenotypic analysis of lymphocytes in RA and, 1230
- CD4 cells
  - autoreactivity of, N-acetylprocainamide and, 995
  - $\gamma$ -IFN and, in collagen arthritis in mice, 1297
  - hyperactivity of, IL-2 and, in scleroderma, 401
  - in RA, 52, 1230
  - in SLE, 88
- CD5 expression, B cells and, in Sjögren's syndrome, 642
- CD8 cells
  - phenotypic analysis of, in RA, 1230
  - in SLE, 88
- Cell-mediated immunity
  - IL-2 receptors on lymphocytes in RA and, 1176
  - in scleroderma, 672
  - synovial fluid lymphocytes in JRA and, 780
- Central nervous system (CNS)
  - C3a, C5a and, in SLE, 632
  - in RA, 304, 305
- Centrioles, hybridoma SLE anticytoskeletal antibodies and, 864
- Cerebral lupus, brain lesion identified by MRI in, 159
- Cerebritis, lupus, 632, 1105
- Cervical rotation, warming up and, in anthropometric tests in AS, 549
- Cervical spine
  - mandibular dimensions in JRA and, 602
  - in RA, 918
- Chemiluminescence, inhibition of neutrophil stimulation and, 1081
- Chemotherapy, irradiation, CD5 expression and, in Sjögren's syndrome, 642
- Chest
  - anterior, tenderness in, in fibromyalgia, 182
  - expansion of, in AS, 549, 1111
- Chicken studies, characterization of Scl-70 antigen, 108
- Childhood arthropathy, HLA-B27-associated, 1165

- Childhood multicentric reticulohistiocytosis, 1588
- Chlamydial antigen, 914, 937
- Cholesterol
- crystals, in spondylepiphyseal dysplasia, 282
  - in dyslipoproteinemia in pediatric SLE, 859
  - emboli syndrome, mimicking polyarteritis, 570
  - hemisuccinate, oral encapsulated indomethacin in rats and, 414
  - lipoprotein, in dyslipoproteinemia in pediatric SLE, 859
- Chondrocalcinosis
- in spondylepiphyseal dysplasia, 282
  - in surgically resected joints, 750
- Chondrocytes
- articular, rabbit, recombinant human IL-1 $\beta$  and, 1290
  - cartilage and, 258, 561
  - lipids in, in CPPD crystal deposition disease, 1057
  - nalidixic acid, cinoxacin,  $\beta$ -cyanoalanine and, 455
  - OA cartilage morphology in knee in STR/IN mice and, 898
- Chondroitin sulfate, human cartilage and, 1028
- Chorea, oral contraceptives, anticardiolipin antibodies and, 575
- Chorionic gonadotropin, in RA in men, 1314
- Chrysotherapy. *See also* Auranofin, Gold
- T cells, IL-2 and, in RA, 176
- Chymopapain, keratan sulfate, cartilage proteoglycan degradation in knee and, 557
- Cinoxacin, nalidixic acid,  $\beta$ -cyanoalanine, chondrocytes and, 455
- Circulating anticoagulant, in SLE, 923, 1210
- Circulating immune complexes. *See also* Immune complexes
- DNA binding specificity in SLE and, 367
- Cirrhosis
- methotrexate in RA and, 167
  - primary biliary, antimitochondrial antibodies in PSS and, 386
- Clostridial septic arthritis, 295
- Cognitive factors, pain management in RA and, 593
- Cognitive function, parenteral adrenocorticotrophic hormone, indomethacin and, in gout, 803
- Collagen
- activation of rat synovium by iron and, 653
  - antibodies to, in rheumatic diseases, 325
  - arthritis, 927, 1297, 1406, 1413
  - C1q autoantibodies and, in SLE, 457
  - enzyme-induced cartilage transformation and, 210
  - in RA, 776, 1465
  - type II, IL-1 production by, 1508
  - type IV, antibodies and, in Raynaud's phenomenon, 1432
- Collagenase
- cloning of scleroderma fibroblasts and, 1221
  - enzyme-induced cartilage transformation and, 210
  - immune injury, TLI and, in RA, 21
  - in PSS, fibroblasts, penicillamine, CuSO<sub>4</sub> and, 964
  - purified cartilage proteoglycan and, 258
  - in synovial fluid, in shoulder arthropathy, 882
- College of American Pathologists test for RF and, 432
- Communication training, pain management in RA and, 593
- Community health programs, in multipurpose arthritis centers, 1574
- Comorbidity, income loss in polyarthritis and, 348
- Complement
- activation of
    - C3a, C5a and, in SLE, 632
    - C5b-9, disease activity and, in SLE, 188
    - monoclonal RF-IgG immune complexes and, 99
    - depletion of, in lupus pregnancy, 358
    - disease activity in essential cryoglobulinemia and, 1558
    - protein synthesis, synovial fibroblasts and, 1365
    - receptors of, CR1, 99, 153
    - in SLE, 632, 1211
  - Complement C1, protein synthesis and, 1365
  - Complement C1q
    - autoantibodies, in SLE, 457
    - joint destruction and, in RA, 37
  - Complement C2, protein synthesis and, 1365
  - Complement C3
    - CR1, immune complexes and, in rheumatic diseases, 153
    - monoclonal RF-IgG immune complexes and, 99
    - protein synthesis and, 1365
    - in RA, 21, 585
    - in SLE, 188, 632, 729
  - Complement C3a, anaphylatoxins, in SLE, 632
  - Complement C4
    - monoclonal RF-IgG immune complexes and, 99
    - protein synthesis and, 1365
    - in SLE
      - allotypes, 1171
      - C5b-9, disease activity and, 188
      - IL-2 and, 729
      - molecular heterogeneity of, 736
  - Complement C4A, deficiency of, in SLE in black Americans, 1171
  - Complement C4b, allotypes, null alleles and, in Felty's syndrome, 984
  - Complement C5, protein synthesis and, 1365
  - Complement C5a, anaphylatoxins, in SLE, 632
  - Complement C5b-9, terminal complement complex, disease activity in SLE and, 188
  - Complement CH50, C1q autoantibodies in SLE and, 457
  - Complementary DNA, 16/6 idiotype-positive anti-DNA antibody and, 1429
  - Compliance, in cardiovascular fitness training in fibromyalgia, 1135
  - Computed tomography (CT)
    - apophyseal arthritis, lumbar spine and, in AS, 798
    - axial, to examine subchondral bone in experimental OA, 1400
    - brain lesions identified by MRI in SLE and, 159
    - in polyarteritis nodosa, 683
    - in spinal cord compression by epidural lipomatosis in JRA, 447
    - in spondylolisthesis, synovial cysts and sciatica, 288
  - Computers
    - AI/RHEUM knowledge-based, uses of, 219
    - in diagnosis of polyarteritis nodosa, 1117, 1128
  - Concanavalin A
    - in adjuvant-induced polyarthritis, 769
    - low-dose methotrexate in RA and, 167
    - synovial fibroblast-T cell interactions and, 947
  - Congenital heart block, in neonatal lupus, 697



- Connective tissue  
cloning of scleroderma fibroblasts and, 1221  
matrix, bone cells,  $\gamma$ -IFN, tumor necrosis factor and, 1500
- Connective tissue disease  
AIDS mimicking Sjögren's syndrome and SLE, 272  
anti-HaT-1 antibody system in RA and, 135  
methotrexate in steroid-resistant SLE and, 612  
mixed. *See* Mixed connective tissue disease  
osteogenesis imperfecta and, 1  
skeletal muscle involvement in, in mice, 806  
T cell cloning and cyclophosphamide in, 757  
U1 RNP 68-kd protein autoantigen in, 616  
use of AI/RHEUM knowledge-based computer in, 219
- Contraceptives, oral, antiphospholipid antibodies and, 575
- Coombs-positive hemolytic anemia, propylthiouracil in cats and, 688
- Coping strategies, pain management in RA and, 593
- Corticosteroid drugs  
CD5 expression in Sjögren's syndrome and, 642  
in dyslipoproteinemia in pediatric SLE, 859  
eicosanoid metabolism in collagen arthritis and, 1406  
in JRA, 447, 602  
in RA, 956, 973  
in SLE, androgens and, 150  
in subacute cutaneous lupus erythematosus, 1007
- Cortisol, in RA in men, 1314
- Costochondral involvement, in systemic candidiasis in heroin addicts, 793
- Council on Rheumatologic Care, ARA, 1217
- Counterimmunoelectrophoresis, U1 RNP 68-kd protein autoantigen and, 616
- Cranial arteritis, HLA-DR4 antigen in polymyalgia rheumatica and, 678
- Cranium, lesions in, identified by MRI in neuropsychiatric SLE, 159
- C-reactive protein  
in RA, 784, 906  
sulfasalazine in AS and, 1111
- Creatine kinase, in scleromyxedema myopathy, 1437
- Creatinine clearance, adrenocorticotrophic hormone and indomethacin in gout and, 803
- Crepitus, in acromegalic arthropathy, 1022
- CREST syndrome  
anticentromere antibodies and anti-topo I in, 378  
in scleroderma  
antimitochondrial antibodies and, 386  
renal vascular involvement and, 393  
serum autoantibodies and, 196
- Crohn's disease  
arthritis and, 1077  
IgG glycosylation in, 333
- Cryoglobulinemia  
essential, assessment of disease activity in, 1558  
essential mixed, monoclonal RF-IgG immune complexes in, 99
- Crystals  
calcium phosphate, in Milwaukee shoulder, 408  
cholesterol, in spondyloepiphyseal dysplasia, 282  
CPPD, 282, 1057  
hydroxyapatite, inhibition of neutrophil stimulation by, 1081
- Crystals (*cont'd*)  
livedo reticularis, gangrene and, in hyperoxaluria, 1199  
MSU, inflammation induced by, diet enrichment and, 1543  
in synovial fluid collagenase in shoulder arthropathy, 882
- Cutaneous involvement  
in postdysenteric reactive arthritis, 1377  
renal vascular involvement in scleroderma and, 393
- Cutaneous mast cells, anti-IgE autoantibodies in SLE and, 1000
- Cutaneous vasculitis, nodulosis and, during methotrexate treatment in RA, 1182
- Cyanogen bromide peptides, IL-1 production by type II collagen and, 1508
- Cyclic adenosine 3',5'-phosphate (cAMP), T cell function phospholipase activity in rat synovial fibroblasts and, 1421  
in SLE and, 88
- Cyclobenzaprime, in fibrositis, 1535
- Cycloheximide, recombinant human IL-1 $\beta$ , rabbit chondrocytes and, 1290
- Cyclooxygenase  
eicosanoid metabolism in murine collagen arthritis and, 1406  
hyaluronic acid stimulation and, 1281  
phospholipase activity in rat synovial fibroblasts and, 1421
- Cyclophosphamide  
intravenous, 693, 1194, 1552  
T cell cloning and, 757  
use of, in rheumatic disease in the Soviet Union, 140  
in Wegener's granulomatosis, 465, 1068, 1073
- Cyclosporin A, bromocriptine and, in RA, 1333
- Cystitis, cyclophosphamide and, in Wegener's granulomatosis, 465
- Cytokeratin, hybridoma SLE anticytoskeletal antibodies and, 864
- Cytokines, human, IL-6 in, in RA and inflammatory arthritis, 784
- Cytoplasm  
lipids in, in pigmented villonodular synovitis, 1442  
synovial fibroblasts in arthritis and, 339
- Cytoplasmic antibodies, in subacute cutaneous LE, 1007
- Cytoplasmic Hep-2 cellular antigens, anti-Ro (SS-A) antibodies in mice and, 227
- Cytosine, DNA binding specificity in SLE and, 367
- Cytoskeletal filaments, hybridoma SLE anticytoskeletal antibodies and, 864
- Cytoskeletal neurofilament protein antigens, antibodies to, in neuropsychiatric SLE, 623
- Cytotaxins, fasting in RA and, 585
- Cytotoxic cells. *See* Suppressor/cytotoxic cells
- Cytotoxicity, antibody-dependent cellular, in scleroderma, 1524

## D

- D polypeptide, anti-Sm and, in SLE, 1563
- DBA/1 mice, collagen arthritis and  $\gamma$ -IFN in, 1297
- Degenerative spondylolisthesis, synovial cysts, sciatic syndrome and, 288
- Dehydroepiandrosterone sulfate, in RA, 973, 1314
- Dehydrotestosterone, in RA in men, 1314

- Delayed-type hypersensitivity, to oxypurinol, adverse reactions to allopurinol and, 436
- Dendritic cells, in Lyme synovitis, 487
- Dentistry, in jaw deformity in JRA, 1305
- Dermal fibroblasts, cloning of, in scleroderma, 1221
- Dermatomyositis (DM)
- anti-threonyl-tRNA synthetase in, 515
  - naifold capillary microscopy in, 116
- Desmin, h<sub>2</sub>bridoma SLE anticytoskeletal antibodies and, 864
- Destructive arthritis
- joint damage in experimental hemophilic arthritis, 1148
  - of shoulder joint, synovial fluid collagenase in, 882
- Destructive spondylarthropathy, chronic renal failure and, 1331
- Dexamethasone
- eicosanoid metabolism in murine collagen arthritis and, 1406
  - hyaluronic acid stimulation and, 1281
  - urokinase, plasminogen activator mRNA and, in fibroblasts, 1046
- D-glucuronic acid, synovial fluid antioxidant activity in RA and, 63
- Diabetes mellitus, lupus pregnancy and, 358
- Diarrhea
- in postdysenteric reactive arthritis, 1377
  - low-dose methotrexate in RA and, 167
- Dibutyl cAMP, phospholipase in rat synovial fibroblasts and, 1421
- Diclofenac, FDA approval of, 1450
- Diet enrichment in MSU crystal-induced acute inflammation, 1543
- Differentiation antigens, T cells, phenotypic analysis in RA and, 1230
- Diffuse scleroderma
- antimitochondrial antibodies in, 386
  - antinucleolar antibodies in, 525
  - autoantibodies in, 196
  - cutaneous, natural killer cells in, 1515
  - renal vascular histology and morphometry in, 393
- Diflunisal-associated thrombocytopenia, in RA, 148
- Digital pitting scars, serum autoantibodies in PSS and, 196
- Diglyceride lipase, IL-1 and, in rat synovial fibroblasts, 1421
- Dinitrophenol, IgE and, in transient arthritis in rats, 1063
- Diphosphonate, osteocalcin and, in Paget's disease of bone, 1142
- Diphosphoryl lipid A, synoviocyte PGE<sub>2</sub> synthesis and, in rabbits, 238
- Disability
- income loss in polyarthritis and, 348
  - in RA, 333, 1245
  - flat foot and, 441
- Disaccharides, chondroitin in cartilage and, 1028
- Discoid lesions, in subacute cutaneous LE, 1007
- Disease activity
- assessment of, in essential cryoglobulinemia, 1558
  - CD5 expression in Sjögren's syndrome and, 642
  - chlamydial antigen in Reiter's syndrome and, 937
  - IL-2 receptors and, 844, 1358
  - IL-6 and, 784
  - in JRA, 602, 979
  - in lupus pregnancy, 358
- Disease activity (*cont'd*)
- osteocalcin and, in Paget's disease of bone, 1142
  - PR4 idiotype in autoimmune diseases and, 1097
  - in RA
    - effect of fasting on, 585
    - GST and peripheral blood lymphocytes in, 909
    - joint counts in hand and, 44
    - network regulation and, 834
    - outpatient team care and, 471
    - pain management and, 593
    - RF synthesis and, 1090
  - in SLE
    - androgens and, 150
    - B cell hyperactivity and, 80
    - C3a, C5a and, 632
    - C5b-9 and, 188
    - IL-2 and, 729
    - TLI in lupus nephritis and, 850
- Disease duration
- collagen antibodies in rheumatic diseases and, 325
  - mandibular dimensions and, in JRA, 602
  - parotid and minor salivary gland biopsy in Sjögren's syndrome and, 662
  - in RA, 333, 1346
  - in Reiter's syndrome, 428
  - socioeconomic status, health status and, in SLE, 423
- Disease flares, in SLE, 188, 632, 1563
- Disease remission, and naifold capillary microscopy in PM and DM, 116
- Arthritis Helplessness Index and, 876
  - bromocriptine in postpartum collagen-induced arthritis and, 927
  - eicosanoid metabolism in murine collagen arthritis and, 1406
  - predictors of pain and function in OA and, 204, 1452
  - in SLE, 423, 817
- Disease status, in RA, 593, 1090
- Distal dysphagia, in scleromyxedema myopathy, 1437
- Disulfides
- cartilage matrix glycoprotein in synovial fluid in human OA and, 553
  - fibroblast proliferation, penicillamine, CuSO<sub>4</sub> and, 964
- DMSO, use of, in rheumatic disease in the Soviet Union, 140
- DNA
- anti-native, 688
  - antimitochondrial antibodies in scleroderma and, 386
  - binding of, 367, 864
  - characterization of Scl-70 antigen and, 108
  - double-stranded, 367, 457
  - DQ $\beta$  polymorphism and, in Felty's syndrome, 990
  - human parvovirus B19, in synovial fluid, 279
  - PR4 idiotype in autoimmune diseases and, 1097
  - psoriatic arthritis, immunoglobulin gene polymorphism and, 276
  - in RA, 72, 1555
  - 16/6 idiotype-positive anti-DNA antibody and, 1429
  - in SLE, 367, 738, 1371
  - synovial fluid lymphocytes in JRA and, 780
  - synthesis of, 780, 964, 1272
  - T cells and, 995, 1371, 1555
  - U1 RNP 68-kd protein autoantigen and, 616

DNase, peripheral fluorescent ANA in polymyositis and, 1322

Double-stranded DNA, in SLE, 367, 457

DQ locus, in Lyme synovitis, 487

DQB polymorphism, genetics and, in Felty's syndrome, 990

DR+ T cells, network regulation in RA and, 834

DR-DQ haplotypes, in RA, 27

DR4

- allotypes, in mixed connective tissue disease, 131
- associated DR-DQ haplotype, in RA, 72

Drugs

- actinomycin D, 1290
- allopurinol, 436
- allergies to, propylthiouracil in cats and, 688
- antibiotic, 295
- antifungal, 1213
- antimicrobial, 1068, 1073
- antituberculous, 1311
- auranofin, 9, 909, 979
- bromocriptine, 927, 1333
- carprofen, 1450
- chymopapain, 557
- corticosteroid, 150, 447, 602, 642, 859, 956, 973, 1007
- cyclobenzaprine, 1535
- cycloheximide, 1290
- cyclophosphamide, 140, 465, 693, 757, 1068, 1073, 1194, 1552
- cyclosporin A, 1333
- dexamethasone, 1046, 1281, 1406
- diclofenac, 1450
- diflunisal, 148
- DMSO, 140
- folinic acid, 906
- glucocorticoid, 667, 1046, 1068, 1073, 1281
- GST, 9, 702, 909
- hydroxychloroquine, 15, 299, 1007, 1252, 1584
- ibuprofen, 813, 1406
- immunosuppressive, 683, 1068, 1073
- indomethacin, 414, 762, 1281, 1406, 1421
- leucovorin, 906, 1587
- methotrexate, 167, 299, 305, 612, 906, 1090, 1437, 1457, 1465, 1584, 1585, 1586, 1587
- methylprednisolone, 140, 1194
- Motrin, 299
- N-acetylprocainamide, 995
- naproxen, 1406
- NSAID, 140, 1252, 1311, 1406
- outpatient team care in RA and, 471
- parenteral adrenocorticotrophic hormone, 803
- Parlodel, 927
- penicillamine, 15, 147, 964, 1090, 1252, 1515
- penicillin, 295
- phenothiazines, 923
- piroxicam, 1406
- prednisolone, 973
- prednisone, 167, 1437
- procainamide, 995
- propylthiouracil, 688
- slow-acting antirheumatic, 9, 15, 146, 299, 956, 1252
- second-line, 1090
- steroid, 333, 447, 612, 642, 850

#### Drugs (cont'd)

- sulfamethoxazole. *See* Trimethoprim/sulfamethoxazole
- sulfasalazine, 702, 1111
- tertatolol, 145
- thalidomide, 145
- trimethoprim/sulfamethoxazole, 1068, 1073
- warfarin, 1453

Dry eyes or mouth, parotid and minor salivary gland biopsy in Sjögren's syndrome and, 662

Dysentery, in reactive arthritis, 1190, 1377

Dyslipoproteinemia, in pediatric SLE, 859

Dyspepsia, adrenocorticotrophic hormone and indomethacin in gout and, 803

Dysphagia, in scleromyxedema myopathy, 1437

Dysplasia

- epiphyseal, camptodactyly, arthropathy and, 935
- spondylepiphyseal, synovial complications in, 282

Dysprosium 165-ferric hydroxide, repeat radiation synovectomy with, in RA knee, 789

#### E

E polypeptide, anti-Sm and, in SLE, 1563

Ear, nodulosis and vasculitis during methotrexate in RA and, 1182

Edema, renal vascular involvement in scleroderma and, 393

Education

- formal, clinical status in RA and, 1346
- income loss in polyarthritis and, 348

Effusions, in childhood tuberculous rheumatism, 1311

Egg phosphatidylcholine monophasic vesicles, oral encapsulated indomethacin in rats and, 414

Ehlers-Danlos syndrome, systemic joint laxity, temporomandibular joint and, 1259

Eicosanoid metabolism, inhibitors of, in murine collagen arthritis, 1406

Eicosapentaenoic acid

- fasting in RA and, 585
- in MSU crystal-induced inflammation, 1543

Elbow

- in childhood multicentric reticulohistiocytosis, 1588
- in idiopathic hypereosinophilic syndrome, 120
- joint, in postdysenteric reactive arthritis, 1377

Elderly

- giant cell inflammation, amyloidosis, temporal artery and, 1186
- women

  - radial and spinal bone mineral density in, 891
  - synovial fluid collagenase in shoulder arthropathy in, 882

Electromyography, in diagnosis of polyarteritis nodosa, 1128

Electron microscopy studies

- chlamydial antigen in Reiter's syndrome, 937
- immunogold and peripheral fluorescent ANA in PM and, 1322
- lipids in CPPD crystal deposition disease, 1057
- of liver, after methotrexate in RA, 1465
- in scleromyxedema myopathy, 1437
- of synovial fibroblasts in arthritis, 339

Encapsulated indomethacin, in rats, 414

- Endocarditis, bacterial, IL-2 receptors and disease activity in, 1358
- Endomysial inflammation, in connective tissue disease in mice, 806
- Endonuclease, *Sst* I, psoriatic arthritis, Ig, genetics and, 276
- Endothelial cells  
activation of rat synovium by iron and, 653  
human microvascular, in scleroderma, 1524  
synovial fibroblast-T cell interactions and, 947
- Endothelial venules, in Lyme synovitis, 487
- Endothelium, endothelial cellular cytotoxicity in scleroderma and, 1524
- Endotoxin, chlamydial antigen in Reiter's syndrome and, 937
- Enteric arthritis, in Crohn's disease, 1077
- Enteric-coated sulfasalazine, in AS, 1111
- Enterocolitis, necrotizing, in polyarteritis nodosa, 683
- Enzyme linked-immunosorbent assay (ELISA)  
anti-68K polypeptide reactivity and, 1265  
anti-threonyl-tRNA synthetase in myositis and, 515  
characterization of Scl-70 antigen and, 108  
IL-2R, disease activity and, in rheumatic diseases, 1358  
in RA, 834, 844  
recombinant La antigen in, 506  
serum keratan sulfate in OA and, 648  
in SLE, 367, 496, 1000
- Enzymes  
anti-threonyl-tRNA synthetase in myositis and, 515  
articular cartilage transformation induced by, 210  
in Milwaukee shoulder, 408  
multiple acyl coenzyme A dehydrogenase deficiency and, 695  
plasma and bone osteocalcin in rat collagen arthritis and, 1413  
in RA, 585, 1230
- Eosinophilia  
in idiopathic hypereosinophilic syndrome, 120  
synovial fluid, in Lyme disease, 1384
- Epidemiologic studies  
incidence and clinical presentation of temporal arteritis, 745  
Reiter's syndrome in Rochester, Minnesota, 428
- Epidural lipomatosis, spinal cord compression by, in JRA, 447
- Epiphyseal dysplasia, camptodactyly, arthropathy and, 935
- Epitopes, anti-68K polypeptide reactivity and, 1265
- Epstein-Barr virus (EBV)  
B cells and, in Sjögren's syndrome, 1014, 1481  
fibrositis and, 1455
- Erdheim-Chester disease, hydrocalycosis and arthropathy in, 1215
- Erosions  
bone, in progressive ankylosis in mice, 1390  
purified cartilage proteoglycan and, 258  
in RA, 37, 44, 315, 333, 1452
- Erosive arthritis  
adult T cell leukemia, proliferative synovitis and, 1076  
rheumatoid, 72, 299
- Erythema, in subacute cutaneous LE, 1007
- Erythrocyte sedimentation rate  
IL-2R, disease activity and, in rheumatic diseases, 1358
- Erythrocyte sedimentation rate (*cont'd*)  
in RA  
formal education, clinical status and, 1346  
low-dose methotrexate and, 167  
methotrexate, leucovorin and, 906  
tumor necrosis factor and, 1041  
sulfasalazine in AS and, 1111
- Erythrocytes  
characterization of Scl-70 antigen and, 108  
CR1, immune complexes and, in rheumatic diseases, 153
- Erythroderma, in scleromyxedema myopathy, 1437
- Erythropoietin, immunoreactive, anemia and, in RA, 1318
- Escherichia coli*  
autoantibodies to intracellular proteins in SLE and, 1337  
U1 RNP 68-kd protein autoantigen in, 616
- Essential cryoglobulinemia  
assessment of disease activity in, 1558  
mixed, monoclonal RF-IgG immune complexes in, 99
- Estradiol  
in RA  
in men, 1314  
osteoporosis and, in postmenopausal women, 973
- Estrogen, osteoporosis and, in RA, in postmenopausal women, 973
- Estrone, osteoporosis and, in RA, in postmenopausal women, 973
- Etiopathogenesis, of arthritis, cartilage pathology, immune synovitis and, 248
- Eukaryotes, autoantibodies to intracellular proteins in SLE and, 1337
- Exercise  
cardiovascular fitness training in primary fibromyalgia, 1135  
effect of, on anthropometric tests in AS, 549
- Exophiala mansonii*, tenosynovitis caused by, 1213
- Experimental arthritis, hemophilic, joint damage in, 1148
- Experimental OA  
examination of subchondral bone by CT in, 1400  
hyaluronic acid depletion in, in dogs, 538
- Extraarticular features  
in postdysenteric reactive arthritis, 1377  
in progressive ankylosis in mice, 1390  
of RA, IgG glycosylation and, 333
- Extracellular matrix, OA cartilage morphology in knee in STR/IN mice and, 898
- Extraglandular involvement, parotid and minor salivary gland biopsy in Sjögren's syndrome and, 662
- Extremities  
distal, protease inhibitors in experimental arthritis and, 1156  
function of, AIMS and, in RA, 714
- Eye  
dry, parotid and minor salivary gland biopsy in Sjögren's syndrome and, 662  
in postdysenteric reactive arthritis, 1377  
vasoocclusive retinopathy, C3a, C5a and, in SLE, 632

## F

F(ab')<sub>2</sub>  
fragments

- F(ab')<sub>2</sub> (*cont'd*)  
 anti-IgE autoantibodies in SLE and, 1000  
 C1q autoantibodies in SLE and, 457  
 monoclonal antibodies, network regulation in RA and, 834
- Face, jaw deformity in JRA and, 1305
- Factor analysis, of AIMS in RA, 714
- Factor B, factor H, complement protein synthesis and, 1365
- Family dynamics, pain management in RA and, 593
- Fascial inflammation, in connective tissue disease in mice, 806
- Fasting, in RA, 585
- Fatigue, cyclobenzaprine and, in fibrositis, 1535
- Fatty acids  
 diet enrichment in MSU crystal-induced inflammation and, 1543  
 effect of fasting on, in RA, 585
- Fc fragments, in SLE and, 457, 1000
- Fc receptors  
 IgG, large granular lymphocytes and, in RA, 31  
 RF, antiidiotypes and, 1204
- FDA Arthritis Advisory Committee, NSAID and, 1450
- Feet  
 peripheral gangrene in hyperoxaluria and, 1199  
 in progressive ankylosis in mice, 1390  
 in psoriatic arthritis and AIDS, 1034  
 in RA  
 flat, tendon rupture and, 441  
 methotrexate and, 167, 577  
 tophi on, uric acid and, in lymphedema, 813
- Feline studies, anti-rDNA antibodies and propylthiouracil, 688
- Felty's syndrome  
 C4B-null alleles in, 984  
 DQ $\beta$  polymorphisms and genetics in, 990  
 large granular lymphocytes in RA and, 31
- Femoral articular cartilage, pathology of, immune synovitis and, 248
- Femoral bone mineral density, sex hormones, osteoporosis and, in RA, 973
- Femoral condyle, spontaneous cartilage degeneration in guinea pig and, 561
- Femoral head, CT evaluation of subchondral bone in experimental OA and, 1400
- Femoropatellar joint  
 in camptodactyly, arthropathy, and epiphyseal dysplasia, 935  
 OA cartilage morphology in STR/IN mice and, 898
- Femorotibial joint, eicosanoid metabolism in murine collagen arthritis and, 1406
- Ferric citrate, activation of rat synovium by, 653
- Ferritin, activation of rat synovium by, 653
- Fetal loss  
 in lupus pregnancy, 358  
 lupus anticoagulant, anti-Ro (SS-A) antibodies and, in SLE, 302
- Fibers, enzyme-induced cartilage transformation and, 210
- Fibrillar, antinucleolar antibodies in SSc and, 525
- Fibrillation, cartilage degeneration in guinea pig and, 561
- Fibrin, chlamydial antigen in Reiter's syndrome and, 937
- Fibrinogen  
 fibrinoid necrosis, renal vascular involvement in PSS and, 393  
 in RA, 734, 1465
- Fibroblasts  
 proliferation of, 964, 1272  
 in scleroderma  
 cloning of, 1221  
 endothelial cellular cytotoxicity and, 1524  
 immunologic dysfunction and, 672  
 synovial  
 activation of rat synovium by iron and, 653  
 complement protein synthesis and, 1365  
 cultured, changes in, in arthritis, 339  
 hyaluronic acid stimulation of, 1281  
 T cell interactions and, 947  
 urokinase-type plasminogen activation mRNA in, 1046
- Fibrocarrilage, cartilage matrix glycoprotein in synovial fluid in OA and, 553
- Fibromyalgia  
 anatomic tenderness sites in, 182  
 primary, cardiovascular fitness training in, 1135
- Fibronectin  
 inhibition of neutrophil stimulation and, 1081  
 in liver after methotrexate in RA, 1465
- Fibrosis  
 pulmonary interstitial, autoantibodies in PSS and, 196  
 in RA, 167, 956, 1457, 1465
- Fibrositis  
 cardiovascular fitness and, 1135  
 cyclobenzaprine in, 1535  
 EBV and, 1455
- Filaments, hybridoma SLE anticytoskeletal antibodies and, 864
- Finger-to-floor test, warming up and, in AS, 549
- Fingers, flexion of, in idiopathic hypereosinophilic syndrome, 120
- Fish oil, in diet enrichment in MSU crystal-induced inflammation, 1543
- 5-azacytidine, N-acetylprocainamide, T cell autoreactivity and, 995
- 5-lipoxygenase, eicosanoid metabolism in murine collagen arthritis and, 1406
- Flat foot, rheumatoid, tibialis posterior tendon rupture and, 441
- Flavoprotein, mitochondrial, fibroblasts in arthritis and, 339
- Flexibility exercises, cardiovascular fitness in primary fibromyalgia and, 1135
- Flexion, finger, in idiopathic hypereosinophilic syndrome, 120
- Flow cytometry  
 arthritis-associated changes in synovial fibroblasts and, 339  
 network regulation in RA and, 834
- Fluorescent ANA, peripheral, autoantibodies and, in polymyositis, 1322
- Foam cells, lipids in pigmented villonodular synovitis and, 1442
- Folate, methotrexate and, in RA, 906
- Folinic acid, methotrexate and, in RA, 906
- Follicle-stimulating hormone, in RA in men, 1314



Forskolin, T cell function and, in SLE, 88  
 Fractures, IL-1 production by type II collagen and, 1508  
 Functional ability  
   in acromegalic arthropathy, 1022  
   self-evaluation processes, adjustment to RA and, 1245  
 Functional status  
   predictors of, in OA knee or hip, 204, 1452  
   in RA, 593, 667, 721

## G

Glm(a) allotype, in RA, 60  
 Galactose, abnormal IgG glycosylation in RA and, 333  
 Gallium scintigraphy, costochondral involvement in heroin addicts and, 793  
 $\gamma$ -carboxyglutamic acid-containing protein, in Paget's disease of bone, 1142  
 Gamma globulin, treatment of gold-induced thrombocytopenia with, 454  
 $\gamma$ -IFN  
   collagen arthritis in mice and, 1297  
   complement protein synthesis and, 1365  
   in RA, 1041, 1209  
   recombinant, effect of, on bone cells, 1500  
 $\gamma$ -linoleic acid, in MSU crystal-induced inflammation, 1543  
 Gangrene, peripheral, livedo reticularis and, in hyperoxaluria, 1199  
 Gastric ulcers, encapsulated indomethacin in rats and, 414  
 Gastroenteritis, postdysenteric reactive arthritis and, 1377  
 Gastrointestinal involvement  
   activation of rat synovium by iron and, 653  
   encapsulated indomethacin in rats and, 414  
   in polyarteritis nodosa, 683  
   in RA  
     adverse effects of methotrexate and, 305  
     GST, sulfasalazine and, 702  
     toxicity of NSAID and, 1450  
 Gc globulin, inhibition of neutrophil stimulation and, 1081  
 Gelatinase, purified cartilage proteoglycan and, 258  
 Generalized osteoarthritis, serum keratan sulfate in, 648  
 Genetics  
   in Felty's syndrome  
     C4B-null alleles and, 984  
     DQB polymorphism and, 990  
   large granular lymphocytes in RA and, 31  
   of osteogenesis imperfecta, 1  
   psoriatic arthritis and immunoglobulin gene polymorphism, 276  
   in rheumatology in the Soviet Union, 140  
   16/6 idiotype-positive anti-DNA antibody,  $V_H$  gene and, 1429  
   T cells and, 572, 757, 1371  
   urokinase, plasminogen activator mRNA and, in fibroblasts, 1046  
   in *Yersinia* arthritis, 533  
 Genomes  
   16/6 idiotype-positive anti-DNA antibody and, 1429  
   T cells and, 1371, 1555  
 Germinal center B cells, in Lyme synovitis, 487  
 Giant cell arteritis, HLA-DR4 antigen in polymyalgia rheumatica and, 678

Giant cell inflammation, amyloidosis in temporal arteries and, 1186  
 Global assessment  
   cardiovascular fitness in primary fibromyalgia and, 1135  
   low-dose methotrexate in RA and, 167  
 Glomerular basement membrane, from normal kidney, 570  
 Glomerular membrane, from kidney in lupus nephritis, 570  
 Glomerulonephritis, cyclophosphamide and methylprednisolone in vasculitis and, 1194  
 Glucocorticoid drugs. *See also* Corticosteroid drugs, Steroid drugs  
   hyaluronic acid stimulation and, 1281  
   infection in RA, OA, or soft tissue rheumatism and, 667  
   trimethoprim/sulfamethoxazole and, in Wegener's granulomatosis, 1068, 1073  
   urokinase, plasminogen activator mRNA and, in fibroblasts, 1046  
 Glutathione, fibroblasts, penicillamine,  $\text{CuSO}_4$  and, 964  
 Glycolipid-I, phenolic, PR4 idiotype in autoimmune diseases and, 1097  
 Glycoprotein  
    $\alpha_1$ -acid, IL-6 and, 784  
   cartilage matrix, in synovial fluid in human OA, 553  
   inhibition of neutrophil stimulation and, 1081  
   phenotypic analysis of lymphocytes in RA and, 1230  
 Glycosaminoglycans  
   cloning of scleroderma fibroblasts and, 1221  
   IL-1 production by type II collagen and, 1508  
 Glycosylation, IgG, in chronic inflammatory diseases, 333  
 Gm allotype, in MCTD, 131  
 Gold. *See also* Auranofin, Chrysotherapy, Sodium aurothiomalate  
   injectable, 702, 979  
   oral, immune thrombocytopenia and, 299  
   in RA  
     methotrexate, hydroxychloroquine and, 1584  
     TLI, joint damage and, 146  
 Gold-induced thrombocytopenia, gamma globulin treatment of, 454  
 Gold salts, in RA, RF synthesis and, 1090  
 Gold sodium thiomalate (GST)  
   comparison with auranofin, 9  
   low-dose, fibroblasts, IL-1, macrophages and, 1272  
   in RA  
     comparison with sulfasalazine, 702  
     peripheral blood lymphocyte depletion and, 909  
   T cells, IL-2 and, 176  
 Gonadotropins, chorionic, in RA in men, 1314  
 Gorilla studies, spondylarthropathy, 934  
 Gout, acute  
   IL-2 receptors and disease activity in, 1358  
   parenteral adrenocorticotropic hormone and indomethacin in, 803  
 Gram-negative organism-associated synovitis, synovocyte  $\text{PGE}_2$  synthesis by LPS and, 238  
 Granular lymphocytes, large, in RA, 31  
 Granulomatosis  
   acute pericardial tamponade in, 300  
   Wegener's. *See* Wegener's granulomatosis  
 Granulomatous inflammation, protease inhibitors in experimental arthritis and, 1156

Granulomatous tenosynovitis, *Mycobacterium terrae* and, 932

Grip strength  
in RA  
formal education, clinical status and, 1346  
leucovorin, methotrexate and, 906  
sulfasalazine, GST and, 702

Growth and development, mandibular dimensions in JRA and, 602

Growth cartilage, chondroitin sulfate in, 1028

Growth factor  
endothelial cellular cytotoxicity in scleroderma and, 1524  
hybridoma plasmacytoma, in RA and inflammatory arthritides, 784

Growth hormone, in acromegalic arthropathy, 1022

Guanine, DNA binding specificity in SLE and, 367

Guinea pig studies  
CT evaluation of subchondral bone in experimental OA, 1400  
spontaneous cartilage degeneration, 561

Gut, bacteria in, arthritis in Crohn's disease and, 1077

## H

<sup>3</sup>H-thymidine, B cell hyperactivity in SLE and, 80

Hairy cell leukemia, presenting as lupus-like illness, 566

Hand  
joints of, 44, 315, 1452  
in psoriatic arthritis and AIDS, 1034  
in RA, 44, 167, 1182

Haptoglobins  
IL-6 in RA and inflammatory arthritides and, 784  
inhibition of neutrophil stimulation and, 1081

Hartley guinea pigs, spontaneous cartilage degeneration in, 561

Hashimoto's thyroiditis, episodic polyarthralgia in, 303

HaT-1 antigen, anti-HaT-1 antibody system in RA and, 135

Headache  
adrenocorticotrophic hormone and indomethacin in gout and, 803  
low-dose methotrexate in RA and, 167

Health assessment, outpatient team care in RA and, 471

Health care, ARA role in, 1217

Health status  
AIMS and, in RA, 714  
socioeconomic status and, in SLE, 423

Heart block, congenital, in neonatal lupus, 697

HeLa cells  
autoantibodies to intracellular proteins in SLE and, 1337  
U1 RNP 68-kd protein autoantigen and, 616

Helper cells  
PGE<sub>2</sub> modulation of RF synthesis and, 1473  
TLI in lupus nephritis and, 850

Helper/inducer cells  
cAMP metabolism and, in SLE, 88  
in RA, 21, 52, 480, 1230  
in synovitis, 480

Helplessness, Arthritis Helplessness Index subscale for, clinical correlates of, 876

Hematologic malignancy, TLI in lupus nephritis and, 850

Hematoma, intraplacental, in lupus pregnancy, 358

Hematopoietic hyperplasia, protease inhibitors of experimental arthritis and, 1156

Hematuria, cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis and, 465

Hemoglobin, immunoreactive erythropoietin and, in RA, 1318

Hemolytic anemia, Coombs-positive, propylthiouracil in cats and, 688

Hemophilic arthritis, experimental, joint damage in, 1148

Hemorrhage, circulating anticoagulant, hypoprothrombinemia and, in SLE, 1210

Hemorrhagic cystitis, cyclophosphamide and, in Wegener's granulomatosis, 465

HEp-2 cells  
anti-Ro (SS-A) monoclonal antibodies in mice and, 227  
peripheral fluorescent ANA in polymyositis and, 1322

HEp-2 cellular antigens, nuclear, anti-Ro (SS-A) monoclonal antibodies in mice and, 227

Hepatocyte lysosomes, after methotrexate in RA, 1465

Hepatolenticular degeneration (Wilson's disease), presenting as isolated arthritis of hip, 573

Heroin addicts, costochondral involvement in, in systemic candidiasis, 793

Herpes zoster, low-dose methotrexate in RA and, 167

Hexuronate, hyaluronic acid depletion in canine OA and, 538

Hind III fragments, C4 molecular heterogeneity in SLE and, 736

Hip  
aseptic necrosis of, MRI of, 570  
chondrocalcinosis after joint resection in, 750  
joint, 573, 648  
neuropathic, 1571  
OA, 204, 648, 844, 1452

Histamine  
anti-IgE autoantibodies in SLE and, 1000  
IgE and, in transient arthritis in rats, 1063  
immunologic dysfunction in scleroderma and, 672

Histology, renal vascular, in SSc, 393

HLA  
allotypes, immunoglobulin allotypes and, in MCTD, 131  
antigens, 140, 678  
class II gene polymorphism, DR4-associated DR-DQ haplotype in RA, 72  
genes, Ro (SS-A) autoantibodies in SLE and, 496  
haplotypes, C4 molecular heterogeneity in SLE and, 736  
typing for, in postdysenteric reactive arthritis, 1377

HLA-A1, antigen, in MCTD, 131

HLA-B7, in postdysenteric reactive arthritis, 1377

HLA-B8  
allele, Ro (SS-A) autoantibodies and, in SLE, 496  
antigen, in MCTD, 131

HLA-B27  
anterior uveitis in AS and, 1454  
arthropathy associated with, in childhood, 1165  
*Klebsiella* and, in AS, 453  
in postdysenteric reactive arthritis, 1377  
in *Yersinia* arthritis, 533

HLA-Bw60, in postdysenteric reactive arthritis, 1377

HLA-D, region epitopes, T cells and, in juvenile arthritis, 575, 1334

- HLA-DQ**  
 $\beta$  gene, in Felty's syndrome, 990  
 specificity, Ro (SS-A) autoantibodies and, in SLE, 496
- HLA-DQw1/HLA-DQw2 allele**, Ro (SS-A) autoantibodies and, in SLE, 496
- HLA-DR**  
 antigens, 1230, 1568  
 in Lyme synovitis, 487  
 positivity for, immunologic dysfunction in scleroderma and, 672  
 in RA, 72, 480, 834  
 specificity, Ro (SS-A) autoantibodies and, in SLE, 496
- HLA-DR1**  
 positivity, in postdysenteric reactive arthritis, 1377  
 serum autoantibodies in SSc and, 196
- HLA-DR2**  
 allele, Ro (SS-A) autoantibodies and, in SLE, 496  
 antigen, 131, 1568  
 positivity for, in postdysenteric reactive arthritis, 1377
- HLA-DR3**  
 anticardiolipin antibodies and, in SLE, 1568  
 antigen, in MCTD, 131  
 in subacute cutaneous LE, 1007
- HLA-DR4**  
 antigen, 131, 678  
 C4B-null alleles in Felty's syndrome and, 984
- HLA-DR5**, serum autoantibodies in SSc and, 196
- HLA-DR7**, anticardiolipin antibodies and, in SLE, 1568
- HLA-DRw52 allele**, Ro (SS-A) autoantibodies and, in SLE, 496
- HLA-DR-DQ haplotypes**, in RA, 72
- HNK-1 antigen**, large granular lymphocytes in RA and, 31
- Hormones**, parenteral adrenocorticotrophic, indomethacin and, in gout, 803
- Horseradish peroxidase**, fibroblasts, penicillamine,  $\text{CuSO}_4$  and, 964
- Human immunodeficiency virus (HIV)**, in AIDS mimicking Sjögren's syndrome and SLE, 272
- Human studies**  
 animal model of spondylarthropathy and, 1390  
 anti-Ro (SS-A) monoclonal antibodies in mice and, 227  
 anti-68K polypeptide reactivity, 1265  
 cartilage matrix proteoglycan in synovial fluid in OA, 553  
 chondroitin sulfate in cartilage, 1028  
 fibroblasts in  
   proliferation of, penicillamine, and  $\text{CuSO}_4$ , 964  
   synovial, stimulation of hyaluronic acid and, 1281  
   urokinase-type plasminogen activator and mRNA, 1046  
 hybridoma SLE anticytoskeletal antibodies, 864  
 IL-1, 126, 762, 1272, 1290, 1508  
 IL-6, 784  
 joint damage in experimental hemophilic arthritis and, 1148  
 muscle in connective tissue disease in mice and, 806  
 parvovirus B19 DNA in synovial fluid, 279  
 $\text{PGE}_2$  modulation of RF synthesis, 1473  
 protease inhibitors in experimental arthritis in rats and, 1156  
 in RA  
   anti-HaT-I antibody system, 135  
   anti-native type II collagen, 776
- Human studies (cont'd)**  
 IL-2 receptors, 844  
 sex hormones in men, 1314  
 in scleroderma  
   antimitochondrial antibodies, 386  
   microvascular endothelial cells, 1524  
 16/6 idiotype-positive anti-DNA antibody, 1429  
 in SLE  
   autoantibodies to intracellular proteins, 1337  
   novel neuronal antigen (97K), 1492  
   T cell function, 88  
   synovial fibroblast-T cell interactions, 947  
   tumor necrosis factor,  $\gamma$ -IFN, and bone cells, 1500  
 U1 RNP 68-kd protein autoantigen, 616
- Humoral immune response**, cartilage pathology, synovitis and, 248
- Hyaline cartilage**, matrix of, glycoprotein in, in synovial fluid in human OA and, 553
- Hyaluronic acid**  
 antioxidant activity in RA and, 60  
 depletion of, in canine OA, 538  
 stimulation of, 1281
- Hybridoma**  
 cell lines, anti-Ro (SS-A) monoclonal antibodies in mice and, 227  
 lupus autoantibodies, cytoskeletal filaments, DNA binding and, 864  
 plasmacytoma growth factor (IL-6), 784  
 PR4 common idiotype in autoimmune disease and, 1097
- Hydralazine**, N-acetylprocainamide, T cell autoreactivity and, 995
- Hydrarthrosis**, IgE and, in transient arthritis in rats, 1063
- Hydrocalycosis**, arthropathy and, in Erdheim-Chester disease, 1215
- Hydrogen peroxide**, fibroblasts, penicillamine,  $\text{CuSO}_4$  and, 964
- Hydrophobic amino acids**, antimitochondrial antibodies in PSS and, 386
- Hydroxyapatite**  
 characterization of Scl-70 antigen and, 108  
 crystals, inhibition of neutrophil stimulation by, 1081  
 IL-1 production by type II collagen and, 1508
- Hydroxychloroquine**  
 gold, methotrexate and, in RA, 1584  
 immune thrombocytopenia after oral gold and, 299  
 in JRA, 15, 1252  
 in subacute cutaneous LE, 1007
- Hydroxyproline**  
 excretion of, osteocalcin and, in Paget's disease of bone, 1142  
 IL-1 production by type II collagen and, 1508
- Hypereosinophilic syndrome**, idiopathic, arthritis in, 120
- Hypermobile joint syndrome**, temporomandibular joint dysfunction and, 1259
- Hyperoxaluria**, livedo reticularis and peripheral gangrene in, 1199
- Hyperplasia**  
 hematopoietic, protease, experimental arthritis and, 1156  
 synoviocyte, in synovitis in RA, 956
- Hyperreactivity**, of CD4+ cells, IL-2 and, in scleroderma, 401

Hypersensitivity, delayed-type, adverse reactions to allopurinol and, 436  
 Hypertension, pulmonary serum autoantibodies in PSS and, 196  
 Hypertrophic OA, serum keratan sulfate in, 648  
 Hypertrophy, articular response to purified cartilage proteoglycan and, 258  
 Hypervascularity, activation of rat synovium by iron and, 653  
 Hypocomplementemia  
   IL-2 in SLE and, 729  
   in lupus pregnancy, 358  
 Hypophysis, sex hormones in RA in men and, 1314  
 Hypoproteorubinemia, hemorrhage, circulating anticoagulant and, in SLE, 1210  
 Hypoxanthine-guanine phosphoribosyltransferase (HGPRT), T cell cloning, cyclophosphamide and, 757

# I

Ia antigen, in synovial fluid lymphocytes in JRA, 780  
 Ibuprofen  
   aseptic meningitis induced by, 813  
   eicosanoid metabolism in murine collagen arthritis and, 1406  
 Idiopathic destructive arthritis, of shoulder, synovial fluid collagenase in, 882  
 Idiopathic hypereosinophilic syndrome, arthritis in, 120  
 Idiopathic OA, chondrocalcinosis after joint resection in, 750  
 Idiotypes  
   positive, 16/6, anti-DNA antibody, 1429  
   PR4 common, in autoimmune rheumatic disease, 1097  
 IgA  
   RF, immune injury, TLI and, in RA, 21  
   sulfasalazine in AS and, 1111  
 IgD-bearing B cells, in Lyme synovitis, 487  
 IgE  
   anti-IgE autoantibodies in SLE and, 1000  
   antigen-specific, in transient arthritis in rats, 1063  
 IgG  
   antibodies, 776, 1337  
   anticardiolipin antibodies, in Lyme disease, 1052  
   collagen antibodies in rheumatic diseases and, 325  
   EBV, B cells and, in Sjögren's syndrome, 1014  
   glycosylation of, in chronic inflammatory diseases, 333  
   immune complexes, monoclonal RF and, 99  
   immune synovitis, cartilage pathology and, 248  
   PGE<sub>2</sub> modulation of RF synthesis and, 1473  
   RF, TLI and, in RA, 21  
   7S, C1q autoantibodies in SLE and, 457  
   sulfasalazine in AS and, 1111  
   TLI in lupus nephritis and, 850  
 IgG3, antimitochondrial antibodies in scleroderma and, 386  
 IgM  
   anticardiolipin antibodies, 1052, 1212  
   EBV, B cells and, in Sjögren's syndrome, 1014  
   PGE<sub>2</sub> modulation of RF synthesis and, 1473  
   reduction of, in SLE, 1213  
   RF  
     IgM anticardiolipin antibody and, 1212

IgM (cont'd)  
   in RA, synthesis of, 1090  
   sulfasalazine in AS and, 1111  
   TLI in lupus nephritis and, 850  
 Iliopsoas bursitis, unusual features of, 1331  
 Immune complexes  
   C1q autoantibodies in SLE and, 457  
   erythrocytes, CRI, IC and, in rheumatic diseases, 153  
 Immune dysfunction, IL-2 receptors and, in RA, 844  
 Immune-mediated disease syndromes, propylthiouracil in cats and, 688  
 Immune response  
   humoral, cartilage pathology, synovitis and, 248  
   IL-2 in SLE and, 729  
   IL-2R, disease activity and, in rheumatic diseases, 1358  
   joints and, 52, 1148  
   in RA  
     RF, anti-idiotypes, Fc receptors and, 1204  
     TLI and, 21  
 Immune thrombocytopenia, oral gold and, 299  
 Immunization, *Salmonella typhi*, anterior uveitis in AS after, 1454  
 Immunoblotting  
   anti-Ro (SS-A) monoclonal antibodies in mice detected by, 227  
   anti-68K polypeptide reactivity and, 1265  
   in detection of anticentromere antibodies and anti-topo I, 378  
   in detection of antimitochondrial antibodies in PSS, 386  
   network regulation in RA and, 834  
   peripheral fluorescent ANA in polymyositis and, 1322  
   PR4 idiotype in autoimmune disease and, 1097  
   in SLE  
     anti-Sm polypeptides and, 1563  
     autoantibodies to intracellular proteins and, 1337  
     hybridoma anticytoskeletal antibodies and, 864  
     U1 RNP 68-kd protein autoantigen and, 616  
 Immunocytochemistry, chlamydial antigen in Reiter's syndrome and, 937  
 Immunodiffusion  
   in detection of anticentromere antibodies and anti-topo I, 378  
   U1 RNP 68-kd protein autoantigen detected by, 616  
 Immunofluorescence  
   joint damage in experimental hemophilic arthritis and, 1148  
   liver studied by, after methotrexate in RA, 1465  
 Immunogenetics  
   in subacute cutaneous LE, 1007  
   postdysenteric reactive arthritis and, 1377  
 Immunoglobulins  
   allotypes of, in MCTD, 131  
   B cells and, 80, 1481  
   depletion of, in lupus pregnancy, 358  
   gene polymorphism and, in psoriatic arthritis, 276  
   PGE<sub>2</sub> modulation of RF synthesis and, 1473  
   in RA, 52, 60, 1481  
   16/6 idiotype-positive anti-DNA antibody and, 1429  
   in SLE, 80, 1000  
   sulfasalazine in AS and, 1111

- Immunogold electron microscopy, fluorescent ANA in PM and, 1322
- Immunohistochemical studies, collagen arthritis and  $\gamma$ -IFN in mice and, 1297
- Immunologic dysfunction, in scleroderma, 672
- Immunomodulation, T cells, IL-2, GST and, in RA, 176
- Immunopathology, endothelial cellular cytotoxicity in PSS and, 1524
- Immunoperoxidase staining, immunologic dysfunction in PSS and, 672
- Immunoprecipitation  
antinuclear antibodies in PSS and, 525  
in SLE, 1492, 1563
- Immunoreactivity  
in erythropoietin, in RA, anemia and, 1318  
hybridoma anticytoskeletal antibodies in SLE and, 864  
of recombinant La antigen in ELISA, 506  
U1 RNP 68-kd protein autoantigen and, 616
- Immunoregulation  
CD5 expression in Sjögren's syndrome and, 642  
PGE<sub>2</sub> modulation of RF synthesis and, 1473  
T cell, in rheumatoid synovitis, 1075
- Immunosuppression, methotrexate in RA and, 167, 305
- Immunosuppressive drugs  
in polyarteritis nodosa, 683  
trimethoprim/sulfamethoxazole and, in Wegener's granulomatosis, 1068, 1073
- Impotence, in scleroderma, 148
- IMR-6 cells, 97K antigen in SLE and, 1492
- Income loss, in symmetric polyarthritis, 348
- Indomethacin  
aminobisphosphonate, IL-1, bone resorption and, in mice, 762  
eicosanoid metabolism in murine collagen arthritis and, 1406  
hyaluronic acid stimulation and, 1281  
parenteral adrenocorticotrophic hormone and, in acute gout, 803  
in rats  
encapsulated, 414  
phospholipase activity in synovial fibroblasts, 1421
- Inducer cells. *See also* Helper/inducer cells  
in joints in RA, 52
- Infarction, placental, in lupus pregnancy, 358
- Infection  
anticardiolipin antibodies and, in Lyme disease, 1052  
EBV, fibrositis and, 1455  
human parvovirus B19 DNA, in synovial fluid, 279  
in RA, OA, and soft tissue rheumatism, 667  
reactive arthritis and, 1190, 1377  
*Strongyloides stercoralis*, mimicking SLE, 930  
TLI in lupus nephritis and, 850  
trimethoprim/sulfamethoxazole in Wegener's granulomatosis and, 1068, 1073
- Infectious mononucleosis, acute periartthritis in, 931
- Inflammation  
abnormal IgG glycosylation and, 333  
aminobisphosphonate, IL-1, bone resorption and, in mice, 762  
C3a, C5a and, in SLE, 632  
costochondral involvement in heroin addicts and, 793
- Inflammation (*cont'd*)  
giant cell, amyloidosis in temporal arteries and, 1186  
IL-1 and, 126, 480  
IL-2 receptors and, 844, 1358  
inhibition of neutrophil stimulation and, 1081  
of joints  
damage to, in experimental hemophilic arthritis, 1148  
 $\gamma$ -IFN and, in collagen arthritis in mice, 1297  
laxity of, in temporomandibular joint dysfunction, 1259  
in parotid gland, in Sjögren's syndrome, 662  
perimysial/endomysial, in connective tissue disease, 806  
protease inhibitors in experimental arthritis and, 1156  
in RA  
fasting and, 585  
IL-1, HLA-DR and, 480  
IL-2 receptors and, 844  
joint stability of, 267  
long-term bolus methotrexate and, 1457  
phenotypic analysis of lymphocytes and, 1230  
in scleromyxedema myopathy, 1437  
synovial  
in adjuvant-induced polyarthritis and, 769  
fibroblasts and, 339, 947  
hyaluronic acid stimulation and, 1281  
in Lyme synovitis, 487  
T cells and, 947
- Inflammatory arthritides, IL-6 in, 784
- Injectable gold  
auranofin in JRA and, 979  
sulfasalazine and, in RA, 702
- Inorganic pyrophosphate, in calcium phosphate deposition arthropathy and Milwaukee shoulder, 408
- Institute of Rheumatology, USSR, 140
- Interferon (IFN)  
 $\beta_2$  (IL-6), in RA and inflammatory arthritides, 784  
gamma, 1041, 1297
- Interleukin-1 (IL-1)  
 $\beta$ , effects of, on rabbit articular chondrocytes, 1290  
bone resorption by, aminobisphosphonate and, in mice, 762  
fibroblasts, penicillamine, CuSO<sub>4</sub> and, 964  
hyaluronic acid stimulation by, 1281  
low-dose gold and, 1272  
phospholipase  
A<sub>2</sub> and, in human synovial cells, 126  
stimulation of, in synovial fibroblasts and, 1421  
production of, by type II collagen, 1508  
purified cartilage proteoglycan and, 258  
in RA, 21, 480  
urokinase, plasminogen activator mRNA and, in fibroblasts, 1046
- Interleukin-2 (IL-2)  
CD5 expression in Sjögren's syndrome and, 642  
phytohemagglutinin and, in SLE, 826  
in PSS, 401  
in RA, 844, 1176, 1358, 1590  
receptors for, 729, 1358  
in SLE, 729  
T cells, GST and, 176
- Interleukin-6, in RA and inflammatory arthritides, 784
- Internal organ involvement, antinuclear antibodies in PSS and, 525



International Committee on Antinuclear Antibodies, 1331  
 International League Against Rheumatism, 1331  
 International Union of Immunological Societies, 1331  
 Interphalangeal joints, in progressive ankylosis in mice, 1390  
 Interstitial fibrosis, pulmonary, autoantibodies in PSS and, 196  
 Interstitial pneumonitis, in ANA-negative SLE, 545  
 Intestinal involvement  
   C3a, C5a and, in SLE, 632  
   in rat studies  
     small, activation of rat synovium by iron and, 653  
     ulcers, encapsulated indomethacin in rats and, 414  
 Intima, renal vascular involvement in scleroderma and, 393  
 Intraarticular corticosteroids, in synovitis in RA, 956  
 Intracellular antigens, novel neuronal antigen (97K) in SLE and, 1492  
 Intracellular proteins, autoantibodies to, in SLE, 1337  
 Intractable RA, TLI and joint damage in, 146  
 Intralesional corticosteroid drugs, in subacute cutaneous LE, 1007  
 Intraplacental hematoma, in lupus pregnancy, 358  
 Intravenous cyclophosphamide  
   in aplastic anemia in SLE, 693  
   nonlymphocytic leukemia after, in lupus nephritis, 1552  
 Ionomycin, phytohemagglutinin, IL-2 and, in SLE, 826  
 Ionophore A23187, fasting in RA and, 585  
 Iron, activation of rat synovium by, 653  
 Iron deficiency anemia, immunoreactive erythropoietin and, in RA, 1318  
 Irradiation, chemotherapy, CD5 expression and, in Sjögren's syndrome, 642  
 Ito cells, liver ultrastructure after methotrexate in RA and, 1465

## J

Jaw, in JRA, 602, 1305  
 Jejunum, C3a, C5a and, in SLE, 632  
 Joints  
   acromegalic arthropathy and, 1022  
   ankle, protease inhibitors in experimental arthritis and, 1156  
   apophyseal, lumbar motion in AS and, 798  
   ARA revised criteria for classification of RA and, 315, 1452  
   aspiration of, in clostridial septic arthritis, 295  
   atrophic, 1571  
   axial, 37, 1390  
   cartilage matrix glycoprotein in synovial fluid in human OA and, 553  
   counts of, in RA, 44, 1346  
   damage to, TLI and, in RA, 146, 1148  
   deformity of, in hand in RA, 44  
   destruction of, 37, 480, 1508  
   diseases of  
     APD, IL-1, and bone resorption in mice and, 762  
     immune injury, TLI and, in RA, 21  
     in postdysenteric reactive arthritis, 1377  
     in the Soviet Union, 140  
     serum keratan sulfate in, 648  
   erosions of, 37, 44

## Joints (cont'd)

femoropatellar, 898, 935  
 femorotibial, in murine collagen arthritis, 1406  
 fluid in, hyaluronic acid stimulation and, 1281  
 function of, 471, 1390  
 $\gamma$ -IFN and, in collagen arthritis, 1297  
 hand, 44, 315, 1452  
 hypermobile, temporomandibular joint dysfunction and, 1259  
 involvement of  
   antinucleolar antibodies in PSS and, 525  
   bromocriptine in collagen arthritis and, 927  
 knee  
   cartilage degeneration in, in guinea pig, 561  
   OA cartilage morphology of, in STR/IN mice, 898  
   purified cartilage proteoglycan and, 258  
   rabbit, keratan sulfate, cartilage proteoglycan and, 557  
   synovitis in, in RA, 956  
   laxity of, in temporomandibular joint dysfunction, 1259  
   malalignment of, in hand in RA, 44  
   metacarpal, low-dose methotrexate in RA and, 167  
   metacarpophalangeal, 315, 1390, 1452  
   metatarsophalangeal, 1390, 1453  
   in Milwaukee shoulder, 408  
   narrowing of, in hip in Wilson's disease, 573  
   neuropathic, acute, 1571  
   pain in, 167, 303  
   peripheral, 37, 533, 1390  
   in progressive ankylosis in mice, 1390  
   proximal interphalangeal, 315, 1390, 1452  
   replacement of, 267, 648  
   resection of, chondrocalcinosis after, 750  
   shoulder, synovial fluid collagenase in destructive arthritis in, 882  
   stability of, in RA, 267  
   synovial, 238, 1063  
   temporomandibular, 602, 1259  
   trauma to, clostridial septic arthritis and, 295  
   wrist, 44, 315, 1377, 1452  
   zygapophyseal, synovial cyst of, 288  
 Juvenile arthritis, T cells in, 575, 1334  
 Juvenile rheumatoid arthritis (JRA)  
   auranofin in, 979  
   jaw deformity in, 1305  
   mandibular dimensions and asymmetry in, 602  
   penicillamine and hydroxychloroquine in, 1252  
   slow-acting antirheumatic drugs in, 15, 1252  
   spinal cord compression by epidural lipomatosis in, 447  
   synovial fluid lymphocytes in, 780

## K

K lymphocytes, endothelial cellular cytotoxicity in PSS and, 1524  
 Keratan sulfate  
   cartilage proteoglycan degradation in rabbit knee and, 557  
   OA cartilage morphology in knee in STR/IN mice and, 898  
   serum, in OA, 648  
 Kidney, biopsy of, in diagnosis of polyarteritis nodosa, 1117, 1128  
 Kinase, T cell function, cAMP and, in SLE, 88

*Klebsiella*, HLA-B27 and, in AS, 453

## Knee

- arthritis in, in B cell chronic lymphocytic leukemia, 815
- cartilage in, OA lesions in, in STR/IN mice, 898
- chondrocalcinosis after joint resection of, 750
- effusions of, in childhood tuberculous rheumatism, 1311
- in Erdheim-Chester disease, 1215
- hyaluronic acid depletion in canine OA and, 538
- joint
  - cartilage degeneration in, in guinea pig, 561
  - damage to, in experimental hemophilic arthritis, 1148
  - in postdysenteric reactive arthritis, 1377
  - purified cartilage proteoglycan and, 258
  - transient arthritis in rats in, 1063
- medial, tenderness of, in fibromyalgia, 182
- neuropathic, 1571
- in OA, 204, 844, 1452
- in RA
  - repeat radiation synovectomy in, 789
  - synovitis in, 956
- rabbit, keratan sulfate, cartilage proteoglycan degradation and, 557
- in spondylepiphyseal dysplasia, 282
- synovium in, activation of, in rats, 653
- trauma to, complement protein synthesis and, 1365

## L

- La antigen, recombinant, in ELISA, 506
- La (SS-B) autoantibodies, in SLE, 496
- Lamina, internal elastic, amyloidosis of, giant cell inflammation and, 1186
- Laminin
  - antibodies and, in Raynaud's phenomenon, 1432
  - disease activity in essential cryoglobulinemia and, 1558
- Lateral spine, in apophyseal arthritis in AS, 798
- Laxity, joint, in temporomandibular joint dysfunction, 1259
- Lectin, OA cartilage morphology in knee in STR/IN mice and, 898
- Leg
  - in iliopsoas bursitis, 1331
  - livedo reticularis in hyperoxaluria and, 1199
  - pseudothrombophlebitis in, 1591
- Leprosy, PR4 idiotype in autoimmune rheumatic diseases and, 1097
- Lesions
  - avascular, nailfold capillary microscopy and, in PM and DM, 116
  - eicosanoid metabolism in murine collagen arthritis and, 1406
  - nodular, in pigmented villonodular synovitis, 1442
  - OA, in knee cartilage of STR/IN mice, 898
  - skin, in progressive ankylosis in mice, 1390
  - in SLE, 159, 1000
  - spontaneous cartilage degeneration in guinea pig and, 561
  - in subacute cutaneous LE, 1007
- Leu-1 cells, B cells and, in Sjögren's syndrome, 642
- Leu-2a cells, IL-2 in PSS and, 401
- Leu-3+ cells, in RA, 52
- Leu-3a cells
  - IL-2 in PSS and, 401

Leu-3a cells (*cont'd*)

in RA, TLI and, 21

Leucovorin, methotrexate and, in RA, 906, 1587

## Leukemia

- adult T cell, proliferative synovitis and, 1076
- B cell chronic lymphocytic, knee arthritis in, 815
- hairy cell, presenting as lupus-like illness, 566
- nonlymphocytic, after cyclophosphamide in lupus nephritis, 1552

Leukocyte function-associated 1 (LFA-1) antigen, phenotypic analysis of lymphocytes in RA and, 1230

## Leukocytes

- endothelial cellular cytotoxicity in scleroderma and, 1524
- IL-2 receptors in SLE and, 729
- tumor necrosis factor in RA and, 1041

Leukopenia, methotrexate in RA and, 167, 305

## Leukotrienes in RA

- B<sub>4</sub>, fasting and, 585
- biosynthesis of, effect of fasting on, 585

Lewis rats, protease inhibitors in experimental arthritis in, 1156

LFA-1 antigen, phenotypic analysis of lymphocytes in RA and, 1230

LFA-3 antigen, synovial fibroblast interactions with, 947

## Ligaments

- anterior cruciate, hyaluronic acid depletion in canine OA and, 538
- posterior longitudinal, ossification of, in AS, 452

Limited scleroderma, cutaneous, serum autoantibodies in, 196

## Linoleic acid

- fasting in RA and, 585
- gamma, in MSU crystal-induced inflammation, 1543

Lipase, diglyceride, IL-1 and, in rat synovial fibroblasts, 1421

## Lipids

- in articular tissue in CPPD crystal deposition disease, 1057
- diphosphoryl A, synoviocyte PGE<sub>2</sub> synthesis and, in rabbits, 238
- microspherules of, in pigmented villonodular synovitis, 1442

Lipomatosis, epidural, spinal cord compression by, in JRA, 447

## Lipopolysaccharides (LPS)

- complement protein synthesis and, 1365
- low-dose gold, fibroblasts, IL-1 and, 1272
- synoviocyte PGE<sub>2</sub> synthesis by, in rabbits, 238

## Lipoproteins

- apolipoproteins, inhibition of neutrophil stimulation and, 1081
- cholesterol in, in dyslipoproteinemia in pediatric SLE, 859

Liposomes, encapsulated indomethacin in, in rats, 414

Livedo reticularis, peripheral gangrene and, in hyperoxaluria, 1199

## Liver

- adverse reactions to methotrexate in RA and, 305
- antimitochondrial antibodies in scleroderma and, 386
- antinuclear antibodies in scleroderma in, in rats, 525
- biopsy of, 167, 1117, 1128
- peripheral fluorescent ANA in, in PM, 1322
- protease inhibitors in experimental arthritis and, 1156
- U1 RNP 68-kd protein autoantigen and, 616

- Low back pain  
in postdysenteric reactive arthritis, 1377  
in *Yersinia* arthritis, 533
- Low-dose methotrexate, in RA, 167
- Lumbar spine  
apophyseal arthritis and, in AS, 798  
in gorilla spondylarthropathy, 934  
in spondylepiphyseal dysplasia, 282  
spondylolisthesis, synovial cysts, sciatica and, 288
- Lumbosacral spine, acromegalic arthropathy in, 1022
- Luminal occlusion, renal vascular involvement in PSS and, 393
- Lung involvement  
adverse reactions to methotrexate in RA and, 305  
serum autoantibodies in SSc and, 196
- Lupus. *See also* Systemic lupus erythematosus  
arthritis, IgE and, in transient arthritis in rats, 1063  
autoantibodies in, DNA binding and, 367  
cerebral, brain lesions identified by MRI in, 159  
cerebritis, 632, 1105  
hybridoma anticytoskeletal antibodies in, 864  
N- $\alpha$ -ethylprocainamide, T cell autoreactivity and, 995  
PR4 idiotype and, 1097  
retinopathy in, 1105  
risk of, in newborns of mothers with SLE, 697  
subacute cutaneous LE, 1007  
tertatolol-induced, 145
- Lupus anticoagulant  
arterial thrombosis and, 570  
circulating, in lupus pregnancy, 358  
in SLE, 302, 864  
oral contraceptives and, 575
- Lupus-like illness, hairy cell leukemia presenting as, 566
- Lupus-like syndrome, propylthiouracil in cats and, 688
- Lupus nephritis  
acute nonlymphocytic leukemia after, 1552  
B lymphocyte function after TLI in, 1481  
glomerular membrane from kidney in, 570  
TLI in, 850
- Lupus pregnancy, placental changes in, 358
- Luteinizing hormone, in RA in men, 1314
- Lyme disease  
anticardiolipin antibodies in, 1052  
synovial fluid eosinophilia in, 1384
- Lymphadenopathy  
anti-IgE autoantibodies in SLE and, 1000  
propylthiouracil in cats and, 688
- Lymphedema, foot, uric acid levels and, 813
- Lymphoblastoid cells, B, DQB polymorphism in Felty's syndrome and, 990
- Lymphocytes  
anti-68K polypeptide reactivity and, 1265  
in childhood tuberculous rheumatism, 1311  
chlamydial antigen in Reiter's syndrome and, 937  
 $\gamma$ -interferon and, in collagen arthritis in mice, 1297  
K, endothelial cellular cytotoxicity in scleroderma and, 1524  
in Lyme synovitis, 487  
peripheral blood. *See* Peripheral blood lymphocytes  
PGE<sub>2</sub> modulation of RF synthesis and, 1473  
in RA
- Lymphocytes (*cont'd*)  
IL-2 receptors and, 844  
large granular, 31  
low-dose methotrexate and, 167  
in joints, 52  
phenotypic analysis of, 1230  
in synovitis, 956  
synovial, chlamydial antigen and, 914  
reactivity of, to oxypurinol and allopurinol, 436  
synovial fluid, in JRA, 780  
T. *See* T cells
- Lymphocytic leukemia, B cell, knee arthritis in, 815
- Lymphoid cells  
aminobisphosphonate, IL-1, bone resorption and, in mice, 762  
in Lyme synovitis, 487
- Lymphokines, aminobisphosphonate, IL-1, bone resorption and, in mice, 762
- Lymphoma  
malignant, CD5 expression in Sjögren's syndrome and, 642  
non-Hodgkin's T cell, of synovium, monarthritis and, 571
- Lymphotoxin, hyaluronic acid stimulation by, 1281
- Lysosomes, hepatocyte, after methotrexate in RA, 1465
- Lysozymes, fasting in RA and, 585

## M

- M2 complex, antimitochondrial antibodies in scleroderma and, 386
- Macrophages  
hyaluronic acid stimulation and, 1281  
low-dose gold, fibroblasts, IL-1 and, 1272  
in Lyme synovitis, 487  
synovial, chlamydial antigen in Reiter's syndrome and, 937
- Magnetic resonance imaging (MRI)  
of aseptic necrosis of hip, 570  
in neuropsychiatric SLE, 159, 623  
in RA  
for flat foot, 441  
for subluxation of the cervical spine, 304
- Major histocompatibility complex, in postdysenteric reactive arthritis, 1377
- Malalignment, of joints of hand, in RA, 44
- Malignancy  
anticardiolipin antibodies, anti-topo I and, in rheumatic diseases, 378  
bladder, cyclophosphamide and, in Wegener's granulomatosis, 465  
lupus nephritis and, 850, 1552  
naifold capillary microscopy and, in PM and DM, 116  
T cell cloning, cyclophosphamide and, 757
- Malignant lymphoma, CD5 expression in Sjögren's syndrome and, 642
- Mandible, in JRA, 602, 1309
- Mandibular condyle, temporomandibular joint disease, joint laxity and, 1259
- Master cells  
aminobisphosphonate, IL-1, bone resorption and, in mice, 762

### Mast cells (*cont'd*)

- cutaneous, anti-IgE autoantibodies in SLE and, 1000
- immunologic dysfunction in scleroderma and, 672
- synovial, in transient arthritis in rats, 1063

### Matrix

- breakdown of, enzyme-induced cartilage transformation and, 210
- cartilage, glycoprotein in, in synovial fluid in human OA, 553
- degeneration of, lipids in, CPPD crystals and, 1057

- Medial tibial plateau, spontaneous cartilage degeneration in guinea pig and, 561

- Melanoma cell lines, aminobisphosphonate, IL-1, bone resorption and, in mice, 762

- Meningeal rheumatoid nodules, in rheumatoid pachymeningitis, 570

- Meningitis, aseptic, ibuprofen-induced, 813

### Meniscus

- lipids in, in CPPD crystal deposition disease, 1057
- spontaneous cartilage degeneration in guinea pig and, 561

- Menopause, sex hormones, osteoporosis, and, RA after, 973

- Mental health questionnaires, self-measurement of functional status in RA and, 721

- Messenger RNA (mRNA), urokinase-type plasminogen activator in fibroblasts and, 1046

- Metabolism, oxidative, diet and, in MSU crystal-induced inflammation, 1543

- Metacarpal joint, low-dose methotrexate in RA and, 167

- Metacarpophalangeal joints, ARA 1987 revised criteria for classification of RA and, 315, 1452

- Metachromasia, of purified articular cartilage, proteoglycans and, 258

- Metalloproteinase, synovial fluid collagenase in shoulder arthropathy and, 882

### Metatarsophalangeal joints

- in RA, 1453
- swelling of, in progressive ankylosis in mice, 1390

### Methotrexate

- intravenous, in scleromyxedema myopathy, 1437
- in RA

- accelerated nodulosis and vasculitis during, 1182
- bone marrow suppression in, after surgery, 1586

- fatal pneumonitis in, 1585
- gold, hydroxychloroquine and, 1584

- leucovorin and, 906, 1587
- liver ultrastructure after, 1465

- long-term bolus, liver studies of, 1457
- long-term prospective study of, 577

- low-dose, 167, 299, 906
- RF synthesis and, 1090

- in steroid-resistant SLE, 612

- Methylcellulose suspension, oral encapsulated indomethacin in, in rats, 414

### Methylprednisolone

- intravenous pulse, in progressive necrotizing vasculitis, 1194
- use of, in rheumatology in the Soviet Union, 140

- Microangiopathy, in lupus retinopathy, 1105

- Microbes, in postdysenteric reactive arthritis, 1377

- Microfilaments, hybridoma SLE anticytoskeletal antibodies and, 864

- Micrognathia, in JRA, 1305

- Microhematuria, cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis and, 465

- Microspherules, lipid, in pigmented villonodular synovitis, 1442

- Microtubules, hybridoma SLE anticytoskeletal antibodies and, 864

- Microvascular endothelial cells, in scleroderma, 1524

- Milwaukee shoulder syndrome, PPI and nucleotide pyrophosphohydrolase in, 408

- Minerals, density of, in radial and spinal bone, 891

- Mitochondria, autoantibodies to, in SSc, 386

- Mitochondrion-like organelles, synovial fibroblasts in arthritis and, 339

### Mitogens

- pokeweed, 1473, 1481
- in RA

- IL-2 receptors on lymphocytes and, 1176
- in joint, phenotypes and, 52

- stimulation by, B cells and, after TLI, 1481
- synovial fibroblast-T cell interactions and, 947

- Mitosis, activation of rat synovium by iron and, 653

- Mixed connective tissue disease (MCTD). *See also* Connective tissue disease

- anti-68K polypeptide reactivity and, 1265
- HLA and immunoglobulin allotypes in, 131

- use of AI/RHEUM knowledge-based computer in, 219

- Mixed cryoglobulinemia, essential, monoclonal RF-IgG immune complexes in, 99

- Mixed hemadsorption assay, in study of novel neuronal antigen in SLE, 1492

- Monarthritis, revealing non-Hodgkin's T cell lymphoma of synovium, 571

- Monarticular joint disease, in reactive arthritis, 1377

- Monoclonal anti-(U1)snRNP, murine, anti-68K polypeptide reactivity and, 1265

### Monoclonal antibodies

- antiproteoglycan, immune synovitis, cartilage and, 248
- anti-Ro (SS-A), in Ro (SS-A)-immunized mice, 227

- common idiotype PR4 in autoimmune diseases and, 1097
- in Lyme synovitis, 487

- in RA, 52, 1230

- Monoclonal IgE, transient arthritis in rats and, 1063

- Monoclonal RF-IgG immune complexes, complement and, 99

### Monocytes

- human, IL-1 production by type II collagen and, 1508
- hyaluronic acid stimulation and, 1281

- IL-2 and, 401, 826
- in RA, 1209, 1481

- synovial fibroblast-T cell interactions and, 947

- Monokines, hyaluronic acid stimulation and, 1281

### Mononuclear cells

- activation of rat synovium by iron and, 653
- aminobisphosphonate, IL-1, bone resorption and, in mice, 762

- arthritis in Crohn's disease and, 1077
- peripheral blood. *See* Peripheral blood mononuclear cells in RA, 52, 956

- synovial fluid, 780, 1555

- Mononuclear cells (*cont'd*)  
 urokinase, plasminogen activator mRNA and, in fibroblasts, 1046
- Mononuclear phagocytes  
 fibroblast proliferation, penicillamine, CuSO<sub>4</sub> and, 964  
 low-dose gold, fibroblasts, macrophages, IL-1 and, 1272
- Mononucleosis, infectious, acute peri-arthritis in, 931
- Monosodium urate (MSU) crystals  
 inflammation induced by, diet enrichment and, 1543  
 inhibition of neutrophil stimulation and, 1081
- Mood Adjective Checklist, outpatient team care in RA and, 471
- Morbidity  
 diagnosis of polyarteritis nodosa by decision analysis model and, 1117, 1128  
 income loss in polyarthritis and, 348
- Morning stiffness  
 ARA revised criteria for classification of RA and, 315, 1452  
 cyclobenzaprine and, in fibrositis, 1535  
 sulfasalazine in AS and, 1111
- Morphology, of OA lesions in knee cartilage of STR/IN mice, 898
- Morphometry, renal vascular histology and, in SSc, 393
- Mortality, diagnosis of polyarteritis nodosa by decision analysis model and, 1117
- Mouse studies. *See also* BALB/c mice, C3H/HeJ mice, DBA/1 mice, MRL-*lpr/lpr* autoimmune mice, (New Zealand black × New Zealand white)F<sub>1</sub> mice, STR/IN mice  
 aminobisphosphonate, IL-1, bone resorption and, 762  
 anti-Ro (SS-A) antibodies in Ro (SS-A)-immunized mice, 227  
 anti-68K polypeptide reactivity, 1265  
 bromocriptine in postpartum collagen-induced arthritis, 927  
 CD5 expression in Sjögren's syndrome and, 642  
 collagen arthritis, 1297, 1406  
 eicosanoid metabolism inhibitors in collagen arthritis, 1406  
 progressive ankylosis, 1390
- Mouth, dry, parotid and minor salivary gland biopsy in Sjögren's syndrome and, 662
- MRL-*lpr/lpr* autoimmune mice, muscle involvement in connective tissue disease in, 806
- Mucosal involvement, in postdysenteric reactive arthritis, 1377
- Multicentric reticulohistiocytosis, childhood, 1588
- Multiple acyl coenzyme A dehydrogenase deficiency, riboflavin-responsive, proximal myopathy and, 695
- Multipurpose Arthritis Centers, ten-year progress report, 1574
- Murine progressive ankylosis, 1390
- Muscle  
 biopsy  
 in diagnosis of polyarteritis nodosa, 1117, 1128  
 in pseudothrombophlebitis, 1591  
 in scleromyxedema myopathy, 1437  
 sural nerve, in systemic necrotizing vasculitis, 149  
 skeletal, in connective tissue disease in mice, 806  
 strength, in scleromyxedema myopathy, 1437  
 tightness of, cyclobenzaprine and, in fibrositis, 1535
- Musculoskeletal involvement, in psoriatic arthritis and AIDS, 1034
- Mycobacterium leprae*-derived antigen, PR4 idiotype in autoimmune diseases and, 1097
- Mycobacterium terrae* tenosynovitis, 932
- Mycosis fungoides, in polyarthritis, 1335
- Myeloma, IgE, anti-IgE autoantibodies in SLE and, 1000
- Myofibril vacuolar changes, in scleromyxedema myopathy, 1437
- Myofibrillar loss, in connective tissue disease in mice, 806
- Myoglobinuria, pseudothrombophlebitis and, 1591
- Myopathy  
 multiple acyl coenzyme A dehydrogenase deficiency and, 695  
 scleromyxedema, 1437
- Myositis  
 antinuclear antibodies in SSc and, 525  
 anti-threonyl-tRNA synthetase in, 515  
 costochondral involvement in heroin addicts and, 793  
 nailfold capillary microscopy and, in PM and DM, 116
- N
- N-acetyl-D-glucosamine, synovial fluid antioxidant activity in RA and, 63
- N-acetylprocainamide, T cell autoreactivity and, 995
- Nailfold capillary microscopy, in PM and DM, 116
- Nalidixic acid, cinoxacin,  $\beta$ -cyanoalanine, chondrocytes and, 455
- Naproxen  
 eicosanoid metabolism in murine collagen arthritis and, 1406  
 phospholipase activity in rat synovial fibroblasts and, 1421
- Native collagen, antibodies to, 325, 776
- Native DNA, DNA binding specificity in SLE and, 367
- Natural killer cells, in SSc, 1515
- Nausea, low-dose methotrexate and, in RA, 167
- Necrosis  
 aseptic, of hip, MRI of, 570  
 fibrinoid, renal vascular involvement in scleroderma and, 393  
 muscle, in connective tissue disease in mice, 806
- Necrotizing enterocolitis, in polyarteritis nodosa, 683
- Necrotizing vasculitis  
 cyclophosphamide and methylprednisolone in, 1194  
 livedo reticularis and gangrene in hyperoxaluria and, 1199  
 systemic, sural nerve biopsy in, 149
- Neonatal lupus, risk of, in newborns of mothers with SLE, 697
- Nephrectomy, livedo reticularis and peripheral gangrene after, 1199
- Nephritis, lupus  
 B lymphocyte function after TLI in, 1481  
 leukemia after intravenous cyclophosphamide in, 1552  
 TLI in, 850
- Nerve  
 biopsy of, in diagnosis of polyarteritis nodosa, 1117, 1128  
 in connective tissue disease in mice, 806  
 Nerve conduction velocity, in diagnosis of polyarteritis nodosa, 1128



- Nerve root compression, spondylolisthesis, synovial cysts, sciatica and, 288
- Neuroblastoma cell lines, novel neuronal antigen (97K) in SLE and, 1492
- Neurofilaments, antibodies to, in neuropsychiatric SLE, 623
- Neurologic involvement
- anticardiolipin antibodies and, in Lyme disease, 1052
  - brain lesions identified by MRI in SLE, 159
  - impotence in scleroderma, 148
  - in RA, 304
  - spinal cord compression by epidural lipomatosis in JRA, 447
- Neuromuscular involvement, in connective tissue disease in mice, 806
- Neuronal antigens, novel (97K), in SLE, 1492
- Neuropathic joint, acute, 1571
- Neuropathy, thalidomide-induced, in RA, 145
- Neuropsychiatric SLE
- antineurofilament antibodies in, 623
  - identification of brain lesions by MRI in, 159
- Neutral collagenase, purified cartilage proteoglycan and, 258
- Neutropenia, large granular lymphocytes and, in RA, 31
- Neutrophils
- C3a, C5a and, in SLE, 632
  - chlamydial antigen in Reiter's syndrome and, 937
  - inhibition of stimulation of, by hydroxyapatite crystals, 1081
  - in RA, 63, 585
- (New Zealand black  $\times$  New Zealand white)F<sub>1</sub> mice, muscle involvement in connective tissue disease in, 806
- 97K antigen, novel neuronal antigen in SLE, 1492
- NMB-7 cell line, novel neuronal antigen (97K) in SLE and, 1492
- Nodules
- lesions in, pigmented villonodular synovitis and, 1442
  - rheumatoid, 315, 570, 1452
  - subcutaneous, 120, 1182
- Nodulosis, accelerated, methotrexate in RA and, 1182
- Non-Hodgkin's T cell lymphoma, of synovium, monoarthritis revealing, 571
- Nonlymphocytic leukemia, acute, after intravenous cyclophosphamide in lupus nephritis, 1552
- Nonsteroidal antiinflammatory drugs (NSAIDs)
- in childhood tuberculous rheumatism, 1311
  - gastrointestinal toxicity of, 1450
  - in JRA, 1252
  - in rheumatology in the Soviet Union, 140
- Nontraumatic compartmental syndrome, of calf, pseudo-thrombophlebitis caused by, 1591
- Novel neuronal antigens, in SLE, 1492
- Nuclear HEP-2 cellular antigens, anti-Ro (SS-A) monoclonal antibodies in mice and, 227
- Nuclear pore complexes, peripheral fluorescent ANA in PM and, 1322
- Nuclear ribonucleoprotein (nRNP)
- Ro (SS-A) autoantibodies and, in SLE, 496
  - small, U1, 1265
- Nuclease, characterization of Scl-70 antigen and, 108
- Nucleolar antigens, autoantibodies to, in SSc, 525
- Nucleotide pyrophosphohydrolase, in calcium phosphate deposition arthropathy and Milwaukee shoulder, 408
- Null alleles
- C4 molecular heterogeneity in SLE and, 736
  - C4B, in Felty's syndrome, 984
- O**
- O antigen, synovocyte PGE<sub>2</sub> synthesis by LPS and, 238
- Obituary, Steigerwald, James Carl, 929
- Octacalcium phosphate, inhibition of neutrophil stimulation and, 1081
- Olecranon bursitis, in idiopathic hypereosinophilic syndrome, 120
- Oligonucleotides, DQ $\beta$  polymorphism and, in Felty's syndrome, 990
- Oral contraceptives, antiphospholipid antibodies and, 575
- Oral gold, immune thrombocytopenia and, 299
- Oropharynx, EBV, B cells and, in Sjögren's syndrome, 1014
- Orthodontics, in jaw deformity in JRA, 1305
- Orthopedics, in outpatient team care in RA, 471
- Ossification, of posterior longitudinal ligament in AS, 452
- Osteitis
- costochondral involvement in heroin addicts and, 793
  - protease inhibitors of experimental arthritis and, 1156
- Osteoarthritis (OA)
- acromegalic arthropathy and, 1022
  - cartilage matrix glycoprotein in synovial fluid in, 553
  - collagen antibodies in, 325
  - enzyme-induced cartilage transformation in, 210
  - experimental, 538, 1400
  - generalized, serum keratan sulfate in, 648
  - hypertrophic, serum keratan sulfate in, 648
  - IL-1 in, 126, 1500
  - IL-2 receptors in RA and, 844
  - IL-6 in RA and inflammatory arthritides and, 784
  - infection in, 667
  - joint resection in, chondrocalcinosis after, 750
  - lesions in, in knee cartilage of STR/IN mice, 898
  - predictors of pain and function in, 204, 1452
  - purified cartilage proteoglycan and, 258
  - RA and, 63, 1314
  - spondylolisthesis, synovial cysts, sciatica and, 288
- Osteoarthropathy
- acute neuropathic joint and, 1571
  - of hip, Wilson's disease presenting as, 573
- Osteoblasts, tumor necrosis factor,  $\gamma$ -IFN, bone cells and, 1500
- Osteocalcin
- diphosphonate and, in Paget's disease of bone, 1142
  - plasma and bone levels of, in rat collagen arthritis, 1413
- Osteochondrodysplasias, in spondylepiphyseal dysplasia, 282
- Osteochondromata, in spondylepiphyseal dysplasia, 282
- Osteogenesis imperfecta, osteoporosis, connective tissue disease and, 1
- Osteopenia
- bone mineral density in, 891
  - periarticular, revised criteria for RA and, 315, 1452
  - in Wilson's disease, 573
- Osteoporosis
- collagen antibodies in, 325

Osteoporosis (*cont'd*)  
 osteogenesis imperfecta and, 1  
 radial and spinal bone mineral density and, 891  
 sex hormones and, in RA, 973  
 Osteosarcoma, aminobisphosphonate, IL-1, bone resorption and, 762  
 Osteotomy, Le Fort I, in jaw deformity in JRA, 1305  
 Outcome studies, socioeconomic status, health status and, in SLE, 423  
 Outpatient care, team, in RA, 471  
 Overlap syndromes  
 anti-threonyl-tRNA synthetase in myositis and, 515  
 CD5 expression and, in Sjögren's syndrome, 642  
 HLA-DR4 antigen in polymyalgia rheumatica and, 678  
 Oxidative metabolism, diet enrichment in MSU crystal-induced inflammation and, 1543  
 Oxypurinol, lymphocyte reactivity to, allopurinol and, 436

## P

Pachymeningitis, rheumatoid, 570  
 Paget's disease  
 of bone, diphosphonate and osteocalcin in, 1142  
 collagen antibodies in, 325  
 Pain  
 in acute neuropathic joint, 1571  
 adrenocorticotrophic hormone and indomethacin in gout and, 803  
 apophyseal arthritis in AS and, 798  
 cardiovascular fitness in primary fibromyalgia and, 1135  
 chronic, tenderness in, 182  
 cyclobenzaprine and, in fibrositis, 1535  
 joint, 167, 348  
 low back. *See* Low back pain  
 predictors of, in OA knee or hip, 204, 1452  
 in RA  
 AIMS and, 714  
 index of, abnormal IgG glycosylation and, 333  
 management of, 593  
 tendon rupture, flat foot and, 441  
 Pannus, in RA  
 fibroblasts, penicillamine, CuSO<sub>4</sub> and, 964  
 gold, fibroblasts, macrophages, IL-1 and, 1272  
 Papular rash, in scleromyxedema myopathy, 1437  
 Papulosquamous disease, in subacute cutaneous LE, 1007  
 Parenteral adrenocorticotrophic hormone, indomethacin and, in acute gout, 803  
 Parlodol, in postpartum collagen-induced arthritis, 927  
 Parotid gland, biopsy of, in Sjögren's syndrome, 662  
 Parvovirus B19 DNA, human, in synovial fluid, 279  
 Patella, OA cartilage morphology in, in STR/IN mice, 898  
 Patient assessment  
 cardiovascular fitness in primary fibromyalgia and, 1135  
 of cyclobenzaprine-treated fibrositis patients, 1535  
 global assessment, low-dose methotrexate in RA and, 167  
 outpatient team care in RA and, 471  
 Patient evaluation process, adjustment to RA and, 1245  
 Pediatric systemic lupus erythematosus (SLE). *See also* Systemic lupus erythematosus  
 dyslipoproteinemia in, 859

Penicillamine  
 fibroblast proliferation by, 964  
 in JRA, 15, 1252  
 natural killer cells in SSc and, 1515  
 RF synthesis and, in RA, 1090  
 Penicillin, in clostridial septic arthritis, 295  
 Peptides  
 autoantibodies to intracellular proteins in SLE and, 1337  
 cyanogen bromide, IL-1 production by type II collagen and, 1500  
 Periarthritis, acute, in infectious mononucleosis, 931  
 Periarticular osteopenia, ARA 1987 revised criteria for classification of RA and, 315, 1452  
 Periarticular tissue, in progressive ankylosis in mice, 1390  
 Pericardial tamponade, acute, in Wegener's granulomatosis, 300  
 Perichondritis, costochondral involvement in heroin addicts and, 793  
 Pericytes, activation of rat synovium by iron and, 653  
 Perilobular inflammation, methotrexate in RA and, 1457  
 Perimysial/endomysial inflammation, in connective tissue disease in mice, 806  
 Peripheral arthritis, HLA and immunoglobulin allotypes in MCTD and, 131  
 Peripheral arthropathy, acromegaly and, 1022  
 Peripheral blood  
 arthritis in Crohn's disease and, 1077  
 B cells, hyperactivity of, in SLE, 80  
 cell phenotypes in RA joint and, 52  
 lymphocytes in  
 anti-68K polypeptide reactivity and, 1265  
 in childhood tuberculous rheumatism, 1311  
 IL-2 in PSS and, 401  
 in RA, 21, 909, 1176, 1230  
 reactivity of, to oxypurinol, allopurinol and, 436  
 T cell cloning, cyclophosphamide and, 757  
 mononuclear cells  
 IL-1 production by collagen and, 1508  
 in juvenile arthritis, 1334  
 RF synthesis in RA and, 1090  
 TLI and, 850, 1481  
 synovial fibroblast-T cell interactions and, 947  
 Peripheral fluorescent ANA, novel autoantibodies and, in PM, 1322  
 Peripheral gangrene, livedo reticularis and, in primary hyperoxaluria, 1199  
 Peripheral joints  
 destruction of, C1q and, in RA, 37  
 in progressive ankylosis in mice, 1390  
 in *Yersinia* arthritis, 533  
 Peripheral mononuclear phagocytes, fibroblasts, penicillamine, CuSO<sub>4</sub> and, 964  
 Peripheral vascular disease, serum autoantibodies in PSS and, 196  
 Persistent classic RA, stability of normal joints in, 267  
 Phagocytes  
 fibroblast proliferation, penicillamine, CuSO<sub>4</sub> and, 964  
 mononuclear, gold, fibroblasts, macrophages, IL-1 and, 1272  
 Pharmacists, in outpatient team care in RA, 471  
 Pharmacokinetics, of methotrexate in RA, 305

- Pharyngeal dysphagia, in scleromyxedema myopathy, 1437
- Phenidone, eicosanoid metabolism in collagen arthritis and, 1406
- Phenolic glycolipid-1, PR4 idiotype in autoimmune diseases and, 1097
- Phenothiazine-induced SLE, with superior vena cava syndrome, 923
- Phenotypes  
cloning of scleroderma fibroblasts and, 1221  
lymphocyte analysis and, in RA, 1230
- Phorbol myristate acetate, phytohemagglutinin, IL-2 and, in SLE, 826
- Phosphate  
basic calcium (BCP), crystals, 408, 1081  
hybridoma anticytoskeletal antibodies in SLE and, 864  
IgE and, in transient arthritis in rats, 1063
- Phosphatidylcholine, oral encapsulated indomethacin in rats and, 414
- Phospholipase  
A<sub>2</sub>, IL-1 and, in human synovial cells, 126  
IL-1 stimulation of, in rat synovial fibroblasts, 1421
- Phospholipids  
fasting in RA and, 585  
hybridoma anticytoskeletal antibodies in SLE and, 864  
oral encapsulated indomethacin in rats and, 414
- Phosphoprotein, hybridoma SLE anticytoskeletal antibodies and, 864
- Photosensitivity, in subacute cutaneous LE, 1007
- Physical function, AIMS in RA and, 714
- Physician assessment  
cardiovascular fitness in primary fibromyalgia and, 1135  
in cyclobenzaprine-treated fibrositis patients, 1535  
global, low-dose methotrexate in RA and, 167
- Phytohemagglutinin  
CD5 expression in Sjögren's syndrome and, 642  
IL-2 and, 401, 826
- Pigmented villonodular synovitis  
lipid microspherules in, 1442  
in spondylepiphyseal dysplasia, 282
- Pima Indian studies, RF in prediction of RA in, 1239
- Pinocytosis, activation of rat synovium by iron and, 653
- Piroxicam, eicosanoid metabolism in murine collagen arthritis and, 1406
- PL-7 antigen, anti-threonyl-tRNA synthetase in myositis and, 515
- Placenta  
antimitochondrial antibodies in scleroderma and, 386  
changes in, in lupus pregnancy, 358
- Plant seed oil, in diet enrichment in MSU crystal-induced inflammation, 1543
- Plasma cells, chlamydial antigen in Reiter's syndrome and, 937
- Plasma osteocalcin, in rat collagen arthritis, 1413
- Plasminogen activator  
hyaluronic acid stimulation and, 1281  
IL-2, phospholipase A<sub>2</sub> and, in human synovial cells, 126  
urokinase, mRNA, synovial fibroblasts and, 1046
- Platelets  
chlamydial antigen in Reiter's syndrome and, 937  
fasting in RA and, 585
- Platelets (*cont'd*)  
gamma globulin in gold-induced thrombocytopenia and, 454
- PM-Scl antigen, antinucleolar antibodies in SSc and, 525
- Pneumatosis intestinalis, in polyarteritis nodosa, 683
- Pneumonitis  
interstitial, in ANA-negative SLE, 545  
methotrexate, in RA, 1585
- Pokeweed mitogen  
B cell function and, after TLI in RA and lupus nephritis, 1481  
PGE<sub>2</sub> modulation of RF synthesis and, 1473
- Poly(ADP)-ribose, PR4 idiotype in autoimmune diseases and, 1097
- Polyamine synthesis, recombinant human IL-1 $\beta$ , rabbit chondrocytes and, 1290
- Polyarteritis, cholesterol emboli syndrome mimicking, 570
- Polyarteritis nodosa  
cyclophosphamide and methylprednisolone in vasculitis in, 1194  
diagnosis of, 1117, 1128  
gastrointestinal involvement in, 683
- Polyarthralgia, in Hashimoto's thyroiditis, 303
- Polyarthritis  
adjuvant-induced, synovial cells in, 769  
income loss in, 348  
mycosis fungoides in, 1335  
nonerosive, in idiopathic hypereosinophilic syndrome, 120
- Polyarticular joint disease, in reactive arthritis, 1377
- Polyclonal anti-Ro (SS-A), anti-Ro (SS-A) monoclonal antibodies in mice and, 227
- Polyclonal B cells  
activation of, EBV and, in Sjögren's syndrome, 1014  
autoantibodies to intracellular proteins in SLE and, 1337  
CD5 expression in Sjögren's syndrome and, 642
- Poly(dA-dC)-poly(dG-dT), Poly(dG-dC)-poly(dG-dC), Poly(dG-m<sup>5</sup>dC)-poly(dG-m<sup>5</sup>dC), DNA binding specificity in SLE and, 367
- Poly(dT), PR4 idiotype in autoimmune diseases and, 1097
- Polyethylene glycol, oral encapsulated indomethacin in, rats, 414
- Polymerase I, RNA, antinucleolar antibodies in PSS and, 525
- Polymers, DNA binding, lupus autoantibodies and, in SLE, 367
- Polymorphisms  
DQB $\beta$ , genetics and, in Felty's syndrome, 990  
immunoglobulin gene, in psoriatic arthritis, 276
- Polymorphonuclear neutrophils, chlamydial antigen in Reiter's syndrome and, 937
- Polymyalgia rheumatica, HLA-DR4 antigen in, 678
- Polymyositis (PM)  
anti-threonyl-tRNA synthetase in myositis and, 515  
naifold capillary microscopy in, 116  
peripheral fluorescent ANA in, 1322
- Polynucleotides, DNA binding specificity in SLE and, 367
- Polypeptides  
antinucleolar antibodies in SSc and, 525  
hyaluronic acid stimulation by, 1281  
peripheral fluorescent ANA in PM and, 1322  
68K, autoantibodies, reactivity of, 1265  
synovial cells in adjuvant-induced polyarthritis and, 769

- Polysaccharides  
 purified cartilage proteoglycan and, 258  
 synovocyte PGE<sub>2</sub> synthesis, LPS and, in rabbits, 238
- Poncet's disease (tuberculous rheumatism), childhood, 1311
- Portal inflammation, long-term bolus methotrexate in RA and, 1457
- Portal vein, in polyarteritis nodosa, 683
- Postdysenteric reactive arthritis, salmonellosis and, 1377
- Posterior longitudinal ligament, ossification of, in AS, 452
- Postural changes, in AS, 570
- PR4 common idiotype, in autoimmune rheumatic disease, 1097
- Prednisolone, sex hormones, osteoporosis and, in RA, 973
- Prednisone  
 low-dose methotrexate in RA and, 167  
 oral, in scleromyxedema myopathy, 1437  
 in polyarteritis nodosa, 1194
- Pregnancy  
 bromocriptine in postpartum collagen arthritis and, 927  
 in SLE  
 C3a, C5a and, 632  
 placental changes in, 358
- Prevalence studies, diagnosis of PAN by decision analysis model and, 1117
- Primary biliary cirrhosis, antimitochondrial antibodies in scleroderma and, 386
- Primary fibromyalgia, cardiovascular fitness training program in, 1135
- Primary Raynaud's disease, anticentromere antibodies and anti-topo I in, 378
- Primary Raynaud's phenomenon, antibodies against basement membrane antigens in, 1432
- Primary Sjögren's syndrome  
 B cells and CD5 expression in, 642  
 parotid and minor salivary gland biopsy in, 616
- Problem-solving techniques, pain management in RA and, 593
- Procainamide, T cell autoreactivity, N-acetylprocainamide and, 995
- Procollagen, type I, in osteogenesis imperfecta, 1
- Progressive ankylosis, in mice, 1390
- Progressive systemic sclerosis (PSS). *See also* Scleroderma, Systemic sclerosis  
 fibroblast cloning in, 1221  
 IL-2 in, 401
- Prokaryotes, autoantibodies to intracellular proteins in SLE and, 1337
- Prolactin  
 bromocriptine in postpartum collagen-induced arthritis and, 927  
 in RA in men, 1314
- Proliferative synovitis, adult T cell leukemia and, 1076
- Proline, antimitochondrial antibodies in scleroderma and, 386
- Propylthiouracil, anti-native DNA antibodies in cats receiving, 688
- Prostacyclin, endothelial cellular cytotoxicity in scleroderma and, 1524
- Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>)  
 IL-1, phospholipase A<sub>2</sub> and, in human synovial cells, 126  
 modulation of RF synthesis and, 1473
- Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) (*cont'd*)  
 phospholipase activity in rat synovial fibroblasts and, 1421  
 recombinant human IL-1 $\beta$ , rabbit chondrocytes and, 1290  
 synovocyte synthesis of, by LPS, 238  
 TLI and, in RA, 21
- Prostaglandins (PG)  
 aminobisphosphonate, IL-1, bone resorption and, in mice, 762  
 bone cells,  $\gamma$ -IFN, tumor necrosis factor and, 1500  
 phospholipase activity in rat synovial fibroblasts and, 1421
- Prostanoid release, recombinant human IL-1 $\beta$ , rabbit chondrocytes and, 1290
- Prosthetic valve replacement, intracardiac thrombus in SLE with lupus anticoagulant and, 1453
- Protease inhibitors in experimental arthritis, 1156
- Protein  
 cartilage matrix proteoglycan in synovial fluid in human OA and, 553  
 characterization of Scl-70 antigen and, 108  
 complement synthesis, synovial fibroblasts and, 1365  
 flavoprotein, mitochondrial, synovial fibroblasts in arthritis and, 339  
 inhibition of neutrophil stimulation and, 1081  
 low-dose methotrexate in RA and, 167  
 in lymphocytes, in childhood tuberculous rheumatism, 1311  
 osteocalcin, in Paget's disease of bone, 1142  
 recombinant La antigen in ELISA and, 506  
 in scleroderma and, 386, 525, 1221, 1524  
 in SLE, 88, 564, 623, 859, 864, 1337  
 synovial cells in adjuvant-induced polyarthritis and, 769  
 26-kd (IL-6), in RA and inflammatory arthritides, 784  
 U1 RNP 68-kd, autoantigen, 616
- Proteinase, alpha<sub>1</sub>, inhibitor of neutrophil stimulation and, 1081
- Proteinuria  
 GST, sulfasalazine and, in RA, 702  
 IL-2 in SLE and, 729
- Proteoglycan  
 cartilage, 248, 258, 557, 648  
 enzyme-induced cartilage transformation and, 210  
 hyaluronic acid depletion in canine OA and, 538  
 spontaneous cartilage degeneration in guinea pig and, 561
- Proximal dysphagia, in scleromyxedema, 1437
- Proximal interphalangeal joints  
 ARA revised criteria for classification of RA and, 315, 1452  
 swelling of, in progressive ankylosis in mice, 1390
- Proximal myopathy  
 multiple acyl coenzyme A dehydrogenase deficiency and, 695  
 in scleromyxedema, 1437
- Proximal scleroderma, anticentromere antibodies and anti-topo I in, 378
- Pseudogout. *See* Chondrocalcinosis
- Pseudothrombophlebitis, caused by nontraumatic calf compartmental syndrome, 1591
- Psoriasis, liver ultrastructure after methotrexate in, 1465
- Psoriatic arthritis  
 AIDS and, 1034  
 immunoglobulin gene polymorphism and, 276  
 synovial fibroblast-T cell interactions in, 947



Psychological factors, as predictor of pain and function in OA, 204, 1452  
 Psychological status, in RA, 593, 714  
 Psychosocial factors  
   cardiovascular fitness in primary fibromyalgia and, 1135  
   clinical correlates of the Arthritis Helplessness Index and, 876  
   outpatient team care in RA and, 471  
   self-evaluation process, adjustment to RA and, 1245  
 PtK2 cells, peripheral fluorescent ANA in PM and, 1322  
 Pulmonary interstitial fibrosis, serum autoantibodies in SSC and, 196  
 Pulmonary involvement, nailfold capillary microscopy and, in PM and DM, 116  
 Pyrogen, IL-1 production by type II collagen and, 1508  
 Pyrophosphate  
   inorganic, in Milwaukee shoulder, 408  
   synovial fluid collagenase in shoulder arthropathy and, 882  
 Pyrophosphohydrolase, nucleotide, in calcium phosphate deposition arthropathy and Milwaukee shoulder, 408

## Q

Quality of life, AIMS in RA and, 714  
 Questionnaires  
   Arthritis Helplessness Index, 876  
   functional status, 721

## R

Rabbit studies  
   articular responses to purified cartilage proteoglycan, 258  
   effect of recombinant human IL-1 $\beta$  on chondrocytes of, 1290  
   joint damage in experimental hemophilic arthritis, 1148  
   keratan sulfate after cartilage proteoglycan degradation in knee and, 557  
   synovocyte PGE<sub>2</sub> synthesis by LPS, 238  
 Radiation synovectomy, with dysprosium 165-ferric hydroxide, in RA knee, 789  
 Radiography  
   as predictor of pain and function in OA knee or hip, 204, 1452  
   in apophyseal arthritis in AS, 798  
   in RA, 44  
   prediction of RA by RF and, 1239  
 Radius, bone mineral density of, 891  
 Range of motion, joint counts in hand in RA and, 44  
 Rash  
   GST, sulfasalazine and, in RA, 702  
   papular, in scleromyxedema myopathy, 1437  
 Rat studies. *See also* Sprague-Dawley rats  
   activation of synovium by iron, 653  
   adjuvant-induced polyarthritis, 769  
   anti-HaT-1 antibody system in RA, 135  
   IL-1 and, 762, 1421  
   oral encapsulated indomethacin, 414  
   peripheral fluorescent ANA in human PM and, 1322  
   plasma and bone osteocalcin in collagen arthritis, 1413  
   of scleroderma, 386, 525  
   transient arthritis, synovial mast cells and IgE in, 1063

Raynaud's disease  
   anticentromere antibodies and anti-topo I in, 378  
   natural killer cells in SSC and, 1515  
 Raynaud's phenomenon  
   antibodies against basement membrane antigens in, 1432  
   nailfold capillary microscopy and, in PM and DM, 116  
   nodulosis, vasculitis and, during methotrexate in RA, 1182  
 Reactive arthritis  
   postdysenteric, salmonellosis outbreak and, 1377  
   *Shigella sonnei* infection and, 1190  
   synovial fibroblasts in, 339  
   tumor necrosis factor in RA and, 1041  
   *Yersinia* arthritis and, 533  
 Recombinant autoantigens, U1 RNP 68-kd protein, 616  
 Recombinant  $\gamma$ -IFN, human, effect of, on bone cells, 1500  
 Recombinant human interleukin-1  
   effects of, on rabbit articular chondrocytes, 1290  
   urokinase, plasminogen activator mRNA and, in fibroblasts, 1046  
 Red blood cells, IgG glycosylation in RA and, 333  
 Reference reagents for ANA, 1331  
 Reiter's syndrome  
   chlamydial antigen in synovial membrane in, 937  
   epidemiology of, 428  
 Relaxation training, pain management in RA and, 593  
 Renal disease, TLI in lupus nephritis and, 850  
 Renal failure, chronic, destructive spondylarthropathy and, 1331  
 Renal function, pseudothrombophlebitis and, 1591  
 Renal involvement  
   Ro (SS-A) autoantibodies in SLE and, 496  
   in scleroderma, 196, 393, 525  
   in Wegener's granulomatosis, 1068, 1073  
 Renal stones, drug-containing, 1450  
 Respiratory tract infections, trimethoprim/sulfamethoxazole in Wegener's granulomatosis and, 1068, 1073  
 Restriction endonuclease *Sst* I, in psoriatic arthritis, Ig gene polymorphism and, 276  
 Restriction fragment length polymorphisms, T cell receptors and  
   in RA, 1555  
   in SLE, 1371  
 Reticulohistiocytosis, multicentric, childhood, 1588  
 Retinoic acid, urokinase, plasminogen activator mRNA and, in fibroblasts, 1046  
 Retinopathy, in SLE, 632, 1105  
 Rheumatic diseases  
   anticentromere antibodies and anti-topo I in, 378  
   autoimmune, common idiotype PR4 in, 1097  
   childhood HLA-B27-associated arthropathy and, 1165  
   collagen antibodies in, 325  
   complement complex C5b-9 in, 188  
   erythrocytes, CR1, and immune complexes in, 153  
   hyaluronic acid stimulation in, 1281  
   IL-2 receptors and disease activity in, 1358  
   in the Soviet Union, 140  
   as studied in multipurpose arthritis centers, 1574  
   temporomandibular joint dysfunction and, 1259  
   use of AI/RHEUM knowledge-based computer in, 219



## Rheumatism

- soft tissue, infection in, 667
- tuberculous, childhood, 1311

## Rheumatoid arthritis (RA)

- accelerated nodulosis during methotrexate treatment in, 1182
- adjustment in, 1245
- AIMS factor analysis in, 714
- antibodies to native type II collagen in, 776
- anti-HaT-1 antibody system in, 135
- anti-human immunoglobulin in, 60
- antioxidant activity of synovial fluid and hyaluronic acid in, 63
- Arthritis Helplessness Index in, 876
- atlantoaxial subluxation in, 918
- B lymphocyte function after TLI in, 1481
- bromocriptine and cyclosporin A in, 1333
- C1q and joint destruction in, 37
- C4B-null alleles in Felty's syndrome and, 984
- CD5 expression in Sjögren's syndrome and, 642
- central nervous system in, 304
- classic, 267
- collagen (type II) production of IL-1 and, 1508
- collagen antibodies in, 325
- collagenase in synovial fluid in, 882
- criteria for classification of (1987 revisions), 315, 1452
- diffusional-associated thrombocytopenia in, 148
- disease activity in, 1358
- DQB polymorphism, Felty's syndrome and, 990
- DR4-associated DR-DQ haplotype in, 72
- fasting in, 585
- flat feet in, tibialis posterior tendon rupture and, 441
- folinic acid in, 906
- formal education and clinical status in, 1346
- functional status in, self-measurement of, 721
- GST in, 176, 702, 909
- hand in, 44
- health status model in, 714
- hyaluronic acid in, 63
- $\beta$ -IFN and monocyte activation in, 1209
- IgG glycosylation in, 333
- IL-1 in, 126, 480, 1508
- IL-2 in
  - receptors, 844, 1176, 1358
  - in synovial fluid, 1590
- IL-6 in, 784
- immune injury and TLI in, 21
- immunoreactive erythropoietin in, 1318
- infection in, 667
- intractable, TLI and joint damage in, 146
- joints in
  - counts of, in hand, 44
  - damage to, TLI and, 146
  - destruction of, C1q and, 37
  - stability of, 267
- large granular lymphocytes in, 31
- leucovorin and methotrexate in, 906, 1587
- liver after methotrexate treatment in, 1457, 1465
- Lyme synovitis and, 487
- metatarsophalangeal joint in, 1453

## Rheumatoid arthritis (RA) (cont'd)

- methotrexate in, 167, 299, 305, 577, 906, 1182, 1457, 1465, 1584, 1585, 1586, 1587
  - monocyte activation and  $\gamma$ -IFN in, 1209
  - Motrin in, 299
  - MRI in cervical spine subluxation in, 304
  - network regulation in, 834
  - neurologic involvement in, 304
  - outpatient team care in, 471
  - pachymeningitis in, 570
  - pain management in, 593
  - pannus in, 964, 1272
  - peripheral blood lymphocyte depletion after GST treatment in, 909
  - PGE<sub>2</sub> modulation of RF synthesis and, 1473
  - phenotypes in, joints and, 52
  - phospholipase A<sub>2</sub> in human synovial cells in, 126
  - PR4 idiotype in, 1097
  - prediction of, by RF, 1239
  - repeat radiation synovectomy in knee in, 789
  - RF in, 1090, 1204, 1239
  - Ritchie articular index in, 906
  - self-evaluation processes and adjustment in, 1245
  - seropositive, 72, 776, 789
  - sex hormones in, 973, 1314
  - in the Soviet Union, 140
  - subluxation of cervical spine in, MRI in, 304
  - sulfasalazine in, 702
  - synovial fibroblasts in, 339, 947
  - synovial fluid in, 63, 1555, 1590
  - synovial lymphocytes and chlamydial antigen in, 914
  - synovitis in, 956, 1075
  - T cells in, 176, 947, 1075, 1555
  - thalidomide-induced neuropathy in, 145
  - TLI in, 21, 1481
  - vasculitis during methotrexate in, 1182
- ## Rheumatoid factor (RF)
- anti-idiotypes, Fc receptors and, 1204
  - hybridoma SLE anticytoskeletal antibodies and, 864
  - IgM, IgM anticardiolipin antibodies and, 1212
  - monoclonal, IgG immune complexes, complement and, 99
  - in RA, 21, 52, 315, 1090, 1239, 1452
  - synthesis of, PGE<sub>2</sub> modulation of, 1473
  - tests for, 432
- ## Rheumatoid nodules
- ARA revised criteria for classification of RA and, 315, 1452
  - meningeal, in rheumatoid pachymeningitis, 570
- ## Rheumatoid pachymeningitis, 570
- ## Rheumatoid pannus, low-dose gold, fibroblasts, macrophages, IL-1 and, 1272
- ## Rheumatoid synovium, Lyme synovitis and, 487
- ## Rheumatology and rheumatologists
- ARA and, 1217
  - description of rheumatology practice, 152
  - evaluation of clinical competence of training programs in, 1447
  - in outpatient team care in RA, 471
  - in the Soviet Union, 140
  - use of AI/RHEUM knowledge-based computer, 219

Rheumatology education  
 ARA role in, 1217  
 evaluation of clinical competence in, 1447  
 in multipurpose arthritis centers, 1574  
 Riboflavin, multiple acyl coenzyme A dehydrogenase deficiency and, 695  
 Ribonucleic acid (RNA)  
 anti-Ro (SS-A) antibody detection in mice and, 227  
 immunoprecipitation, anti-Sm polypeptides and, in SLE, 1563  
 messenger, urokinase-type plasminogen activator and, 1046  
 polymerase I, antinucleolar antibodies in PSS and, 525  
 transfer, anti-threonyl, in myositis, 515  
 U1, anti-68K polypeptide reactivity and, 1265  
 Ribonucleoprotein (RNP)  
 nuclear, Ro (SS-A) autoantibodies and, in SLE, 496  
 U1 RNP 68-kd protein autoantigen and, 616  
 U1 small nuclear, anti-68K polypeptide reactivity of, 1265  
 Ritchie articular index, leucovorin, methotrexate and, in RA, 906  
 RNase, peripheral fluorescent ANA in PM and, 1322  
 Ro (SS-A)  
 antigen, anti-Ro (SS-A) monoclonal antibodies and, 227  
 autoantibodies, in SLE, 496  
 mice immunized by, anti-Ro (SS-A) antibodies in, 227  
 Rupture, tibialis posterior tendon, as cause of rheumatoid flat foot, 441

## S

Sacroiliitis, in *Yersinia* arthritis, 533  
 Salivary gland, biopsy of, 272, 662  
*Salmonella typhi*, anterior uveitis in HLA-B27-associated AS and, 1454  
 Salmonellosis, postdysenteric reactive arthritis after outbreak of, 1377  
 Salt, DNA binding specificity in SLE and, 367  
 Scapula, posterior, tenderness of, in fibromyalgia, 182  
 Scarring, in subacute cutaneous LE, 1007  
 Schirmer's test  
 parotid and minor salivary gland biopsy in Sjögren's syndrome and, 662  
 in thyroid disorders in SLE with Sjögren's syndrome, 1079  
 Schober's test, in AS, 549, 798  
 Sciatic syndrome, degenerative spondylolisthesis, synovial cysts and, 288  
 Scl-70 antigen, characterization of, 108  
 Scleroderma. *See also* Progressive systemic sclerosis, Systemic sclerosis  
 autoantibodies to nucleolar antigens in, 525  
 diffuse, 195, 386, 525  
 fibroblasts in, 964, 1221  
 human microvascular endothelial cells in, 1524  
 immunologic dysfunction in, 672  
 impotence in, 148  
 limited cutaneous, serum autoantibodies in, 196  
 proximal, anticentromere antibodies and anti-topo I in, 378  
 renal vascular histology and morphometry in, 393  
 serum autoantibodies in, 196  
 in the Soviet Union, 140

Scleromyxedema myopathy, 1437  
 Secondary Raynaud's disease, anticentromere antibodies and anti-topo I in, 378  
 Secondary Raynaud's phenomenon, antibodies against basement membrane antigens in, 1432  
 Secondary Sjögren's syndrome, thyroid disorders in, in SLE, 1079  
 Seizures, in neuropsychiatric SLE, brain lesions identified by MRI in, 159  
 Senile amyloidosis, giant cell inflammation and, 1186  
 Septic arthritis, clostridial, 295  
 Seronegative RA, thrombocytopenia after oral gold treatment in, 299  
 Seropositive RA  
 anti-native type II collagen in, 776  
 erosive, DR4-associated DR-DQ haplotype in, 72  
 repeat radiation synovectomy in, 789  
 Serum autoantibodies, in SSc, 196  
 Serum amyloid P component, eicosanoid metabolism in murine collagen arthritis and, 1406  
 Serum keratan sulfate  
 cartilage proteoglycan degradation in rabbit knee and, 557  
 in OA, 648  
 7S IgG, C1q autoantibodies in SLE and, 457  
 17 beta-estradiol, in RA in men, 1314  
 Sex  
 formal education, clinical status and, in RA, 1346  
 incidence of temporal arteritis and, 745  
 infection in RA, OA, or soft tissue rheumatism and, 667  
 Sex hormones  
 in RA  
 in men, 1314  
 osteoporosis and, 973  
 Sharp-Purser test, assessment of atlantoaxial instability with, 918  
 Sheep red blood cell agglutination test  
 prediction of RA by RF and, 1239  
 for RF, 432  
*Shigella sonnei* infection, reactive arthritis and, 1190  
 Shoulder  
 joint, arthropathy of, synovial fluid collagenase in, 882  
 neuropathic, 1571  
 in postdysenteric reactive arthritis, 1377  
 tenderness of, in fibromyalgia, 182  
 Shulman disease, SLE after, 694  
 Sicca complex, Ro (SS-A) autoantibodies in SLE and, 496  
 Sicca syndrome, thyroid disorders and, in SLE with Sjögren's syndrome, 1079  
 Sickness Impact Profile, outpatient team care in RA and, 471  
 6-keto-prostaglandin  $F_{1\alpha}$ , recombinant human IL-1 $\beta$ , rabbit chondrocytes and, 1290  
 16/6 idiotype-positive anti-DNA antibody, 1429  
 68K polypeptide, autoantibodies, reactivity of, 1265  
 Sjögren's syndrome  
 AIDS mimicking, 272  
 anti-HaT-1 antibody system in RA and, 135  
 B cells in, 642, 1014  
 parotid and minor salivary gland biopsy in, 662  
 PR4 idiotype in, 1097  
 secondary, in SLE, thyroid disorders in, 1079  
 Skeletal muscle, in connective tissue disease in mice, 806

## Skin

- anticardiolipin antibodies, anti-topo I and, in rheumatic diseases, 378
- adverse reactions to allopurinol and, 436
- anti-IgE autoantibodies in SLE and, 1000
- in essential cryoglobulinemia, 1558
- fibroblasts in, complement protein synthesis and, 1365
- lesions of, in progressive ankylosis in mice, 1390
- psoriatic arthritis, AIDS and, 1034
- rash, methotrexate in RA and, 305
- in scleroderma, 196, 672, 1221, 1524
- SK-N-Mc cells, 1492
- SK-N-SH cells, 1492
- Sleep
  - cardiovascular fitness in primary fibromyalgia and, 1135
  - cyclobenzaprine and, in fibrositis, 1535
- Slow-acting antirheumatic drugs
  - comparison with auranofin and GST, 9
  - immune thrombocytopenia after oral gold and, 299
  - in JRA, 15, 1252
  - in RA, 146, 956
- Sm polypeptides, antibodies to, in SLE, 1563
- Sm/nRNP, autoantibodies, Ro (SS-A) and, in SLE, 496
- Small intestine, activation of rat synovium by iron and, 653
- Small nuclear ribonucleoprotein (snRNP), U1. *See* U1
- small nuclear ribonucleoprotein
  - <sup>35</sup>S-methionine, complement protein synthesis and, 1365
- Smokeless tobacco, thromboangiitis obliterans and, 812
- Socioeconomic status, health status in SLE and, 423
- Soft tissue
  - rheumatism, infection in, 667
  - swelling, criteria for classification of RA and, 315, 1452
- Solid-phase immunosorbent assay, anti-Ro (SS-A) monoclonal antibodies in mice detected by, 227
- Soviet Union, rheumatology in, 140
- SP2/0 cells, anti-Ro (SS-A) monoclonal antibodies in mice and, 227
- Space of Disse, collagen in, after methotrexate treatment in RA, 1465
- Spectroscopy, synovial fibroblasts in arthritis studied by, 339
- Spinal cord, compression of, by epidural lipomatosis, in JRA, 447
- Spine
  - "bamboo," in progressive ankylosis in mice, 1390
  - bone mineral density of, 891
  - cervical, 304, 602, 918
  - in gorilla spondylarthropathy, 934
  - lumbar, 288, 798
  - lumbosacral, acromegalic arthropathy in, 1022
  - progressive ankylosis of, in mice, 1390
- Spirochetal antigens, in Lyme synovitis, 487
- Spirochetes, anticardiolipin antibodies and, in Lyme disease, 1052
- Spleen, anti-Ro (SS-A) monoclonal antibodies in mice and, 227
- Splenomegaly, large granular lymphocytes and, in RA, 31
- Spondylarthropathy
  - animal model of, progressive ankylosis in mice, 1390
  - destructive, chronic renal failure and, 1331
  - in gorillas, 934

- Spondylepiphyseal dysplasia, late onset, synovial complications of, 282
- Spondylolisthesis, synovial cysts, sciatic syndrome and, 288
- Sprague-Dawley rats
  - diet enrichment in MSU crystal-induced inflammation, 1543
  - transient arthritis in, antigen-specific IgE and, 1063
- Sst I restriction endonuclease, in psoriatic arthritis, 276
- Stable plurilamellar vesicles, oral encapsulated indomethacin in rats and, 414
- Staphylococcus aureus* Cowan 1
  - B cell function and, after TLI, 1481
  - PGE<sub>2</sub> modulation of RF synthesis and, 1473
- Sterility, TLI in lupus nephritis and, 850
- Steroid drugs
  - CD5 expression in Sjögren's syndrome and, 642
  - IgG glycosylation in RA and, 333
  - resistance to, methotrexate and, in SLE, 612
  - spinal cord compression by epidural lipomatosis in JRA and, 447
  - TLI in lupus nephritis and, 850
- Stiffness, in idiopathic hypereosinophilic syndrome, 120
- Stomatitis, in RA, 167, 305, 702, 1587
- STR/IN mice, OA lesions in knee cartilage of, 898
- Streptococcal cell wall-induced arthritis, bis(5-amidino-2-benzimidazolyl)methane in, 1156
- Strongyloides stercoralis* hyperinfection, mimicking SLE, 930
- Su-2E4 lymphocyte cell line, anti-68K polypeptide reactivity and, 1265
- Subacute cutaneous LE, 1007
- Subchondral bone, examination of, by CT in OA, 1400
- Subcutaneous blood vessels, livedo reticularis, gangrene and, in hyperoxaluria, 1199
- Subcutaneous nodules, in idiopathic hypereosinophilic syndrome, 120
- Subcutaneous nodulosis, during methotrexate treatment in RA, 1182
- Subluxation
  - atlantoaxial, assessment of with Sharp-Purser test, 918
  - in cervical spine, in RA, MRI in, 304
- Sulfamethoxazole. *See* Trimethoprim/sulfamethoxazole
- Sulfasalazine
  - in AS, 1111
  - in RA, 702
- Suncreens, in subacute cutaneous LE, 1007
- Superior vena cava syndrome, in phenothiazine-induced SLE, 923
- Superoxides
  - dismutase, fibroblasts, penicillamine, CuSO<sub>4</sub> and, 964
  - production of, in adjuvant-induced polyarthritis, 769
  - release of, inhibition of neutrophil stimulation and, 1081
- Suppressor cells, cAMP and, in SLE, 88
- Suppressor/cytotoxic cells, phenotypic analysis of, in RA, 1230
- Suppressor/inducer cells, in joints in RA, 52
- Sural nerve biopsy, in systemic necrotizing vasculitis, 149
- Surgery
  - jaw, in JRA, 1305
  - joint resection, chondrocalcinosis after, 750
  - methotrexate bone marrow suppression after, 1586

## Surgery (cont'd)

- synovectomy, in clostridial septic arthritis, 295
- in tenosynovitis caused by *Exophiala mansonii*, 1213

## Survival

- serum autoantibodies in SSc and, 196
- in SLE, 1105, 1208

## Swelling

- ARA 1987 revised criteria for classification of RA and, 315
- IgE and, in transient arthritis in rats, 1063
- synovial fibroblasts in arthritis and, 339

## Symmetric polyarthritis, income loss in, 348

- Syndesmophytes, vertebral, in progressive ankylosis in mice, 1390

## Synovectomy

- in RA, 789, 914
- surgical, in clostridial septic arthritis, 295

## Synovial biopsy

- in RA, 21, 956
- in spondylepiphyseal dysplasia, 282

## Synovial cells

- activation of rat synovium by iron and, 653
- in adjuvant-induced polyarthritis, 769
- human, IL-1 and phospholipase A<sub>2</sub> in, 126
- hyaluronic acid stimulation and, 1281
- IL-1 stimulation of phospholipase activity in, in rats, 1421
- T cell interactions with, 947

## Synovial cysts, degenerative spondylolisthesis, sciatic syndrome and, 288

## Synovial fibroblasts

- activation of rat synovium by iron and, 653
- complement protein synthesis and, 1365
- cultured, flow cytometry and, 339
- human, hyaluronic acid stimulation and, 1281
- IL-1 stimulation of phospholipase activity in, in rats, 1421
- T cell interactions and, 947
- urokinase-type plasminogen activator mRNA in, 1046

## Synovial fluid

- analysis of, 152
- in arthritis in Crohn's disease, 1077
- cartilage matrix glycoprotein in, in human OA, 553
- in childhood multicentric reticulohistiocytosis, 1588
- collagenase in, in shoulder arthropathy, 882
- eosinophilia, in Lyme disease, 1384
- fibroblast-T cell interactions in, 947
- human parvovirus B19 DNA in, 279
- in idiopathic hypereosinophilic syndrome, 120
- IL-6 in, 784
- inhibition of neutrophil stimulation and, 1081
- lipids in, in pigmented villonodular synovitis, 1442
- lymphocytes in, 780, 914, 1311
- PPI and NPPH in, in Milwaukee shoulder, 408
- in RA

- antioxidant activity, hyaluronic acid and, 63
- cell phenotypes in joints in, 52
- IL-2 in, 844, 1590
- immune injury, TLI and, 21
- T cell antigen receptor  $\beta$  chain in, 1555
- tumor necrosis factor in, 1041
- in spondylepiphyseal dysplasia, 282

## Synovial infiltration, B cell, in lymphocytic leukemia, knee arthritis and, 815

## Synovial inflammation, in Lyme synovitis, 487

## Synovial iron load, joint damage in experimental hemophilic arthritis and, 1148

## Synovial joint tissue, synoviocyte PGE<sub>2</sub> synthesis, LPS and, 238

## Synovial lining

- activation of rat synovium by iron and, 653
- chlamydial antigen in Reiter's syndrome and, 937
- complement protein synthesis and, 1365
- synovial fibroblast-T cell interactions and, 947
- Synovial lymphocytes, chlamydial antigen and, in RA, 914
- Synovial mast cells, in transient arthritis in rats, 1063

## Synovial membrane

- chlamydial antigen in, in Reiter's syndrome, 937
- lipids in pigmented villonodular synovitis and, 1442

## Synovial tissue

- B cell chronic lymphocytic leukemia, knee arthritis and, 815
- in childhood multicentric reticulohistiocytosis, 1588
- fibroblast-T cell interactions in, 947
- lymphocytes, phenotypic analysis of, in RA, 1230
- in spondylepiphyseal dysplasia, 282
- synovial fibroblasts in arthritis and, 339

## Synoviocytes

- in adjuvant-induced polyarthritis, 769
- hyperplasia of, in synovitis in RA, 956
- PGE<sub>2</sub> synthesis of, LPS and, 238
- purified cartilage proteoglycan and, 258

## Synovitis

- caused by *Exophiala mansonii*, 1213
- chlamydial antigen in Reiter's syndrome and, 937
- chronic, in spondylepiphyseal dysplasia, 282
- human parvovirus B19 DNA in synovial fluid and, 279
- humoral immune response, cartilage pathology and, 248
- pigmented villonodular, 282, 1442
- proliferative, adult T cell leukemia presenting with, 1076
- protease inhibitors of experimental arthritis and, 1156
- purified cartilage proteoglycan and, 258
- in RA, 956
- synoviocyte PGE<sub>2</sub> synthesis by LPS and, 238
- teno-, *Mycobacterium terrum*, 932

## Synovium

- activation of, by iron in rats, 653
- chlamydial antigen in, in Reiter's syndrome, 937
- complications of spondylepiphyseal dysplasia and, 282
- fibroblast-T cell interactions in, 947
- inflammation of, hyaluronic acid stimulation and, 1281
- joint, IgE and, in transient arthritis in rats, 1063
- lipids in, in CPPD crystal deposition disease, 1057
- non-Hodgkin's T cell lymphoma of, monarthritis and, 571
- in RA, 480, 914, 1230

## Systemic candidiasis, costochondral involvement in, in heroin addicts, 793

## Systemic joint laxity, in temporomandibular joint dysfunction, 1259

## Systemic lupus erythematosus (SLE)

- AIDS mimicking, 272
- ANA-negative, interstitial pneumonitis in, 545
- anaphylatoxins in, 632
- androgens in, 150
- anticardiolipin antibodies in, 1211, 1568



Systemic lupus erythematosus (SLE) (*cont'd*)

- antineurofilament antibodies in, 623
- anti-Ro (SS-A) antibodies, lupus anticoagulant, and fetal loss in, 302
- anti-Sm polypeptides in, 1563
- aplastic anemia in, 693
- autoantibodies to intracellular proteins in, 1337
- B cell hyperactivity in, 80
- brain lesions identified by MRI in, 159
- C1q autoantibodies in, 457
- C3a and C5a in, 632
- C4 molecular heterogeneity in, 736
- C4A deficiency in black Americans with, 1171
- C5a in, 632
- C5b-9 and disease activity in, 188
- CD5 expression in Sjögren's syndrome and, 642
- circulating anticoagulant in, 1210
- complement in, 1211
- CR1, immune complexes, and erythrocytes in, 153
- cyclophosphamide in aplastic anemia in, 693
- disease activity in, 80, 188, 817, 1358
- disease flares in, 632, 1563
- DNA binding specificity in, 367
- dyslipoproteinemia in, 859
- fetal loss, lupus anticoagulant, and anti-Ro (SS-A) antibodies in, 302
- genetics and, 572
- hairy cell leukemia presenting as a lupus-like illness, 566
- health status and socioeconomic status in, 423
- HLA-DR antigens and anticardiolipin antibodies in, 1568
- hybridoma anticytoskeletal antibodies in, 864
- hypoprothrombinemia, circulating anticoagulant, and hemorrhage in, 1210
- IgG glycosylation in, 333
- IgM in, 1213
- IL-2 in, 729, 826, 1358
- interstitial pneumonitis in, 545
- intracardiac thrombus and lupus anticoagulant in, 1453
- lupus anticoagulant in, 302, 1453
- neonatal lupus and, 697
- neuropsychiatric, 159, 623
- novel neuronal antigen (97K) in, 1492
- pediatric, dyslipoproteinemia in, 859
- phenothiazine-induced, superior vena cava syndrome in, 923
- PR4 idiotype in, 1097
- pregnancy in, 358
- propylthiouracil in cats and, 688
- retinopathy in, 1105
- Ro (SS-A) autoantibodies in, 496
- Shulman disease and, 694
- Sjögren's syndrome in, thyroid disorders in, 1079
- socioeconomic status and health status in, 423
- in the Soviet Union, 140
- steroid-resistant, methotrexate in, 612
- Strongyloides stercoralis* hyperinfection mimicking, 930
- subacute cutaneous lupus erythematosus and, 1007
- survival in, 1208
- T cells in, 88, 572, 1371
- thyroid disorders and secondary Sjögren's syndrome in, 1079

- Systemic necrotizing vasculitis, sural nerve biopsy in, 149
- Systemic sclerosis (SSc). *See also* Progressive systemic sclerosis, Scleroderma
- anticollagen in Raynaud's phenomenon and, 1432
- autoantibodies in, 196, 386, 525
- natural killer cells in, 1515
- renal vascular histology and morphometry in, 393

T

T cells

- autoreactivity of, N-acetylprocainamide and, 995
- cloning of, cyclophosphamide and, 757
- DR+, 834
- $\gamma$ -IFN and, in collagen arthritis in mice, 1297
- HLA-D region epitopes and, in juvenile arthritis, 575
- IL-2 and, 176, 401, 826
- immunoregulation of, in rheumatoid synovitis, 1075
- interaction of, with synovial fibroblasts, 947
- in juvenile arthritis, 1334
- leukemia of, adult, proliferative synovitis and, 1076
- in Lyme synovitis, 487
- non-Hodgkin's lymphoma of synovium, monarthritis and, 571
- PGE<sub>2</sub> modulation of RF synthesis and, 1473
- phytohemagglutinin, IL-2 and, in SLE, 826
- in RA, 21, 31, 52, 1230, 1555
- in SLE, 88, 572, 1371
- synovial fluid, in JRA, 780
- TLI in lupus nephritis and, 850
- T3 cells, low-dose methotrexate in RA and, 167
- T4 cells, in RA, 52
- Tac antigen, in synovial fluid lymphocytes in JRA, 780
- Tac cells, IL-2 receptors in RA and, 1176
- Taq I fragments, C4 molecular heterogeneity in SLE and, 736
- Tarsal bone, osteocalcin in, in rat collagen arthritis, 1413
- Telangiectasias, serum autoantibodies in SSc and, 196
- Temporal arteritis, incidence and clinical presentation of, 745
- Temporal artery, amyloidosis, giant cell inflammation and, 1186
- Temporomandibular joint
- dysfunction of, systemic joint laxity and, 1259
- mandibular dimensions in JRA and, 602
- Tender points
- in fibromyalgia, 182
- in fibrositis, cyclobenzaprine and, 1535
- Tenderness, anatomic site, 182
- Tendons, tibialis posterior, rupture of, rheumatoid flat foot and, 441
- Tenosynovitis
- caused by *Exophiala mansonii*, 1213
- idiopathic hypereosinophilic syndrome and, 120
- Mycobacterium terrae*, 932
- Teratogenesis, methotrexate in RA and, 305
- Terminal complement complex, C5b-9, disease activity in SLE and, 188
- Tertatolol-induced lupus, 145
- Testicles, biopsy of, in diagnosis of polyarteritis nodosa, 1117, 1128



- Testosterone, in RA, 973, 1314  
 Thalidomide-induced neuropathy, in RA, 145  
 Thiols, fibroblast proliferation, penicillamine, CuSO<sub>4</sub> and, 964  
 Thoracic spine, in gorilla spondylarthropathy, 934  
 Thorax, costochondral involvement in heroin addicts and, 793  
 Threonyl-tRNA synthetase, antibody to, in myositis, 515  
 Thromboangiitis obliterans (Buerger's disease), smokeless tobacco and, 812  
 Thrombocytopenia  
   gold-induced, high-dose gamma globulin treatment of, 454  
   immune, oral gold and, 299  
   in lupus pregnancy, 358  
   in RA, 148, 167  
 Thrombosis  
   arterial, lupus anticoagulant and, 570  
   intracardiac thrombus in SLE with lupus anticoagulant and, 1453  
   venous, in phenothiazine-induced SLE, 923  
 Thromboxane B<sub>2</sub>, recombinant human IL-1 $\beta$ , rabbit chondrocytes and, 1290  
 Thrombus, intracardiac, in SLE, with lupus anticoagulant, 1453  
 Thymocytes, fibroblasts and, 947, 1272  
 Thymus, calf, DNA binding specificity in SLE and, 367  
 Thyroid, in secondary Sjögren's syndrome in SLE, 1079  
 Thyroiditis, Hashimoto's, episodic polyarthralgia in, 303  
 Tibia, cartilage pathology, immune synovitis and, 248  
 Tibial plateau  
   OA cartilage morphology in, in STR/IN mice, 898  
   spontaneous cartilage degeneration in guinea pig and, 561  
 Tibialis posterior tendon rupture, cause of rheumatoid flat foot, 441  
 Tobacco, smokeless, thromboangiitis obliterans and, 812  
 Tonsils, lymphoid tissue of, Lyme synovitis and, 487  
 Tophi  
   lipids in, in CPPD crystal deposition disease, 1057  
   on lymphedematous foot in normouricemic man, 813  
 Topical corticosteroid drugs, in subacute cutaneous LE, 1007  
 Topoisomerase I (topo I) (Scl-70 antigen), characterization of, 108  
 Total lymphoid irradiation (TLI)  
   in lupus nephritis, 850  
   in RA, 21, 146, 1481  
 Total parenteral nutrition, in polyarteritis nodosa, 683  
 Toxicity  
   bladder, cyclophosphamide and, in Wegener's granulomatosis, 465  
   methotrexate, 167, 305, 577, 1586  
 Trabecular bone  
   cells, effect of  $\gamma$ -IFN and tumor necrosis factor  $\alpha$  on, 1500  
   CT examination of, in experimental OA, 1400  
*trans* gene, Ro (SS-A) autoantibodies in SLE and, 496  
 Transaminase, low-dose methotrexate in RA and, 167  
 Transfer ribonucleic acid (tRNA), anti-threonyl, in myositis, 515  
 Transferrin  
   activation of rat synovium by iron and, 653  
   inhibition of neutrophil stimulation and, 1081  
 Transient arthritis, in rats, synovial mast cells, IgE and, 1063  
 Triglycerides, in dyslipoproteinemia in pediatric SLE, 859  
 Trimethoprim/sulfamethoxazole, in Wegener's granulomatosis, 1068, 1073  
 Tritiated arachidonic acid, phospholipase activity in rat synovial fibroblasts and, 1421  
 Trophoblast basement membrane, in lupus pregnancy, 358  
 Trypsin  
   enzyme-induced cartilage transformation and, 210  
   IL-6 in RA and inflammatory arthritides and, 784  
   protease inhibitors in experimental arthritis and, 1156  
 Tuberculin, protein derivatives of, methotrexate in RA and, 167  
 Tuberculous rheumatism (Poncet's disease), childhood, 1311  
 Tumor necrosis factor  
   effect of, on bone cells, 1500  
   hyaluronic acid stimulation by, 1282  
   in RA, 1041  
 21-hydroxylase genes, C4 molecular heterogeneity in SLE and, 736  
 26-kd protein, in RA and inflammatory arthritides, 784  
 Twins, neonatal lupus and, 697
- ## U
- U1 RNA, anti-68K polypeptide reactivity and, 1265  
 U1 RNP  
   68-kd protein autoantigen, 616  
   small nuclear (U1 snRNP), anti-68K polypeptide reactivity and, 1265  
 U3 RNP, complex, antinucleolar antibodies in scleroderma and, 525  
 Ulcers, encapsulated indomethacin in rats and, 414  
 Ultrasound, in rheumatoid flat foot, 441  
 Upper extremities, function of, AIMS in RA and, 714  
 Urea, recombinant La antigen in ELISA and, 506  
 Urethral involvement, in postdysenteric reactive arthritis, 1377  
 Uric acid  
   adrenocorticotrophic hormone and indomethacin in gout and, 803  
   tophi on lymphedematous foot and, 813  
 Urinary hydroxyproline excretion, osteocalcin and, in Paget's disease of bone, 1142  
 Urokinase, plasminogen activator, mRNA and, in synovial fibroblasts, 1046  
 Uronic acid, chondroitin sulfate in cartilage and, 1028  
 Urotoxicity, cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis and, 465  
 USSR, rheumatology in, 140  
 Uveitis, anterior, in HLA-B27-associated AS, 1454
- ## V
- Vacuoles, myofibril, in scleromyxedema myopathy, 1437  
 Valve replacement, intracardiac thrombus in SLE with lupus anticoagulant and, 1453  
 Varus deformity, OA cartilage morphology in knee of STR/IN mice and, 898

Vascular injury, plasma anaphylatoxins and, in SLE, 632

Vascular involvement

- congestion, chlamydial antigen in Reiter's syndrome and, 937
- DNA binding specificity in SLE and, 367
- in scleromyxedema myopathy, 1437
- in SSc, 196, 393, 1524
- in synovitis in RA, 956

Vascular lesions, anti-IgE autoantibodies in SLE and, 1000

Vasculitis

- in connective tissue disease in mice, 806
- disease activity in essential cryoglobulinemia and, 1558
- during methotrexate treatment in RA, 1182
- necrotizing, 149, 1194, 1199
- trimethoprim/sulfamethoxazole in Wegener's granulomatosis and, 1068, 1073

Vasooclusive retinopathy, C3a, C5a and, in SLE, 632

Vena cava, superior, in phenothiazine-induced SLE, 923

Vertebral syndesmophytes, in progressive ankylosis in mice, 1390

Vertebral tuberculosis, childhood, 1311

Very late activation 1 (VLA-1) antigen, phenotypic analysis of lymphocytes in RA and, 1230

VH26 gene, 16/6 idiotype-positive anti-DNA antibody, 1429

Villonodular synovitis, pigmented, lipid microspherules in, 1442

Vimentin, hybridoma SLE anticytoskeletal antibodies and, 864

Viruses

- Epstein-Barr, 1014, 1455, 1481
- Fc receptors, RF, antiidiotypes and, 1204
- HIV, in AIDS mimicking Sjögren's syndrome and SLE, 272
- parvo-, human, in synovial fluid, 279

Visceral angiography, in diagnosis of polyarteritis nodosa, 1117, 1128

Visceral involvement

- serum autoantibodies in SSc and, 196
- skin, disease activity in essential cryoglobulinemia and, 1558

Vision, in lupus retinopathy, 1105

VLA-1 antigen, phenotypic analysis of lymphocytes in RA and, 1230

V<sub>H</sub> gene, 16/6 idiotype-positive anti-DNA antibody encoded in, 1429

## W

Walking, in childhood tuberculous rheumatism, 1311

Walking time, formal education, clinical status and, in RA, 1346

Warfarin, in intracardiac thrombus in SLE with lupus anticoagulant, 1453

Wegener's granulomatosis

- acute pericardial tamponade in, 300
- antimicrobial drugs in, 1068, 1073
- cyclophosphamide-induced bladder toxicity in, 465
- trimethoprim/sulfamethoxazole in, 1068, 1073

Weight, body, prediction of bone mineral density and, 891

Weight bearing, hyaluronic acid depletion in canine OA and, 538

Weight loss, propylthiouracil in cats and, 688

Western blotting

- antineurofilament antibodies in neuropsychiatric SLE and, 623
- in study of novel neuronal antigen (97K) in SLE, 1492

Wilson's disease, presenting as isolated arthritis of hip, 573

Work status, income loss in polyarthritis and, 348

World Health Organization, reference reagents for ANA and, 1331

Wrist

- in idiopathic hypereosinophilic syndrome, 120
- joint, 44, 315, 1377, 1452
- proliferative synovitis of, in adult T cell leukemia, 1076
- in RA, 44, 577
- in spondylepiphyseal dysplasia, 282

## X

Xanthine, synovial fluid antioxidant activity in RA and, 63

## Y

*Yersinia* arthritis, followup study, 533

## Z

Z-DNA, DNA binding specificity in SLE and, 367

Zygapophyseal joints, synovial cysts of, spondylolisthesis, sciatic syndrome and, 288

Zymosan, fasting in RA and, 585